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EXAMINING CHILDHOOD OUTCOMES IN NEONATAL ABSTINENCE 
SYNDROME 
 
 Rates of neonatal abstinence syndrome have been rising over the past several years, 
alongside rising rates of opioid use disorder, propelled by the continuing Opioid Epidemic 
ravaging the country. Children born withdrawing from opioids they were exposed to in 
utero have known health complications through the first year of life that have been studied 
in the current literature. Less is known, however, about the outcomes these children face 
in childhood. As many of these children are progressing to childhood, there is an urgent 
need for healthcare system to prepare to handle the health needs of these children; outcomes 
related to child development for these children have not been well-established within the 
literature. 
 Using data procured from the Kentucky Medicaid Management Information 
System, a study population consisting of all Kentucky children born on Kentucky Medicaid 
between 2014 and 2019 was created. This data was linked to select information available 
on the child’s birth certificate from the Office of Vital Statistics, including indicators of 
prenatal health and certain maternal health characteristics. This study population formed 
the base population for the studies conducted within this chapter and provided a 
homogenous group under a common set of healthcare policies administered by one public 
insurance organization in one southern state.  
Chapter 1 introduces the scope of the problem in Kentucky, as well as establishing 
some background into the condition. In Chapter 2, a literature synthesis was conducted in 
which outcomes in Medicaid populations were assessed and gaps in the literature were 
determined. Chapter 3 provides overarching methodology for the dissertation as well as 
basic demographic information for the entire study population. 
Chapter 4 provided an assessment of socioemotional developmental factors for 
children, which, in the context of this work, was defined as family characteristics and 
structure. Specifically, a mother’s enrollment on Medicaid, the enrollment of siblings on 
Medicaid, evidence of siblings with prenatal exposure to opioids, foster care involvement, 
and whether a child was located at the same household as the mother were assessed. A 
cross-sectional logistic regression analysis was designed to establish the odds of a child 
with prenatal opioid exposure being in a different household than the mother, as well as a 
discussion of the factors that contribute to a child being located at a different address than 
the mother and the implications of that displacement. 
     
 
In Chapter 5, physical health, here defined as gastrointestinal conditions and 
respiratory conditions, were explored through a data exploration that led to a descriptive 
study to establish evidence of whether such an association existed. Asthma created a signal 
indicating that such an association may exist for children prenatally exposed to opioids in 
utero. The population was subset to children born in 2016 through 2019 and a logistic 
regression analysis was again conducted to ascertain whether there was evidence of such 
an association existing that could be explored in later analyses. 
Also in Chapter 5, cognitive development outcomes were assessed, here defined as 
the diagnosis of a mental health condition identified in two previous works on the subject. 
After assessing the prevalence of the conditions in the population of children born in 2014 
and 2015, the population was subset again to only include children born in 2014 and with 
one continuous year of enrollment in the database. Again, a logistic regression analysis was 
conducted to ascertain the odds of a child with prenatal opioid exposure being diagnosed 
with a mental health condition identified in two previous works. 
Finally, in Chapter 6, a longitudinal data analysis was conducted to establish 
whether the expenditures accrued by children with prenatal opioid exposure differed from 
that of their peers over time. A linear mixed model with an exponential power decay 
covariance structure, restricted maximum likelihood estimators, and model-based standard 
errors was utilized in the analysis. 
Chapter 7 provides overall conclusions and policy recommendations for the 
Medicaid system based on the findings of the dissertation. 
 
KEYWORDS: neonatal abstinence syndrome, child development, childhood outcomes, 
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CHAPTER 1.  INTRODUCTION  
1.1 Background 
With the expanding Opioid Epidemic continuing to impact communities across the 
country in the years since approximately 2012, neonatal abstinence syndrome, or NAS, has 
also seen a surge of interest in recent years. Neonatal abstinence syndrome refers to the 
withdrawal symptoms that arise following in utero exposure to substances due to maternal 
use. Recently the term has become synonymous with neonatal opioid withdrawal 
syndrome, or NOWS, but this has not always been the case. 
A simple PubMed search of the literature using the keyword “neonatal abstinence 
syndrome” revealed that the earliest archived article on the subject dates back to 1974: a 
literature review on the subject by Phyllis Burosch.1 Google Scholar could trace the interest 
in the subject back even further, with a literature review by Cobrinik et al. published in 
Pediatrics in 1959.2 A historical perspective published in 2018 in Frontiers of Pediatrics 
traced documentation of the syndrome following exposure to opioids back to 18753; 
Kocherlakota also identified these same origins in a review article published in 2014.4 
Despite the long history, and given the acceleration of the Opioid Epidemic, the 
literature on the subject began its expansion around 2012. 75 articles were archived on 
PubMed in 2012, a 44.23% increase from the 52 articles in 2011. Even with a global 
pandemic in 2020 disrupting academic research, the literature has remained consistently 
above this threshold since 2012; 85 articles have been published between January 1, 2021 
and May 23, 2021 alone. 
Yet despite the increased interest in the subject, significant gaps in the literature 
persist. Childhood outcomes following NAS remain a relatively understudied body of 
work. To understand how a condition experienced in infancy could disrupt childhood 
development, biological aspects at play behind the syndrome must first be understood. 
1.2 Pathophysiology of NAS and Treatment 
In 2014, Kocherlakota noted that the pathophysiological mechanisms of opioid 
withdrawal are relatively unknown and “…is more complex in neonates as a result of 
immature neurologic development, impaired neurologic processing, and complex 
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materno-feto-placental pharmacokinetics.”4 Opioids are central nervous system agents.5 In 
fetal development, the central nervous system is one of the earliest systems to begin 
developing6 and one of the last to complete development, with the prefrontal cortex 
continuing its maturation far past infancy until around age 25.7 
Pregnancy also complicates all aspects of drug action, from metabolism to 
clearance.8 Transport of compounds to the fetus occurs through the maternal circulatory 
system and synctiotrophoblasts5 acting as gatekeepers for the allowance of materials to 
cross the placenta.9 Opioids, in general, have a profile that favors their transport across 
both the blood-brain barrier and the placental barrier.10,11 
While a substance use disorder is a biopsychosocial phenomenon that arises 
following use of a substance of abuse12, tolerance and dependence are biological responses 
to substance use.13 Tolerance refers to the need for increased dosage or administration of 
a substance to elicit a previous effect, and dependence refers to the adaptation of the body 
to a substance to fulfill a certain role.14 Tolerance and dependence are symptoms of a 
substance use disorder, but not a substance use disorder themselves15; tolerance and 
dependence arise following exposure to a substance.13 
Drug withdrawal is a phenomenon that can arise following the cessation of 
exposure to a substance.16 Opioids, both licit and illicit, prescribed and acquired through 
alternative markets, can precipitate withdrawal symptoms.16 Detoxification from these 
substances in adults requires medical supervision, as the withdrawal can be dangerous.17 
For neonates who obtained exposure to a substance during gestation, this is also likely 
true. 
NAS is a multisystemic condition, with the central nervous system, gastrointestinal 
systems, and respiratory systems absorbing the brunt of the burden.18 A large portion of 
neonates with NAS are treated in the neonatal intensive care unit (NICU).19 Treatment 
protocols for NAS vary between hospitals, from the tools used to assess an infant’s need 
for treatment of NAS to the pharmacological treatments utilized in the treatment process 
of the syndrome.20 One of the most popular tools used to assess the need for 
pharmacological treatment in NAS is the Finnegan Score, first published by Dr. Loretta 
Finnegan et al. in 1975.21,22 Another tool growing in popularity was first published in 2017 
after several quality improvement implementation cycles at Yale University, known as Eat 
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Sleep Console.23–25 The goal of both tools is to provide an objective determination of the 
severity of the withdrawal symptoms experienced by a neonate.21,23–25 
In general, when withdrawal symptoms begin in a neonate, non-pharmacological 
treatment therapies, such as swaddling and baby massage, are administered to the child.22 
After repeated scoring, if the score cannot be held constant (i.e., “captured”) below a 
threshold or continues to escalate, pharmacological treatment is administered to the 
infant.22 In instances where the score continues to escalate following administration of a 
pharmacological agent, treatment protocols either switch medications for NAS or add a 
conjugant medication.22 When the score is captured and begins decreasing, a weaning 
protocol off the pharmacological agent is initiated. Three common treatment agents for 
NAS are morphine, a full opioid agonist; phenobarbital, a barbiturate; and clonidine, a 
hypotensive agent.22 Other medications, such as methadone and buprenorphine, have also 
been utilized in the treatment of NAS.22 
Yet despite the dangers of withdrawal for a neonate, death rates in NAS remain 
relatively low.26 Most of the children experiencing the syndrome in infancy will become 
children. Despite a plethora of literature available on infant outcomes in NAS, relatively 
little exploration on child development following NAS has been conducted. 
1.3  Child Development 
To speak of child development is to speak of the way a child grows and copes with 
the world around them.27 Child development is not a straightforward, simple process, but 
rather a result of all the biological, social, and psychological inputs to a child.27 Because 
the process relies so heavily on the subjective experiences throughout a child’s life, no 
child will ever develop in a perfectly optimal environment. Every child will face challenges 
of varying magnitudes throughout their growth and development, with worst case scenario 
being a traumatic experience, and each child will respond to such challenges and traumatic 
events differently.28 
Dr. Laura Berk identified three domains of child development in her textbook on 
the subject: physical development, cognitive development, and socio-emotional 
development.29 Physical development refers to biological and visually apparent indicators 
of the growth trajectory of a child: body composition, pathogenesis, among others.29 
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Cognitive development refers to the neurological and psychological aspects of the process 
of maturation: for instance, the child’s mental health concerns, neurological conditions, 
learning capacity, and communication capabilities.29 Socio-emotional development refers 
to advances in relational milestones, such as the forming of friendships, attachment to 
parents, and a child’s adaptation into societal norms, customs, and contexts.29 Childhood 
outcomes, then, do not solely refer to health outcomes, but the holistic developmental 
outcomes important to the child’s growth and maturity. 
One of the assumptions throughout this work is that NAS results in biological 
manifestations that have the potential to alter the developmental trajectories of the children. 
Many biological inputs, such as prenatal opioid exposure, can be thought of as linear 
processes, with the biological stimulus yielding a biological response30. These stimuli can 
be interfered with and acted upon by other outside forces but, for the most part, the 
consistent predictability of stimulus-response remains a necessary element to ensure 
causality.30 This assumption lends itself to the examination of health utilization and 
outcomes among children with NAS in order to understand the health outcomes of children 
who had NAS. 
Not only are biological factors important in the development of the child, but it is 
well-known that the very social system the child exists also has the potential to alter the 
child’s developmental trajectory.31 The biopsychosocial model of NAS is utilized as the 
conceptual framework throughout this work, implying that the social system in conjunction 
with the biologic input creates demonstrable differences in the development of children 
throughout childhood.31 As such, the social (i.e., the familial) environment in which the 
child develops within is an area of examination to understand the holistic development of 
this population.  
1.4 Purpose 
The purpose of this dissertation is to examine childhood outcomes in neonatal 
abstinence syndrome. Table 1.1 provides an overview of all the questions for research 
within this dissertation, as well as their associated domains of development and hypotheses. 
The analyses and studies within this work intend to provide a more holistic perspective of 
child development by considering socioemotional components of development, physical 
5 
 
health-related components of development, and cognitive health components of 
development for children undergoing this syndrome at birth. In Chapter 2, a literature 
synthesis examining neonatal abstinence syndrome outcomes specifically assessed in 
Medicaid populations was conducted. In Chapter 3, the data source and overarching 
methodologies for the studies examined within this dissertation is discussed. In Chapter 4, 
familial environments and guardianship factors are discussed for this population. Chapter 
5 analyzes select health outcomes for this population. Chapter 6 examines healthcare 
utilization and expenditures for this population. Finally, Chapter 7 provides some 
concluding thoughts on all the studies conducted and policy recommendations based on 




Table 1.1  Questions for research for the dissertation and associated domains of 
development and hypotheses. 
Question Domain of 
Development 
Hypothesis 
Are the family and social 
environments of children with 
NAS diagnoses different from 
that of other children? 
Socio-
emotional 
Children with an NAS diagnosis 
will be more likely to have 
siblings in the Medicaid system 
and be enrolled in a different 
household than their mother 
than children without a 
diagnosis of NAS. 
Are children diagnosed with 
NAS also being diagnosed with 
mental health conditions at ages 1 
and 2 more frequently than other 
children? 
Cognitive Children with a diagnosis of 
NAS will be more likely to be 
diagnosed with a mental health 
condition at an early age 
compared to children without 
the diagnosis. 
Do children diagnosed with NAS 
have more diagnoses of 
gastrointestinal conditions than 
other children? 
Physical Children diagnosed with NAS 
will have more gastrointestinal 
conditions diagnosed than 
children without a diagnosis of 
NAS. 
Do children diagnosed with NAS 
have more diagnosed respiratory 
conditions diagnosed than other 
children? 
Physical Children with a diagnosis of 
NAS will have more respiratory 
conditions diagnosed than 
children without a diagnosis of 
NAS. 
Are children with a diagnosis of 
NAS more expensive for the 





Children with a diagnosis of 
NAS will have higher healthcare 
expenditures than children 
without a diagnosis of NAS 
through the duration of early 
childhood. 
Do children with NAS utilize 





Children with a diagnosis of 
NAS will utilize more health 
services than children without a 
diagnosis of NAS through the 




CHAPTER 2. LITERATURE SYNTHESIS:  NEONATAL ABSTINENCE SYNDROME IN MEDICAID 
POPULATIONS 
2.1 Background 
In an American healthcare context, it is impossible to separate the provision of 
healthcare from a person’s insurance coverage. Children, for the most part, are covered by 
one of three mechanisms: as a dependent on a private insurance plan enrolled in by their 
parents, Medicaid, or through the Children’s Health Insurance Program (CHIP).32 CHIP 
began in 1997.32 States were charged to administer their own CHIP programs for infants 
meeting 200% of the federal poverty line (FPL) threshold; states additionally have the 
option to expand this coverage capacity and most do.32–34 CHIP insures children ages 1 to 
18.34 The missing year in a child’s life before CHIP eligibility begins – the period from 
birth until the first birthday – is most frequently covered as part of a Medicaid program.32,34 
Medicaid as a program began in 1965.35 In its original role, the program existed to 
cover low-income families, children, some older adults, and adults with disabilities.36 
Following the passage of the Affordable Care Act (ACA), Medicaid expanded the coverage 
to include adults without dependent children. Currently, 39 of the 50 States, as well as 
Washington, D.C., have expanded their Medicaid coverage.36,37 Many state regulations and 
state laws, such as Kentucky Revised Statute § 205.592 in Kentucky, require coverage of 
the infant on Medicaid from birth through the first year of life.39  
In NAS, Medicaid has been identified as an important payer source, with more than 
80% of the burden of payment for NAS falling to the Medicaid system.39 Children on 
Medicaid, because of factors related to social determinants of health, face unique 
challenges. Low socioeconomic status, inherent to qualifying a child for Medicaid, has 
been associated with suboptimal child development, particularly in cognitive 
development.40 Thus, examination of Medicaid populations provides important context for 
understanding NAS and child development overall. The purpose of this literature synthesis 
is to synthesize the literature for published articles on NAS outcomes in Medicaid 




A literature synthesis was conducted in the PubMed database using the keyword 
“(neonatal abstinence syndrome OR prenatal expo* OR prenatal opioid expo*) AND 
Medicaid” between March 3, 2020 and May 28, 2021. The literature was then filtered to 
only include research identified as having been published within the past 10 years and in 
English. Resulting articles were then reviewed at an abstract level to determine inclusion 
in the literature synthesis. Following the abstract-level review, the full article was the 
assessed and a determination for inclusion in the final review was made. Resulting articles 
appearing in this synthesis were then compiled into a summary table and common thematic 
elements from the literature were determined to form this literature synthesis. 
2.3 Results 
The initial search result yielded 135 results. Filtering for studies published within the 
past 10 years narrowed the results to include 99 articles, and studies published in English 
did not result in any excluded articles. Abstract review ascertained 66 articles as eligible 
for full review. Full review of the discovered literature left 43 articles available for 
inclusion in this literature synthesis. A flow chart depicting this process is available in 
Figure 2.1. 
The discovered literature ranged from publications in 2012 through 2021. A 
summary of all the included literature with select findings is available in Table 2.1. 
Following full review, four overall themes emerged in the literature synthesized within this 
chapter: studies on prevalence and demographics, as well as validation studies used to 
identify NAS in databases; analyses of infant outcomes; development-related studies; and 
economic impact investigations. 
Two papers had findings that did not match any of these extracted themes. A study 
by Wen et al. published in 2021 found that exposure to prescription opioids in later 
pregnancy (meaning the second and third trimesters) increased the risk of congenital 
malformations.41 Additionally, findings in a health utilization paper by Corr et al. found 
that infants with NAS in Medicaid systems were more likely to have respiratory diagnoses 




2.3.1 NAS Primers: Prevalence, Demographics, and Validation Models 
The prevalence of NAS has been an area of interest for states due to the increased 
attention on the syndrome across the United States. The earliest estimates of this condition 
were established by Patrick et al. in 2012.43 In this study, the authors identified that the 
incidence of NAS between 2000 and 2009 had risen from 1.2 in every 1,000 births to 3.4 
in every 1,000 births.43 In 2013, a study by Pan and Yi found increases in rates of NAS 
between 1999 and 2008, coinciding with increases in rates of the use of opioids; during 
this same time period, alcohol and cocaine use decreased within their study population.44 
Patrick et al. revisited incidence rates of NAS in a 2015 study, finding that a region of the 
United States consisting of Kentucky, Tennessee, Mississippi, and Alabama had the 
highest incidence of NAS, closely followed by the New England states (identified as 
Maine, New Hampshire, Vermont, Massachusetts, Rhode Island, and Connecticut).39 In 
2020, Alemu et al. looked at demographics, length of stay, and hospital characteristics 
associated with NAS, finding that children with NAS were largely male, White, and had 
more clinical conditions than other children; additionally, these children were more rural 
than their counterparts and less likely to be at an urban non-teaching hospital.45 Consistent 
with the findings of Patrick et al. in 2015, Alemu also found that rates of NAS were higher 
in the South and in the Northeast.45 Another 2020 study by Ramphul et al. found that 0.8% 
of all births were NAS births, with the majority of infants born with NAS being male, 
White, and southern.46 A 2021 study by Hirai et al. also investigated changes in rates of 
both NAS and maternal opioid-related diagnoses, both nationwide and for each state within 
the United States, finding that, between 2010 and 2017, rates of NAS increased slightly 
across the United States.47  
Several studies focused solely on NAS in specific states. NAS in Wisconsin was 
investigated by Atwell et al. in 2016, finding that the rate of both NAS and maternal 
substance use was increasing, though maternal substance use was increasing faster than the 
rate of NAS.48 In 2017, Okoroh et al. found that, between 2003 and 2013, rates of NAS 
increased in Louisiana from 2.1 in every 1,000 births to 8 in every 1,000 births while rates 
of exposure to opioids increased from 2.2 in every 1,000 births to 12.6 in every 1,000 
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births.49 In Florida, consistent results were found, with increases in the rate of both NAS 
and SUD diagnoses during the time period investigated by Wang et al.50  
Stabler et al., in 2017, looked at rates of NAS and substance use trends in West 
Virginia between 2007 and 2013, finding that NAS had increased during this time period; 
of note, use of opioids had increased while use of cocaine had decreased.51 In 2018, 
Rogerson et al. did a study on factors associated with NAS in West Virginia, finding that 
areas with higher rates of Medicaid enrollment also had higher rates of NAS.52 In 2021, 
Umer et al. found that the rate of NAS between 2017 and 2019 in West Virginia was higher 
for infants covered by Medicaid, with the rate among the Medicaid population at 85.8 in 
every 1,000 births compared to the state average of 52.4 in every 1,000 births.53 
Hussaini and Garcia Saavedra, in a 2018 study, examined factors associated with 
NAS in Arizona and New Mexico, finding that incidence rates increased in both states 
between 2008 and 2013.54 Findings using data from infants born on Texas Medicaid 
between 2010 and 2014 found that rates of death were increased among the infants with 
known opioid exposure but without a diagnosis of NAS, with about a quarter of these 
deaths due to sudden unexplained infant death.55 Incidence rates of NAS in Nevada were 
also examined by Batra et al. in 2020, finding that, compared to previous 2013 estimates, 
rates of NAS were consistently higher, despite a dip in the incidence rate of NAS in Nevada 
between 2016 and 2018.56 A 2021 study using the population of infants in Oregon Medicaid 
by Ko et al. found that the rate of NAS between 2008 and 2012 was 5.8 in every 1,000 
births.57  
In 2017, a methodology paper by Brogly et al. presented a novel method of 
accounting for confounding that would not otherwise be available in administrative claims 
data.58 Maalouf et al. also ascertained a PPV for the ICD-9 and ICD-10 codes associated 
with NAS.59 ICD-9 code 779.5 had a positive predictive value (PPV) of approximately 
91% while ICD-10 code P96.1 had a PPV of approximately 98.2%.59 
 
2.3.2 Infant Outcomes 
Infant outcomes, defined here as infants throughout the first year of life for a child, 
have been one of the most widely assessed areas of research for children with this 
condition. Many reasons are possible for the increased assessment of outcomes during this 
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period of a child’s life. One potential explanation could be continuity of coverage and loss 
to follow-up after the first year of a child’s life. Studies utilizing administrative claims data 
to follow children, such as was used by Taylor et al., could see coverage for the child 
interrupted following this period as the child is passed to other health insurance coverage 
options or due to changes in parental health insurance coverage.60 Another reason could be 
loss to follow-up from clinics as children age out of programs and providers making 
follow-up or examination beyond this period of a child’s life difficult for researchers. 
Nevertheless, whatever the reason, this period of life for children with NAS has garnered 
significant attention. 
A study by Parlett et al. in 2019 found that commercially-insured infants with NAS 
often had more clinical characteristics suggestive of severe NAS and prescription opioid 
use was more common among commercially-insured mothers of infants with NAS.61 
Additionally, alcohol use and tobacco use seemed to be more common among mothers 
with Medicaid than mothers with commercial insurance.61 
NAS itself was frequently treated as an outcome of interest. In 2015, Desai et al. 
assessed the risk of NAS based on how long a mother had been using an opioid medication 
and the trimester with which the use was taking place, finding that long-term use increased 
the risk of NAS as did use later in pregnancy.62 A similar finding was published in 2020 
by Patorno et al., who examined gabapentin and neonatal outcomes, finding that later use 
of gabapentin increased the risk of adverse neonatal events like neonatal malformations, 
pre-eclampsia, preterm birth, small for gestational age, and NICU admission.63 In 2015, 
Patrick et al. looked at the risk of NAS based on MMEs, finding that the risk of NAS 
largely seems to ceiling among long-acting formulations as MMEs increase, though the 
risk of NAS rises much quicker as MMEs of short-acting opioid formulations increases.64 
Also in 2017, Charles et al. found that NAS was associated with male sex and that male 
infants differed from female infants in several ways that have been shown to influence the 
manifestation of NAS symptomologies.65 A 2020 study by Ma et al. found increased odds 
of NAS and NICU admissions among mothers with serious mental illness and gestational 
opioid use, with the group of mothers using buprenorphine or methadone and the group of 
mothers with opioid use disorder having the highest odds; both of these groups also saw 
increases in NICU admissions.66 Using Pennsylvania Medicaid data, Krans et al. in 2021 
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found that 57.9% of infants were diagnosed with NAS following maternal use of MOUD.67 
The findings of this paper also examined neonatal outcomes as they relate to the duration 
of maternal use of MOUD.67 The authors found that longer duration of MOUD did increase 
the odds of NAS, even after adjustment, but decreased the odds of low birthweight.67 
Finally, in 2021, Patrick et al. published an article using Tennessee Medicaid data 
proposing a model to predict NAS in both a general risk and high risk category.68 
In 2019, Sanlorenzo et al. found that concurrent maternal use of benzodiazepines 
increased the odds of an infant needing pharmacological treatment to relieve NAS 
symptoms.69 Huybrechts et al. found something similar in 2017, adding that 
antidepressants and gabapentin also increased the risk alongside benzodiazepines.70 These 
two additional medications were not consistent with the findings from the Sanlorenzo et 
al. paper.69,70  
Treatment options for infants with NAS also produced several articles included 
within this literature synthesis. Lee et al. published findings from a combined inpatient and 
outpatient clinic for NAS treatment, finding that hospitals with more cases of NAS often 
had lower lengths of stay than other hospitals, but the methadone program seemed to be 
decreasing length of stay until a switch to morphine as the primary medication for the 
treatment of NAS within the hospital occurred in 2013.71 In 2012, a study examining the 
use of acupuncture in the treatment of NAS was published.72 In 2017, Lai et al. published 
findings from a treatment program that allowed children to finish a wean from methadone 
in an outpatient setting, finding that it took approximately 7 days for the infant to reach 
every 24 hour dosing, but that the outpatient program did reduce length of stay in the NICU 
from 12 days to 10 days.73 Maalouf et al. in a 2018 paper also examined outpatient 
pharmacotherapy for these children, finding that phenobarbital is the most common 
medication given for NAS in an outpatient setting, though the length of treatment for 
infants in an outpatient setting is often much longer than patients in an inpatient setting (60 
days of treatment compared to 19 days of treatment).74 
A study by Rebbe et al. also examined hospital factors associated with reports to 
CPS within 7 days of a child being born with prenatal opioid exposure, finding that opioids 
were the most common substance for which a report was made and less prenatal care also 
increased the risk.75 Additionally, serving more Medicaid patients also increased the odds 
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of a report being made to CPS.75 In a similar line of thought, a study by Austin et al. 
investigated diagnoses of injuries, maltreatment, and developmental delays among the 
population of infants born with NAS, finding increased rates of maltreatment among opioid 
exposed children, with 51.4% of maltreatment diagnoses being physical abuse.76 
 
2.3.3 Childhood Cognitive Development 
Childhood cognitive development has also attracted significant attention for 
research in children with NAS. Cognitive development is a critical aspect of child 
development and an element that underlies all other aspects of development for a child: the 
psychiatric profile and integrity of development for a child can alter the progression of a 
childhood experience, and that altered trajectory can impact adulthood. Fill et al. in 2018, 
for instance, examined educational disabilities among Tennessee children diagnosed with 
NAS.77 More children with a history of NAS diagnosis were diagnosed with educational 
disabilities and referred for services than other children; additionally, more children with 
NAS received additional educational services, such as occupational therapy and speech 
therapy.77 The primary driver of these findings seemed to be developmental delays.77 
Sherman et al. looked at diagnoses of mental health conditions for children with a history 
of NAS diagnosis in 2019, finding elevated rates of all conditions for children with NAS.78 
This work was extended by Conner et al. in 2020 to a commercially-insured population, 
finding that the rate of NAS was much higher in the Medicaid population than in the 
commercially-insured population79, as well as finding consistent results to the results found 
by Sherman et al.78,79 
 
2.3.4 Economic Impact 
With the prevalence of NAS being significantly higher in Medicaid populations 
compared to commercially insured populations, the economic impact of these children to 
the Medicaid system has also been assessed. Patrick et al., in 2012, identified a 35% 
increase in costs between 2000 and 2009 for infants with NAS compared to a 30% increase 
among other infants.43 The study in Louisiana Medicaid by Okoroh found that the average 
NICU costs for infants with NAS was almost 4 times higher than NICU costs for other 
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infants between 2003 and 2013.49 In 2018, Winkelman et al. found that infants insured by 
commercial insurance, except between 2011 and 2014, were more costly to treat than 
infants covered by Medicaid, though the differences were not statistically significant.80 
Clemans-Cope et al. found that, while methadone decreased the costs associated with NAS 
treatment for infants, infant costs for all infants of mothers with SUD were higher than 
infant costs for infants of mothers without SUD.81  
In a seminal study on healthcare utilization of infants with NAS, Taylor et al. found 
that infants with NAS had more ED visits and less outpatient visits than the comparator 
group, though the differences seemed to diminish as clinical characteristics were 
considered within analyses.60 This was consistent with the findings of Ko et al. in 2021 
using Oregon Medicaid data, showing increased sick visits and emergency department 
utilization at four weeks and one year.57 Another seminal study by Corr et al. following 
this population of infants for 11 years found similarly, showing increased use of emergency 
departments in the first two years of life for the infants in the study.42 Corr et al. observed 
that differences among utilization between these two groups of infants diminished as the 
children grew older.42 
Dickes et al. in 2017 suggested a cost-saving model for Medicaid, estimating that, 
without intervention, costs to the Medicaid system will continue to rise at a quick rate.82 
2.4 Discussion 
The literature review confirmed that rates of NAS have been rising since 200043, with 
increased attention to the syndrome occurring largely because of the increase in the 
utilization of prescription opioids and the escalation of the Opioid Epidemic64. The 
demographic profile of children with NAS is also largely similar: majority male45,46,65, 
majority White45,46, largely in the South39,45,46 or in New England45,64. A notable exception 
to these findings were from the study of Arizona and New Mexico, in which NAS in New 
Mexico had a different demographic profile than identified in other studies.54 Additionally, 
every study in the literature synthesis that utilized a non-Medicaid data source identified 
Medicaid as the most frequent payer source for NAS.43,52,53,61,75,78–80 
Validation studies for the utilization of Medicaid administrative claims data to 
analyze NAS59, as well as the development of a predictive model68, have also been 
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published in the NAS literature. These studies were conducted using Tennessee Medicaid 
data linked to vital records data as a source dataset59,68; medical records were also obtained 
to ascertain a positive predictive value in the validation study for the Medicaid 
population.59 Nevertheless, these studies provide sufficient evidence that utilizing 
Medicaid administrative claims data with linked records from vital statistics provides a 
sufficient dataset for examining childhood outcomes in NAS. 
Investigation into the first year of life for a child was plentiful in the literature, with 
many of the articles included in this synthesis being cross-sectional in nature.39,43–
49,51,52,54,56,71,75,79,80 This again emphasizes the need for additional investigation into 
childhood outcomes for children with NAS to extend the literature in this area. 
Childhood cognitive development received a significant amount of attention in the 
discovered literature. Both Sherman et al. and Conner et al. investigated the development 
of childhood mental health conditions in this population.78,79 However, the ages 
investigated by both groups of researchers ranged from age one to age five and neither 
analysis investigated the age at which a child was diagnosed. This suggests the potential 
for a child aged one or two to be diagnosed with one of these conditions, which may 
represent the need for additional investigation regarding the source of the diagnosis. 
Largely, debates regarding diagnosing children with mental health conditions at an early 
age has been an issue eliciting much attention83,84; many of the diagnoses obtained by one- 
and two-year-old children should be developmental delays, with estimates for these 
diagnoses at ages 9 and 24 months being as high as 13%.85 Additional investigation is 
warranted to ensure the appropriateness of diagnoses of mental health conditions for these 
populations. 
While a significant amount of literature was found concerning the cognitive 
development of children with a history of NAS, little information on the physical health of 
children with NAS was ascertained in the literature review.41 NAS has been identified as a 
condition that affects multiple physical systems in an infant’s body: the central nervous 
system, the respiratory system, and the gastrointestinal system. Additionally, the brief 
insight by Conner et al. into most frequently prescribed medications for this population 
identified antiasthmatic and bronchodilator agents as a commonly prescribed medication.79 
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Additionally, Corr et al. identified increased rates of respiratory diagnoses among children 
with a history of NAS42, warranting additional investigation.  
Finally, children with NAS have a significant economic impact for the Medicaid 
system. The paper by Taylor et al. showing long-term healthcare utilization of children 
with a diagnosis of NAS is a seminal paper in studies of the economic impact of NAS.60 
This paper showed that differences in healthcare utilization largely decreased over time for 
the group of children with NAS, with clinical characteristics of the children diminishing 
the gap in expenditures even further.60 However, while the work conducted in this analysis 
is exemplary and should be held as the standard for analyses regarding NAS, the period 
examined within this study ranged between 1999 and 2011, prior to the beginning of the 
Opioid Epidemic.60 This may represent a different generation of substance use disorder and 
different ideas surrounding the treatment and continued care of infants with NAS. 
Additionally, the states investigated in the analysis consisted solely of New York and 
Texas60; the findings from these two states may not be generalizable to other populations 
and merits additional investigation in different populations in more recent data. In another 
seminal study, Corr et al. filled some of these gaps by evaluating an eleven-year cohort 
from 2003 to 2013, the longest cohort examined in the literature synthesis.42 These authors 
found similar findings, showing that healthcare utilization among children diagnosed with 
NAS ceased to be statistically different from the comparator group after age 3.42 However, 
like in the Taylor et al. study60, the last year of data in the study population is 2013, 
representing an early period of the Opioid Epidemic42, and thus may not be generalizable 
to the current population of children diagnosed with NAS. 
The work in the next chapters of this dissertation will attempt to fill many of the gaps 













Table 2.1  Summary of literature included in the literature synthesis. 
Year of 
Publication 





























78.1% of children with 
NAS are covered by 
Medicaid. The rate of 
NAS rose between 2000 
and 2009 from 1.2 per 
1,000 births to 3.4 in 
1,000 births, concurrent 
with an increase in total 
costs (an increase of 
35% for expenditures 
associated with NAS, 
30% for all others). 
Length of stay 
associated with NAS 
was consistent for the 



































87% of the infants in the 
study were covered by 
Medicaid. Study 
population consisted of 
157 infants with NAS, 
among which 54 got 
acupuncture. The entire 
study population had a 
total of 92 acupuncture 
treatment sessions. 28 
infants slept through the 
treatment or fell asleep 
upon completion of the 
treatment while better 
feeding was reported 
among 8 of the infants. 











































Neonates affected by 
alcohol and cocaine 
trended down during the 
study period while 




substances of abuse 
trended up. Diagnoses 
related to maternal 
alcohol use remained 
consistent throughout 
the study period while 
maternal cocaine-related 
diagnoses trended 
down. All other drugs 
trended up. In 2001, 
64.3% of the neonates 
affected by substances 
of abuse were covered 
by Medicaid; by 2008, 
this had risen to 77.9%. 
60% of the mothers with 
a substance-related 







Table 2.1 Continued. 
2015 Rishi J. 
Desai, et 
al. 
BMJ Exposure to 
prescription opioid 
analgesics in utero 








Cohort Diagnosis of 
NAS within 





Among the women included in 
the study, 1.7% of women in 
the study had a diagnosis 
related to opioid misuse or 
dependence while all other 
forms of substance use 
disorders (including alcohol) 
were around 9.8% of the 
population. Long-term opioid 
use increased the risk of a 
child being born with NAS 
compared to short-term opioid 
use. Use of opioids later in 
pregnancy increased the risk of 
























rates of NAS; 
geographic 
variation in 






The East South Central region 
of the United States 
(Kentucky, Tennessee, 
Mississippi, and Alabama) and 
New England (Maine, New 
Hampshire, Vermont, 
Massachusetts, Rhode Island, 
and Connecticut) had the 
highest incidence of NAS. The 
average length of stay for 
infants with NAS was 
approximately 16 days; with 
assumed pharmacological 
treatment (defined as any 
length of stay exceeding 6 
days), the average length of 
stay rose to 23 days. 82% of 
the births with a diagnosis of 
NAS were covered by 
Medicaid; Medicaid also bore 
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 Rates of NAS rose in the 
population between 2007 to 
2013 from 0.2% to 7.3%. The 
most common treatments for 
NAS included morphine and 
morphine with adjuvant 
phenobarbital. Length of stay 
was decreased for the 
population treated with 
methadone. Across hospitals, 
the more cases of NAS a 
hospital handled, the lower the 
length of stay tended to be. 
Length of stay increased when 
a switch to morphine was 
made in May 2013. Among 
readmissions in the outpatient 
weaning program, there was 
only one readmission related 
to NAS (specifically due to 

























of the population 
evaluated utilized 
tobacco while 0.8% of 
the population during 
this study period had a 
diagnosis related to 
opioid dependency. The 
rate of NAS increased 
during this period. The 
risk of NAS seemed to 
reach a ceiling as MMEs 
increased and the 
number of daily 
cigarettes increased, but, 
overall, trended upward. 
Short-acting opioids 
increased the risk of 
NAS much faster for the 
MMEs evaluated, 
however, the MMEs 
evaluated were also 








































Rates of NAS and 
maternal substance use 
both increased during 
the study period, but 
maternal substance use 
increased at a faster rate 
than NAS. 82% of the 
deliveries resulting in 
NAS were covered by 
Wisconsin Medicaid. 
Substance use was 
higher in the Medicaid 


























length of stay 
in the NICU; 
time to dosing 
weaned down 
to every 24 
hours; 
readmissions 
 The population was 
majority male (58.5%) 
and majority white 
(71.2%). Medicaid was 
the payer for the 
majority of the births. 
Length of stay was 
approximately 12 days. 
For infants on the 
methadone treatment 
regimen, length of stay 
was approximately 10 
days prior to discharge. 
The average length of 
stay to reach 24-hour 






















linked to Vital 
Statistics 





Mothers of infants born 
male tended to be older and 
heavier smokers. Male 
infants with NAS were born 
earlier (i.e., more preterm), 
but had higher birthweights 
than infants with NAS born 
female. The overall risk of 
NAS was insignificant in 
the unadjusted model but 




























85% of the births in the 
study had Medicaid as the 
payer source. Most of the 
diagnoses were related to 
exposure to opioids (i.e., 
narcotics) and this increased 
over time while the rate of 
cocaine-exposed births 






























During the study period, the 
rate of exposure to 
substances of abuse rose 
from 2.2 in every 1,000 
births to 12.6 in every 1,000 
births while the rate of NAS 
rose from 2.1 in every 1,000 
births to 8 in every 1,000 
births. 20.1% of the mothers 
of the substance exposed 
infants had a diagnosis 
related to opioid use 
disorder or dependence; 
33.2% of those mothers had 
a concurrent mental illness. 
25.1% of mothers of infants 
with NAS had a prescription 
for hydrocodone. 81% of 
the infants with NAS were 
treated in the NICU. The 
NICU costs for infants with 
NAS were roughly four 
times higher than the NICU 
costs for infants without 
NAS. 

































After adjusting for solely 
confounders from the 
Massachusetts MAX data, 
infants with mothers on 
buprenorphine had lower 
risk of both preterm birth 
and low for gestational age 
birthweight compared to 
infants of mothers on 
methadone; after adjustment 
with data from the 
prospective cohort study, 
the risk of preterm birth for 
infants whose mothers were 
treated with buprenorphine 
was lower than mothers 
treated with methadone, but 
the risk of low for 




































the scope of 
the program 
and the length 





Costs related to NAS 
largely increased 
between 2006 and 
2014 in South 
Carolina, with 
Medicaid bearing the 
brunt of the costs. NAS 
rates were projected to 
continue rising 
between 2015 and 
2025, which will lead 
to a concurrent fast rise 
in costs with no 
intervention. 
Increasing eligibility 
into the treatment 
model for NAS studied 
here was projected to 
produce significant 
annual cost savings for 
Medicaid programs. 
2017 Krista F. 
Huybrechts, 
et al. 




















Concurrent use of 
antidepressants, 
benzodiazepines, and 
gabapentin seemed to 
increase the risk of 
neonatal withdrawal 
compared to opioids 
alone; use of 2 or more 
psychotropics also 
increased the risk of 
withdrawal. The risk 
rations were higher for 
all with added 
psychotropic 
utilization. 
2017 Xi Wang, et 
al. 




























Mothers of infants with 
NAS tended to be 
slightly older than 
other mothers, with the 
majority falling 
between 25 to 29 years 
old compared to 18 to 
24 years for mothers of 
infants without NAS. 
Infants with NAS also 
tended to be born more 
preterm than other 
infants. No significant 
differences in prenatal 
care. Tobacco use 
(57.2% vs. 13.7%) and 
antidepressant use 
(13.7% vs. 2.7%) were 
higher among mothers 
of infants with NAS. 
NAS rates increased 
during the study period 








Table 2.1 Continued. 
2018 Mary-
Margaret A. 































No children with a diagnosis 
of NAS had a recorded 
intellectual disability 
recorded as being 
intellectually gifted during 
the study period. Infants with 
NAS had lower birthweights, 
were more preterm, and were 
more likely to have been in 
the NICU. Mothers of infants 
with NAS received less 
prenatal care. More children 
with NAS were referred for 
evaluation of intellectual 
disability (19.3% vs 13.7%) 
and more were considered 
eligible than other infants 
(15.6% vs 11.6%); among 
the reasons for eligibility, 
developmental delays were 
highest (5.3% vs 3.5%). 
More infants with NAS also 






















Rates of NAS  The data seemed to suggest 
that higher concentrations of 
Medicaid coverage 
correlated to increases in 
rates of NAS, and this 
seemed to hold at a national 
level as well. Increased 
access to opioid treatment 
centers seemed to decrease 
the rates of NAS. 
2018 Tyler N. A. 
Winkelman, 
et al. 
Pediatrics Incidence and 












Rates of NAS; 
rate of transfer 
to other 
facilities; 
length of stay; 





Rates of NAS increased 
between 2004 and 2014. 
Infants with a diagnosis of 
NAS covered by Medicaid 
are more male and more 
likely to live in 
socioeconomically 
disadvantaged and/or rural 
areas. Infants with a 
diagnosis of NAS and 
covered by Medicaid also 
seemed to have more 
diagnoses of clinical 
characteristics indicative of 
the condition. Infants with 
NAS covered by Medicaid 
had more hospital transfers 
than infants with private 
insurance. Between 2011 and 
2014, hospital costs related 
to NAS were higher for 









































Rates of NAS rose between 
2008 and 2013 in both 
Arizona and New Mexico, 
though rates were higher in 
Arizona. Coverage by 
Medicaid was high in both 
areas (77.7% in Arizona and 
87.5% in New Mexico). 
Infants born with NAS in 
Arizona were largely white 
and infants born with NAS in 
New Mexico were largely 
Hispanic. Median costs of 
births were $28,000 and 
$23,000 higher for infants 
with NAS in Arizona and 
New Mexico respectively. 
Low birthweight was 
significantly different in New 
Mexico. Lengths of stay were 
13 and 14 days for infants 
with NAS in Arizona and 
New Mexico. 






















visits in 30 





Infants with NAS treated 
inpatient were most 
frequently treated with 
morphine while infants with 
NAS treated outpatient were 
more frequently treated with 
phenobarbital. The length of 
stay for infants treated 
outpatient was 11 days 
compared to 23 days for 
infants treated inpatient. 
Length of treatment for 
infants treated outpatient was 












Infant Pairs With 










Length of stay  85% success in linking 
mother-infant dyads within 
Medicaid; 88% success 
within commercial insurance. 
79% of infants with NAS 
were covered by Medicaid. 
Mothers covered by 
Medicaid had more frequent 
alcohol and tobacco related 
diagnoses while mothers 
covered by commercial 
insurance had more 
prescription opioid use. 
Infants with NAS covered by 
commercial insurance had 
indicators indicating more 
severe NAS than infants with 
NAS covered by Medicaid. 
Similar lengths of stay. Use 
of buprenorphine was more 
common among the 
commercially insured 
population. NICU stays for 
infants with NAS covered by 
commercial insurance were 































Reports to CPS 
within first 7 




High rates of substance 
exposure among Native 
American infants and 
Black infants. Opioids 
were the most common 
substance exposure. 
The odds of a report to 
CPS were 1.32 times 
higher for infants with 
NAS with less prenatal 
care compared to 
infants with more 
prenatal care and were 
1.25 higher in hospitals 
with higher percentages 
of Medicaid coverage 
compared to hospitals 
with more private 
insurance coverage. 
Public payer sources 
increased the odds of a 
report to CPS by 1.74 
compared to other 
payer sources. 





























opioids increased the 
odds of 
pharmacological 
treatment for NAS; the 
other substances 
examined were not 
significant. Infants had 
more respiratory 
complications. 


















Cohort Mental health 
condition 
diagnoses 
 Rates of mental health 
conditions were 
elevated in the 
population of children 
diagnosed with NAS. 
Developmental delays 
were the highest 
percentage of 
diagnosed with mental 
health conditions; 
conduct disorders, 
ADHD, and adjustment 
reactions were also 
high. 
























The positive predictive 
value of NAS using 
779.5 from ICD-9 had 
a PPV of 91% while 
the PPV of P96.1 in 
















with opioid use 
disorder and their 















SUD treatment by 






The prevalence of SUD was 
8.1%, with the prevalence of 
OUD being 2.2% and 5.9% 
for other types of SUD. 
72.8% of mothers received 
treatment in the year before 
or after delivery for SUD. 
Mothers receiving 
methadone began their 
prenatal care later compared 
to other mothers; however, 
methadone also seemed to 
decrease infant costs, though 
infant costs were higher for 
all infants of a mother with 
an SUD compared to 































No evidence of any 
association with adverse 
events for gabapentin use in 
early pregnancy. Use of 
gabapentin in later 
pregnancy increased the risk 
of adverse neonatal 




















Cohort Total inpatient 
days; outpatient 
office visits; ED 













Infants with NAS had more 
ED visits and less outpatient 
visits than other infants. 
Findings were insignificant 
for inpatient days and filled 
prescriptions. Clinical 
characteristics decreased the 
differences among the 
groups. 




























The rate of NAS was much 
higher in the Medicaid-
insured population than in 
the commercially insured 
population. Findings were 
consistent with Sherman et 
al. Some psychotropics 
being used in the population 
of children ages 1 to 5. 
2020 Jifeng 




















Among mothers with a 
severe mental illness, 
approximately 25% of those 
mothers had an opioid-
related diagnosis, compared 
to 11%. After adjustment, 
buprenorphine and 
methadone use increased the 
odds of NAS by 168.93; for 
OUD, aOR of 46.87. All 
opioid diagnoses increased 
the odds of a NICU 
admission. Urban residence 
increased the odds of NAS 





Table 2.1 Continued. 



















length of stay; 
total charges 
2016 83% of the population 
was covered by Medicaid. 
Infants with NAS were 
more likely to be treated 
in a rural hospital than 
other infants and less 
likely to be treated in an 
urban non-teaching 
hospital; the percentage 
was approximately the 
same for both groups 
regarding urban teaching 
hospitals. Infants with 
NAS were more Southern 
or Northeastern than other 
infants. 



































the first year 




Most common diagnoses 
indicative of substance 
exposure among the 
infants were cocaine 
exposure and NAS. 
Maltreatment diagnoses 
were elevated amongst 
infants with prenatal 
opioid exposure. Physical 







An Update on 
the Burden of 
Neonatal 
Abstinence 





NAS; length of 
stay; total 
charges 
2016 NAS births comprised 
0.8% of all the births in 
2016. Most NAS births 
were male, White, and 
Southern. 83.8% of NAS 
births were covered by 
Medicaid. The mean 
length of stay for infants 
with NAS was 16.5 days, 
with a median length of 
stay of 12 days; being 
preterm increased the 
length of stay. 45 infant 
deaths in this group in 
2016, with 60% of the 





























NAS rates decreased 
between 2016 and 2018 
but remained higher than 
2013 estimates. Higher 
rates of NAS among 
white infants and among 
infants insured by 
Medicaid. Higher in urban 
areas and higher in more 
socioeconomically 
disadvantaged areas. 
Hospital factors were not 








































approximately 84% of NAS 
discharges and 77.1% of 
maternal opioid-related 
diagnosis discharges. The 
overall number of births 
nationwide remained 
relatively stable while the rate 
of NAS and maternal opioid-








Validation of a 













Creation of a risk 
stratification model for NAS. 
Lower birthweight and female 
sex at birth reduced the odds 
of developing NAS; 
sustained-release opioids also 
associated with increased risk 
of NAS. Additional evidence 
that gestational age in the 
high-risk model is predictive 
of NAS; in both models, 
increased birth weight seems 
to be protective. Hepatitis C 
in the mother also increases 





associated with the 
use of medications 









MOUD in the 
postpartum 
period; low 
birth weight in 




7.6% of infants had low birth 
weight in the study. 57.9% of 
infants of mothers on MOUD 
were diagnosed with NAS. 
The risk of low birth weight 
decreased as duration of 
MOUD treatment increased, 
but longer treatment duration 
with MOUD also increased 
the odds of NAS. The 
increased risk for NAS was 
non-linear. 
2021 Jean Y. 



































Maternal opioid exposure 
occurred in approximately 
123.1 in every 1,000 births for 
the study population; the rate 
of NAS was 5.8 in every 
1,000 births. Children with 
opioid exposure and/or NAS 
had increased hospitalizations 
at four weeks and one year; 
sick visits and emergency 
department visits were also 
increased for these groups. 





















and Risk of 





















Appeared to be an 
increased risk of 
congenital malformations 
when the fetus was 
exposed to opioids later 
in pregnancy (i.e., the 





































In a study population of 
1,129,032 infants, 7,207 
had known prenatal 
opioid exposure. 4,238 of 
those infants had an NAS 
diagnosis consistent with 
prenatal opioid exposure. 
The group of infants with 
the highest risk of infant 
death was the group of 
infants with prenatal 
opioid exposure but 
without a diagnosis of 
NAS. 25% of the deaths 
were due to sudden 



























54% of the NAS cases 
were diagnosed in the last 
four years of the study. 
Healthcare utilization for 
children with NAS was 
much higher for infants 
with NAS in the first year 
of life and remained 
different through age 3, 
then similar after age 3 
for the children. More 
preventative care and 
vaccines in the group of 
























NAS 2017 to 
2019 
West Virginia Medicaid 
covered approximately 
52.6% of all births during 
the study period. The rate 
of NAS among children 
covered by West Virginia 
Medicaid was 85.8 in 
every 1,000 births; the 
overall state average rate 
of NAS was 52.4 in every 
1,000 births. After 
adjustment for other 
variables, the risk of NAS 
in infants covered by 
Medicaid was 3 times 
higher than infants 
insured by commercial 
insurance. The adjusted 
excess risk of NAS for 
infants covered by 
Medicaid was an excess 




CHAPTER 3. METHODOLOGY AND DEMOGRAPHICS:  NEONATAL ABSTINENCE SYNDROME IN 
THE KENTUCKY MEDICAID ADMINISTRATIVE CLAIMS DATABASE 
3.1 Data Sources and Acquisition 
As Chapter 2 revealed, Medicaid is an important stakeholder in the assessment of 
NAS and children in Medicaid systems have social determinants of health that impact their 
overall wellbeing that differ from children insured through other means. This identifies 
Medicaid as an important data source for the monitoring of children with NAS in claims-
based analyses. 
The Opioid Epidemic has had a palpable impact across the United States, but some 
of the hardest hit areas have borne an extensive burden under the weight of the crisis. In 
Do No Harm, author Wiland identifies Kentucky as one of the hardest hit areas of the 
United States, and one of the states specifically targeted by Purdue Pharma in their 
advertisement of pain relief medications.86 Kentucky has seen rates of maternal opioid use 
disorders rise 273% between 2010 and 2017 and rates of NAS rise 196% during the same 
period.47 
Kentucky was one of the first states to expand their Medicaid system under the 
provisions allowed in the Affordable Care Act87; the expansion occurred at the beginning 
of the study period88. The increase from 135% of the federal poverty line (FPL) to 139% 
FPL grew the Medicaid system significantly.88 In June 2021, enrollment in Kentucky 
Medicaid was approximately 1.7 million89; in a state where the estimated population is 4.5 
million90, this creates an estimated 38% of the population of Kentucky that is enrolled in 
the Kentucky Medicaid system, or 19 in every 50 Kentuckians. The percentage of 
Kentucky children is estimated to likely be higher.91 
In October 1990, Kentucky passed KRS205.592, which specifically defines 
pregnancy and infant eligibility criteria for the Kentucky Medicaid system to 185% FPL.39 
KRS205.592 covers infants through their first year of life.38 Estimates for the annual birth 
rate in Kentucky remain stable at around 65,000 births per year92; under the criteria laid 
out in this law, Medicaid covers approximately 30,000 of those births each year, as 
demonstrated in Table 3.1. 
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After the first year of life, children then become eligible for the Children’s Health 
Insurance Program, or CHIP, which covers children under age 19.34 While CHIP is a 
federal program, each state is permitted to expand the program.93 Under 907 KAR 4:020 
and 4:030, the Kentucky Children’s Health Insurance Program, or KCHIP, was formed.95,96 
KCHIP in Kentucky is under the purveyance of Kentucky Medicaid96, which allows many 
of the children born on Medicaid to be retained for long durations throughout childhood. 
This policy feature in Kentucky allows the creation of long-term cohorts among children 
in the Medicaid system. This feature creates a continuity of service for low-income children 
that is unique to the structure of the Cabinet of Health and Family Services (CHFS) within 
Kentucky, which houses the Kentucky Department for Medicaid Services (DMS).96 
Furthermore, the Office of Vital Statistics (OVS), which compiles and stores information 
from birth certificates and death certificates for citizens of the Commonwealth of 
Kentucky, is also housed within CHFS.97 This multi-department approach to structuring a 
governmental cabinet creates a ripe and rich environment for data sharing and linkage 
across many of these units. 
Deidentified data from the Kentucky Medicaid Management Information System 
(MMIS) was obtained from the Office of Health Data and Analytics (OHDA) within CHFS 
consisting of children born on Kentucky Medicaid between January 1, 2014 and December 
31, 2019. Within OHDA, this data was linked to data from the birth certificate. This period 
was chosen because data sharing between OHDA and OVS dates to birth certificate records 
in 2014 and continues to the present. To maintain deidentification of the linkages between 
the Medicaid data and the OVS data, data linkage was provided and reviewed by OHDA. 
Furthermore, Kentucky Medicaid data has a 6-month lag between the filing of the 
claim and the appearance and distribution from the database. The data was obtained in the 
form of an annual summary; to allow for an entire year to pass in a child’s life, the youngest 
children in this study were born in 2019. Furthermore, because the data required a full year 
of annual summaries, the data was current to the first run of the data, which occurred in 
October and November 2020 and likely does not fully account for all children born in 2019. 
Indeed, in a refresh of the data that was obtained in May of 2021, an additional 257 children 
appeared in this secondary dataset. These 257 children are not accounted for in the analyses 
within this study. 
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An initial discussion surrounding the dissertation data occurred with OHDA in 
February 2020. The acquisition of the data required a completion of a Memorandum of 
Understanding, completed in October 2020. All study protocol were approved by both the 
University of Kentucky (UK) Institutional Review Board (IRB), protocol number 58851, 
and by the CHFS IRB, letter dated June 30, 2020. To safeguard against the potential of 
data being re-identified, and per the terms required within the Memorandum of 
Understanding, cell values less than 10 were suppressed. 
Data processing by OHDA occurs in iterative steps with safeguards in place at each 
level to ensure data quality and accuracy. First, a project manager within OHDA assigns 
an analyst to the data pull; the analyst then communicates with the requestor to clarify 
confusion, express concerns, or suggest changes to the variables being requested. After the 
data pull is completed, the analyst then passes the data off to another analyst for code 
review. Following code review, the data is then passed to the project manager for release 
to the requestor. At each stage, the data analyst documents the processes involved and 
specifics of the data pull. This information is passed along to the requestor in addition to 
the data. The requestor is then tasked with reviewing the data obtained from OHDA for 
accuracy or confusion on variables requested; OHDA relies on communication from the 
requestor and the subject-matter expertise of the requestor to ensure that the data being 
delivered is accurate.  
3.2 Created Database 
The study population consisted of all children born on Kentucky Medicaid between 
January 1, 2014 and December 31, 2019. Children were included in the analysis if they 
were enrolled in Medicaid at the time of their birth. The children were then followed 
forward, and annual summary figures were obtained for each year of life a child remained 
enrolled in the Medicaid system. The children remained in the study population either the 
end of the study period, no longer remaining enrolled, or death resulted in a loss to follow-






The exposure of interest within this work was a diagnosis of NAS at birth. Because 
the data was designed from administrative claims data, a diagnosis of NAS was defined 
using International Classification of Diseases (ICD) diagnosis codes, created and 
classified by the World Health Organization. Of note, the transition from International 
Classification of Diseases, 9th Revision (ICD-9) to International Classification of Diseases, 
10th Revision (ICD-10) occurred in October 2015 in the United States, within the study 
period; as a result, both ICD-9 and ICD-10 codes are utilized throughout this work. 
The way in which an exposure is defined has the potential to alter the findings in any 
statistical work, often through the introduction of misclassification bias into the work itself. 
In most of work surrounding NAS, the definition of NAS used has only included two codes 
to identify the population of interest: in ICD-9, 779.5; in ICD-10, P96.1. This definition of 
NAS has been identified to have high positive predictive value (PPV) in identifying NAS 
and validated by a study in a NICU population at Vanderbilt University.59 779.5 is defined 
under ICD-9 as “Drug withdrawal syndrome in newborn.”99 P96.1 is defined under ICD-
10 as “Neonatal withdrawal symptoms from maternal use of drugs of addiction.”100  
However, a study population by Gangopadhyaya et al. identified an additional code 
within ICD-9 and ICD-10 for identifying neonates prenatally exposed to opioids in utero: 
760.72 and P04.49.100 760.72 is defined under ICD-9 as “Narcotics affecting newborn via 
placenta or breast milk”101. P04.49 is defined under ICD-10 as “Newborn (suspected to be) 
affected by maternal use of other drugs of addiction”.102 
The synonymity of NAS with neonatal opioid withdrawal syndrome (NOWS) is a 
relatively recent phenomenon. The term NAS was first utilized in the literature synthesized 
within the PubMed database in 19741; the term NOWS was first utilized in the literature 
compiled in the PubMed database in 1963.103 Prior to the ambiguity of the Opioid 
Epidemic, NAS could be used to refer to any number of substances, licit and illicit, in utero 
and ex utero, to which a neonate is exposed and subsequently suffers withdrawal from.104  
Within the diagnosis code manuals used by billers in filing administrative claims 
within a clinical setting, both 779.5 and 760.62 and P96.1 and P04.49 have exclusions for 
the other code within the definition in the manual, meaning that the two codes usually are 
not submitted simultaneously (Wendroth, personal communication). However, a biller 
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noted that if the provider denotes both diagnoses, the codes can be submitted together on 
the same claim. (Wendroth, personal communication) Thus, a child identified as in 
withdrawal may carry both diagnoses, but a child prenatally exposed may only carry the 
latter diagnosis. 
The utilization of the NAS code is triggered when the child begins exhibiting 
withdrawal symptoms (Wendroth, personal communication), thus beginning the process of 
documenting Finnegan scoring, initiated by a clinician, most usually a neonatal intensive 
care unit (NICU) nurse, and the application of non-pharmacological treatment 
interventions to ease the infant through the withdrawal. Otherwise, if the infant is known 
to be exposed to opioids but no withdrawal symptoms are identified or observed, the 
neonate receives the other code. (Wendroth, personal communication) Studies examining 
the effects of NAS on long-term childhood health outcomes are frequently implicitly 
examining whether opioids cause longer term effects on children. To examine the studies 
focusing solely on the 779.5/P96.1 coded infants (or the infants with NAS) leaves a 
population of children with similar exposure in the comparator group (infants with 
exposure), when not explicitly excluded from the study population. 
However, these exposed infants did not experience withdrawal in the same manner 
that the NAS infants. The literature suggests that neonates undergoing withdrawal have 
more frequently experienced greater concentration of opioid exposure64 and were more 
likely to be exposed during the later trimesters63, which is a critical period of rapid fetal 
development.29,105 Thus, based on claims made previously in the literature, the exposure 
experience in the infants with NAS likely varies from the exposure experience in the infants 
with exposure. 
Because of the co-existence of these codes, an opportunity arises to examine 
whether long-term effect impact these two groups differently and create a more unexposed 
referent group for comparison. It is worth noting that several other codes, such as 760.75 
in ICD-9106 and P04.41 in ICD-10 for cocaine exposure107, exist in the codex. Polydrug use 
is also a known common occurrence for people who use substances of abuse.108 Several of 
these infants with other codes remain within the comparator population and represent a 




3.2.1.1 Iatrogenic Withdrawal 
ICD-10 contributed P96.2 to the classification system, defined as “Withdrawal 
symptoms from therapeutic use of drugs in newborn”.109 This code is used to explicitly 
identify infants undergoing iatrogenic withdrawal. No such equivalent exists in ICD-9, as 
noted by Maalouf et al.59 In the ICD-9 system, 779.5 was also used to identify infants 
undergoing withdrawal due to ex utero exposure to substances for treatment of medical 
conditions.59 However, rates of iatrogenic withdrawal appear low, with a study by Maalouf 
et al. only identifying 1.2% of NAS codes as iatrogenic withdrawal in a chart review 
conducted at Vanderbilt University.59 Thus, because the rate was assumed to be low, 
additional attempts at identifying these children were not taken and are considered an 
additional limitation to the methodology in these studies. 
 
3.2.2 Additional Variables 
Additional variables obtained for analysis from the Medicaid MMIS system 
included demographic information for the child, summary information on healthcare 
utilization, and select diagnoses of interest. Summary information on the created dataset 
can be found in the Appendix (Appendix 1). Demographic information (sex at birth, race, 
county at the beginning of the year, county at the end of the year, etc.) were obtained from 
the child’s enrollment record.  
Currently, race is not a required field to be reported for enrollment in Kentucky 
Medicaid. OHDA categorizes the population within Kentucky Medicaid into three 
categories: White, Black, and Other. Persons who self-identified, or, in the case of children, 
were identified by a caretaker on their enrollment into Kentucky Medicaid as White were 
included in the White category while persons who self-identified in enrollment as Black 
were categorized as Black. All other races, including observations in which no race was 
reported, was included as Other. This means the Other category contains populations of 
Pacific Islander descent, Asian descent, Native American descent, and Alaskan native 
descent. Additionally, because the population of individuals for whom race is a missing 
category is including in the Other category, some misclassification could be occurring 
because of this categorization, though the capacity to explore such a misclassification is 
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not currently possible given the current inability of Kentucky to mandate the reporting of 
race on the enrollment form. 
A child’s county location was then matched to the associated Rural-Urban 
Continuum code (RUC code) as determined by the USDA in 2013; these codes assisted in 
identifying whether children resided in metro (RUC codes 1 through 3) or non-metro (RUC 
codes 4 through 9) areas of Kentucky.110 The information on county residence was also 
used to create an Appalachian identifier for the children, using the counties identified as 
Appalachian by the Appalachian Regional Commission.111 Information on the RUC code 
as noted by the USDA and a listing of counties identified as Appalachian can be found in 
the Appendix (Appendix 2 and Appendix 3). Appalachian status was particularly identified 
within the context of the analysis given the impact the condition has had on the region in 
recent years, especially within rural Appalachia.112 
Information on healthcare utilization was derived across all the claims databases 
(inpatient, outpatient, pharmacy, etc.) and summarized for each child within the respective 
category. Respiratory, gastrointestinal, and mental health diagnoses were also investigated 
within this dissertation. Diagnoses were also pulled from across the administrative claims 
databases and summarized into two forms: one, a dichotomous indicator variable for each 
child indicating whether that child had received a diagnosis in the category; and two, a 
separate dataset for each category of diagnoses (respiratory, gastrointestinal, and mental 
health) with the child’s unique identifier, each diagnosis code associated with the unique 
identifier, and a dichotomous indicator variable for the age at which each child was 
diagnosed. Mental health variables were identified using the ICD-9 codes identified by 
both Sherman et al.78 and Conner et al.79 Respiratory and gastrointestinal diagnoses were 
identified using the codes from the Healthcare Costs and Utilization Project (HCUP) 
Clinical Classifications Software Refined (CCSR) code lists.113 The categories identified 
by CCSR were also utilized within analyses.113 
Variables obtained from OVS through OHDA included gestational age, maternal 
smoking status, the number of prenatal visits, infant Hepatitis C status, maternal gestational 
diabetes status, and maternal gestational hypertension status. Additionally, information 
from vital statistics was used to link infants to their mothers and additional siblings, 
allowing the investigation of other family members (mother and siblings) on Medicaid 
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from 2014 forward, as well as other siblings (from 2014 forward) that were diagnosed with 
one of the prenatal exposure or NAS codes used within this study. Siblings were not linked 
within this analysis, nor were mothers included for analysis; utilization of these two dyads 
represents a future direction for investigation. 
Many of the variables obtained within the study were obtained in a cross-sectional 
manner, as many of the outcomes of interest within the chapters needed preliminary 
exploratory analyses prior to larger works being conducted. Some variables, however, were 
obtained longitudinally, including the annual summary of healthcare utilization as well as 
the foster care indicator. Variables obtained longitudinally permit investigation into 
changes over time; for healthcare utilization, this is necessary to identify clear patterns in 
healthcare utilization differences between the exposure groups. 
Foster care status was also obtained as a longitudinal variable. Foster care was 
intended by the Adoption and Safe Families Act to be a temporary status for children; as 
such, the law dictates that when a child spends 15 of 22 months out of the custody of the 
parent in foster care, a termination of parental rights occurs.114 Thus, foster care status was 
designed to have a “ticking clock” associated with the status; children spending extended 
time in foster care may be representing children who were not adopted or children entering 
and exiting the foster care system.114 Foster care involvement has been identified as an 
ACE115 and source of trauma in a child’s life and foster care involvement has been shown 
to be associated with several adverse health outcomes, such as hypertension and asthma.116 
Additionally, it is important to the children within this analysis are largely children younger 
than the age at which school and education becomes a factor in a child’s life; teachers are 
one of the most important mandatory reporters of childhood abuse and neglect117, and 
Kentucky is known to have a high report rate to the Department of Community-Based 
Services (DCBS)118, which, in Kentucky, is charged with investigating all reports of child 
maltreatment.119 Therefore, in this age group, much of the abuse and neglect may not be 
identified because children at this age have limited contact with mandatory reporters. 
Outcomes of interest for each chapter are explained in greater detail in each chapter 
of this dissertation. All statistical analytics were conducted using SAS v9.4. Geospatial 
information system (GIS) analyses were conducted using ArcGIS with shape files of 
Kentucky county boundaries obtained from the Kentucky GIS server, KyGeoNet.120 An 
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alpha threshold of 0.05 was utilized; a p-value less than 0.05 indicated a statistically 
significant result. 
3.3 Demographics 
A total of 192,379 children born on Kentucky Medicaid were available for analysis 
within this dissertation. Demographics for the entire study population were assessed using 
frequency analyses and measures of central tendency. Statistically significant differences 
among these strata were identified using chi-square analyses for ordinal variables and 
ANOVA analytics for continuous variables. 
Table 3.1 presents demographic information for the entire study population stratified 
by opioid-related diagnoses. Between 2014 and 2019, 8,232 children (4.28%) were 
diagnosed with NAS while 5,854 children were diagnosed with prenatal opioid exposure 
(3.04%). Around 2016, after the ICD-10 code switch occurred in October 2015, the 
percentage of children diagnosed with the prenatal exposure code jumped from 1 to 2% in 
2014 and 2015 to approximately 4% in 2016 through 2018. An exception to this occurred 
in 2019 when the percentage fell to 2.61% of children receiving an opioid exposure 
diagnosis code; however, it is also worth noting that the number of children diagnosed with 
NAS also fell that same year to 3.69%. 
Annually, approximately 31,000 children were born on Kentucky Medicaid each 
year between 2014 and 2019 (lowest: 31,083 in 2019; highest: 32,956 in 2015). The overall 
population of Medicaid children are majority male (51.27%), majority White (65.87%), 
largely located in a metropolitan area of the state (53.79%), and largely non-Appalachian 
region of the state (69.06%). 
A choropleth map of the raw number of children residing in each county in Kentucky 
at birth over the five-year period is available in Figure 3.1. This map was generated using 
ArcGIS and Arc Map 10.8. Delineation of the categories in the color gradient were 
ascertained using Jenks’ natural breaks. For comparison, a map of the 2010 population 
estimates for Kentucky by county is available in Appendix 4. Of note, many regions of the 
state that, in the 2010 population estimates, do not have large concentrations of the overall 
population of Kentucky, such as areas in the eastern and southeastern portions of the state 
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near the Tennessee and Virginia border, do have large numbers of children born on 
Kentucky Medicaid in those areas.  
One such area is Laurel County, located toward the southern border in the eastern 
portion of the state. In the map in the Appendix, Laurel County is in the same category as 
its neighbor, Pulaski County. In the map in Figure 3.1, however, the concentration of 
children born on Kentucky Medicaid in this county is higher than its neighbor, Pulaski 
County. Laurel County is composed of both London, Kentucky and Corbin, Kentucky; 
Pulaski County’s county seat is Somerset, Kentucky. Though both counties have large 
hospital systems available within them (Lake Cumberland Regional Hospital in 
Somerset121 and CHI Saint Joseph Hospital in London122), the median income for Laurel 
County123 actually exceeds the median income for Pulaski County, Kentucky124, making 
this finding particularly interesting and worth additional examination in future studies. 
Of interest, children with prenatal opioid exposure largely resemble the comparator 
group population demographically. Children diagnosed with NAS, however, have some 
important deviations. The group of children diagnosed with NAS are more White (76.82% 
compared to 66.81% in the opioid exposed group and 65.34% in the comparator group), 
much less Black (2.65% versus 11.26% and 11.95%), were born in more non-metropolitan 
counties (62.03% compared to 42.35% and 45.61%), and more Appalachian (55.93% 
compared to 31.07% and 29.78%). There are several possible explanations for these 
differences. One possible explanation is racial differences in drugs of abuse; another could 
be underdiagnosis of this syndrome in non-White children. 
Figure 3.2 presents a choropleth map of NAS rates across the state across all years, 
based on the number of children within each county during the five-year period, created 
using ArcGIS Arc Map 10.8. These rates were calculated as 
 
𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟 𝑜𝑜𝑜𝑜 𝑁𝑁𝑁𝑁𝑁𝑁 =  
𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑟𝑟𝑟𝑟 𝑜𝑜𝑜𝑜 𝑐𝑐ℎ𝑖𝑖𝑖𝑖𝑖𝑖𝑟𝑟𝑟𝑟𝑛𝑛 𝑤𝑤𝑖𝑖𝑟𝑟ℎ 𝑟𝑟 𝑖𝑖𝑖𝑖𝑟𝑟𝑑𝑑𝑛𝑛𝑜𝑜𝑑𝑑𝑖𝑖𝑑𝑑 𝑜𝑜𝑜𝑜 𝑁𝑁𝑁𝑁𝑁𝑁
𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑟𝑟𝑟𝑟 𝑜𝑜𝑜𝑜 𝑛𝑛𝑛𝑛𝑖𝑖𝑢𝑢𝑛𝑛𝑟𝑟 𝑐𝑐ℎ𝑖𝑖𝑖𝑖𝑖𝑖𝑟𝑟𝑟𝑟𝑛𝑛 𝑛𝑛𝑜𝑜𝑟𝑟𝑛𝑛 𝑤𝑤𝑖𝑖𝑟𝑟ℎ𝑖𝑖𝑛𝑛 𝑟𝑟ℎ𝑟𝑟𝑟𝑟 𝑐𝑐𝑜𝑜𝑛𝑛𝑛𝑛𝑟𝑟𝑐𝑐
× 1,000 
 
For instance, in Jefferson County, a total of 32,704 children from 2014 to 2019 were born 
residents of that county; among those children, a total of 796 children were diagnosed with 
NAS, creating a rate of NAS for 2014 to 2019 within that county of 24.34 in every 1,000 
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births. The delineations between the categories were determined using Jenks’ natural 
breaks. 
NAS rates in Kentucky for this five-year period ranged from 0 in every 1,000 births 
(Livingston County and Lyon County both had 0 NAS births from 2014 to 2019) to 150.55 
in every 1,000 births (the rate in Clay County, Kentucky). As shown in the figure, rates of 
diagnoses of NAS were high in the state in the southeastern portion of the state, or near the 
Tennessee and Virginia borders. The western portion of the state saw the lowest rates of 
NAS within the Kentucky Medicaid population. 
Statistically significant clusters of these rates of NAS were confirmed by the Getis-
Ord Gi* hotspot analysis shown in Figure 3.3. The cluster identified a statistically 
significant hotspot of NAS at the Virginia border, stretching up into the more centralized 
eastern portions of the states. Statistically significant cold spots were shown in the western 
portions of the state. Also of interest, in Figure 3.3, neither of Kentucky’s two largest 
counties, Jefferson or Fayette Counties, were identified as either a cold spot or a hot spot 
for rates of NAS during this time. Also interesting is that the area surrounding Warren 
County, the Bowling Green metro area and home of Western Kentucky University, was 
also identified as a cold spot in the analysis. Factors related to these low rates of NAS in 
these metropolitan areas are likely related to social determinants of health and sociocultural 
factors in these areas that make the risk of NAS lower in such areas in Kentucky. 
As previously mentioned, the unique placement of CHIP within Medicaid allows 
for high retention rates to the Medicaid system, as shown in Table 3.2. Retention ranged 
from approximately 78.3% for a child’s fifth year of life for the 2014 birth year cohort to 
94.3% for the child’s second year of life for the 2018 birth year cohort. Across all birth 
year cohorts, and consistent with expectation, retention diminished as the child grew older, 
but most children could be identified in the Medicaid database for the duration of the study 
period. 
Continuous enrollment by HEDIS standards125 is shown in Table 3.3. Results in 
this table reinforce that most children are being retained to the Medicaid system at a high 
rate and most children also maintain continuous enrollment within the Medicaid system. 
Combining results between Tables 3.2 and 3.3, in the fifth year of a child’s life (or the age 
up to the child’s sixth birthday), for the 2014 birth year cohort, 24,995 children remained 
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in the dataset; of these children, 22,134 (88.55%) were continuously enrolled for that year 
of their life. These large percentages are consistent across the table. 
Just because a child is born in a certain county does not necessarily mean that the 
child stays in that county for the duration of their childhood. Moving and relocation for the 
Medicaid population during childhood is assessed in Table 3.4. A total of 42,393 moves 
occurred between 2014 and 2019 for the children in the study population with 32,333 ever 
relocating, or 16.81% of children in the study population. Extrapolating, that means 10,060 
relocations during this period were duplicate (multiple) relocations of the children to other 
counties; relocations within a county could not be identified by this dataset but may 
represent a future direction for research. As children enter school age, consistency and 
stability become crucial components of ensuring that a child has an optimal environment 
to learn and develop within. Though the data cannot elucidate as to the reason for the 
relocations, a policy recommendation for Medicaid could be additional monitoring and 
managed care engagement for children with multiple relocations to ensure that the child 
has re-established connections with healthcare resources in the new area. 
Maternal and gestational health factors affecting the fetus, as noted from the birth 
certificate, were also available for analysis and are presented in Table 3.5. The data shows 
a wide gap between maternal smoking rates for infants with evidence of in utero opioid 
transfer (i.e., an NAS or opioid exposure diagnosis) compared to the comparator group 
(72.19% and 60.33% compared to 26.02%). Interestingly, rates of maternal hypertension 
and maternal diabetes were lower for the opioid transfer groups than the comparator group. 
This could be due, in part, to the lower number of prenatal visits for the in utero opioid 
transfer groups compared to the comparator group (mean of 9.02 and 9.54 compared to 
11.62), as missing input and an input of unknown were also slightly higher for these groups.  
However, these findings are consistent with recent work showing lower rates of infants 
with NAS among women with diabetes.126 A finding of concern is the number of infants 
noted as having been exposed to hepatitis C  during gestation; among infants with an NAS 
diagnosis, 27.58% were identified as exposed to hepatitis C while 14.18% of infants with 
an opioid exposure diagnosis were identified as exposed to hepatitis C compared to 1.51% 
of the comparator group. As hepatitis C can be transferred through the placenta and has a 
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long latency period, this is an alarming finding that merits further investigation in future 
analyses. 
Gestational age, within the dataset, also presented a challenge. The means and 
medians presented in Table 3.5 are the untransformed gestational ages available from the 
dataset. OHDA censored gestational age greater than 47 weeks but conducted no censoring 
at the bottom of the data. According to the literature, a fetus is considered viable once the 
fetus reaches between 22-25 weeks gestation127; however, survival of neonates born prior 
to this period of viability has been reported, though probability of survival is low.128 In a 
study out of Canada on outcomes related to the use of methadone as a medication for opioid 
use disorder (MOUD) during pregnancy, the authors censored neonates noted as having a 
gestational age less than 23 weeks.129 Additionally, a meta-analysis on survival after 
resuscitation and intensive care of infants born at 22 weeks was conducted by an author 
team in the United States, finding a pooled survival rate of 29% for this group of 
neonates.130 
Approximately 21 children had a gestational age coded as less than 23 weeks in the 
dataset obtained from OHDA (0.01% of children in the dataset). The method used by the 
authors in Canada129 was utilized to bottom censor the data, with neonates coded as having 
a gestational age of 22 weeks or less recoded as missing data due to the low probability of 
survival prior to this period and inability to verify if the data is factual or erroneous. The 
pre-censored measures of central tendency and censored measures of central tendency are 
available in Table 3.6. After censoring, the values did not change significantly.  
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Table 3.1  Demographics of the population of infants born on Kentucky Medicaid 



































































































































4,604 (55.93%) 1,819 (31.07%) 53,097 (29.78%) 59,520 (30.94%) <0.0001 
*A diagnosis of NAS was determined using ICD-9 code 779.5 and ICD-10 code P96.1. Prenatal opioid exposure 
diagnoses were determined using ICD-9 code 760.72 and ICD-10 code P04.49. 
**Birth year cohort was determined based on the year of the date of birth of the infant. Sex at birth was extracted from 
the Medicaid enrollment data in the first year of life. Race was extracted from the Medicaid enrollment data. RUC 
codes were determined based on the county from the address the infant used to enroll in Medicaid at birth, linked to a 
driver containing the 2013 RUC codes as determined by the USDA; a list of Kentucky counties with their associated 
RUC code can be found in the Appendix. Appalachian status at birth was determined based on the list of 54 
Appalachian counties identified by the Appalachian regional commission; a list of the counties considered Appalachian 





Table 3.2  Overall retention, continuous enrollment not considered, within the Kentucky 
Medicaid system for the population of infants born on Kentucky Medicaid between 2014 





2015 2016 2017 2018 2019 Total 
Population 
Birth to 1 31,940 32,956 32,243 32,329 31,828 31,083 192,379 
1 to 2 30,544 31,678 30,862 30,755 30,013 -- 153,852 
2 to 3 28,799 29,537 28,491 27,724 -- -- 114,551 
3 to 4 27,730 28,108 26,767 -- -- -- 82,605 
4 to 5 26,457 26,466 -- -- -- -- 52,923 
5 to 6 24,995 -- -- -- -- -- 24,996 
Overall 
Retention 
78.26% 80.31% 83.02% 85.76% 94.30% 100% -- 
*Infants were included in a year of life if the infant was enrolled at any time during the year of life. Follow-up 





Table 3.3  Continuously enrolled infants by year of life by HEDIS standards for the 
population of infants born on Kentucky Medicaid between 2014 and 2019 for each year 
























Birth to 1 29,067 30,882 29,933 29,893 29,069 28,165 177,009 
1 to 2 25,646 26,329 25,311 24,265 23,580 -- 125,131 
2 to 3 24,807 25,669 24,097 23,751 -- -- 98,324 
3 to 4 24,203 23,937 23,162 -- -- -- 71,304 
4 to 5 22,724 23,501 -- -- -- -- 45,775 
5 to 6 22,134 -- -- -- -- -- 22,134 
*HEDIS: Healthcare Effectiveness Data and Information Set. HEDIS continuous enrollment standards allow no more 
than a 45-day gap (e.g., 87.6% covered days) in coverage within a given year. Infants meeting this criterion were 




Table 3.4 Frequency of relocation within the state for children born on Kentucky 

























Birth to 1 1,805 1,044 1,398 2,187 2,508 2,199 11,141 
1 to 2 2,724 1,859 2,309 2,837 2,253 -- 11,982 
2 to 3 1,064 1,988 2,449 1,980 -- -- 7,481 
3 to 4 1,900 2,368 1,945 -- -- -- 6,213 
4 to 5 2,117 1,800 -- -- -- -- 3,917 
5 to 6 1,659 -- -- -- -- -- 1,659 
Ever 
Relocated 
7,610 6,589 6,081 5,647 4,207 2,199 32,333 
*Children were considered to have relocated if the county of the enrollment address at the beginning of the year of their 




Table 3.5 Maternal and gestational health characteristics of children born on 
Kentucky Medicaid, 2014 to 2019, stratified by opioid-related diagnosis status. 




















































































































































*A diagnosis of NAS was determined using ICD-9 code 779.5 and ICD-10 code P96.1. Prenatal opioid exposure 
diagnoses were determined using ICD-9 code 760.72 and ICD-10 code P04.49. 
**All maternal and gestational health characteristics were extracted from information available on the infant’s birth 
certificate. Missing variables in categorical analyses were considered as a category. Categorical variables coded with a 
“9” were assumed to be unknown and were counted as different than missing to indicate that the field was populated. 
Missing variables coded as “NULL” were later recoded to be missing. 
***OHDA censored and marked as missing gestational ages greater than 45 weeks. Number of prenatal visits coded as 




Table 3.6 Measures of central tendency for gestational age in the population of 
children born on Kentucky Medicaid between 2014 to 2019, before and after 
censoring of the variable, stratified by opioid exposure status. 
NO CENSORING 
 Mean Median Stan. 
Dev. 
Minimum Maximum P-Value 




38.14 39 2.26 23 43 
Comparator 38.63 39 1.74 9 47 
Total 
Population** 
38.60 39 1.76 9 47 
AFTER CENSORING 
 Mean Median Stan. 
Dev. 
Minimum Maximum P-Value 




38.14 39 2.26 23 43 
Comparator 38.63 39 1.73 23 47 
Total 
Population*** 
38.61 39 1.75 23 47 
*A diagnosis of NAS was determined using ICD-9 code 779.5 and ICD-10 code 
P96.1. Prenatal opioid exposure diagnoses were determined using ICD-9 code 760.72 
and ICD-10 code P04.49. Censoring of the gestational age variable required 
censoring cells with gestational age input as 22 weeks or less. 
**A total of 16,004 observations (8.32% of the entire population) were missing. Among children with NAS, 10.31% 
were missing; among children with a diagnosis of prenatal opioid exposure, 8.27% were missing; and among the 
comparator group, 8.23% were missing. 
***A total of 16,025 observations (8.33% of the entire population) were missing. Among children with NAS, 10.31% 
were missing; among children with a diagnosis of prenatal opioid exposure, 8.27% were missing; and among the 







Figure 3.1 Distribution of the children born on Kentucky Medicaid between 2014 







Figure 3.2 Rates of neonatal abstinence syndrome among children born on 





Figure 3.3 Getis-Ord Gi* hotspot analysis of rates of neonatal abstinence syndrome 




CHAPTER 4. SOCIO-EMOTIONAL DEVELOPMENT:  OTHER FAMILY MEMBERS ON MEDICAID 
AND ENROLLMENT ADDRESS IN NEONATAL ABSTINENCE SYNDROME 
4.1 Background 
The importance of the role a child’s family and home environment plays in a child’s 
life cannot be understated.131 These elements of a child’s life become the cornerstone of a 
child’s developmental trajectory, with exposure to these environments becoming the first 
relationships a child ever builds.29,131,132 Children emerge into the world as completely 
dependent creatures; they cannot identify or serve their own needs for the duration of a 
critical period of learning and adapting in early life29,131. The efficacy of the family in 
serving the child’s physical, mental, and emotional wellness become paramount in that 
child maintaining optimal physical health, mental health, and emotional health for the rest 
of their life.131 
When a child is neglected in any one of these areas in these vital periods of life, the 
child faces a significant obstacle in their early development. As such, many adverse 
childhood experiences (ACEs) are associated with the family life of a child.115,133 ACEs 
have known adverse health outcomes.133 While these early experiences do not decide a 
child’s future, they alter the trajectory of that future and place barriers in a child’s pathway 
toward wellness. At the extreme end of ACEs, foster care involvement becomes 
inevitable.115,133 Involvement in the foster care system itself has been identified as an ACE 
and a significant source of trauma, as well as associated with adverse health outcomes, 
both physical and mental, later in a child’s life.115,116 
Current evidence, however, is adamant that children tend to thrive when the 
connection with their mother can be maintained in the hours following birth.134 Even in the 
presence of a suboptimal developmental environment, when a child and their mother can 
bond and connect, the child’s developmental trajectory is different than when such 
connections are not possible.132,134 Children of mothers with substance use disorder, 
however, have a significant disadvantage in this instance. Anecdotal evidence of substance 
use disorders speaks to the consuming nature of the disorder135–139; though a mother could 
be physically present in a child’s life, the mother is not necessarily mentally or emotionally 
present with the child, creating an area of neglect in the child’s development that the child 
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will be tasked with overcoming later in life if the child wants to establish thriving 
relationships with their peers.140 
The family lives of children with NAS have not been well studied. Thus, the purpose 
of this chapter is to examine family life factors associated with NAS, including other family 
members on Medicaid, other siblings with NAS, the household where a child received mail 
among children with NAS, and involvement with the foster care system. 
4.2 Methods 
The entire study population identified in Chapter Three was utilized in the analysis 
to obtain information regarding the families and family life of children with NAS. The 
entire study population was used in this instance due to the nature of the outcomes 
analyzed. Much of the source of the outcomes assessed stemmed from information 
available in the enrollment data available within the Kentucky Medicaid administrative 
claims database and the cross-sectional nature of many of the outcomes, as discussed 
further below. This information was largely considered consistent for the entire annual 
period, regardless of continuous enrollment status for that child. 
Dichotomous, cross-sectional indicator variables available for analysis included 
whether the child ever had a sibling in the Medicaid system, whether a sibling was also 
diagnosed with either NAS or opioid exposure, maternal Medicaid status, and whether the 
child was enrolled in Medicaid at the same address as the mother (assumed to reflect the 
household location of the child). A longitudinal, dichotomous indicator variable reflecting 
foster care status within the year of child’s life was also available for analysis; if the child 
entered the foster care system at any point during that year of life, the variable identified 
such a switch occurred. 
Frequency analyses were conducted to identify differences among the strata, with chi 
square analyses being utilized to identify statistically significant differences among the 




4.2.1 Statistical Analyses 
Following the ascertainment of the frequencies of family characteristics, a logistic 
regression analysis was conducted among the population of children with a mother enrolled 
on Medicaid to ascertain the likelihood of a child being enrolled at the same household 
location as the mother based on opioid exposure status. Because children with foster care 
involvement are inherently placed outside parental custody, these children were excluded 
from the logistic regression analysis. 
A directed acyclic graph (DAG) was designed using DAGitty v.3.0 to identify factors 
associated with both enrollment status and opioid exposure status. Following the bivariable 
and multivariable logistic regression analysis using the factors and minimal sufficient 
adjustment set identified by the DAG, additional logistic regression models were run post 
hoc using both a fully adjusted model composed of all the variables identified in the DAG 
and backwards selection to optimize variable selection to optimize model fit. Model 
selection criteria utilized the c-statistic, Akaike information criterion, and -2 log likelihood 
statistics to identify optimal model fit. Following the selection of a logistic regression 
model, model assumptions were checked to ensure all assumptions to ensure a valid logistic 
regression analysis were met. All statistical analyses were conducted using SAS v9.4 
(Cary, NC). An α-threshold of 0.05 was utilized; p-values less than 0.05 were considered 
statistically significant. 
4.3 Results 
Demographic information for the study population included in this study are 
provided in Chapter 3. Additionally, linkage of the databases to identify the mother and 
any siblings in the Medicaid claims data was explained in greater detail in Chapter 3. Table 
4.1 provides frequency analyses of family characteristics of the children in the study 
population. Between 89.8% to 91.6% of children on Medicaid have a mother that could be 
identified in the Medicaid database; between 44.3% and 48.7% of children also had a 
sibling that could be identified in the database. Among children with some evidence of 
prenatal opioid transfer, 27.8% of children with NAS and 19.1% of children with prenatal 
opioid exposure have a sibling that also acquired one of these codes at birth. 
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Two findings regarding the child’s association with the mother are worth noting. For 
children with a diagnosis of NAS, only 46.44% were always enrolled in Medicaid at the 
same address as the mother; for children with prenatal opioid exposure, this rises slightly 
to 55.96%. This is largely different than the 72.39% of children enrolled at the same address 
as the mother in the comparator group. 
Table 4.2 and Table 4.3 investigate age at entry into the foster care system for these 
children. Table 4.2 investigates age at entry for children based on birth year cohort. Overall, 
it seems that most children in the analysis involved in foster care during this age period 
become involved prior to their first birthday; this is also consistent with the findings of 
Table 4.3. Of note, however, is that, because of the recency of the data (birth cohorts 2014 
to 2019 with information spanning through 2020) means that many of the children in the 
cohort have not yet aged past early years and thus may not have had time to interact with 
the foster care system, so results should be interpreted with caution. 
 
4.3.1 Logistic Regression Analysis 
 
The study population was then subset to the population of children with a mother 
able to be identified in the MMIS system (91.12% of the children in the dataset). This 
subset occurred because the outcome of interest for these analyses, enrollment at an address 
different than the mother’s, is not possible to ascertain if the mother could not be identified 
in the Medicaid claims data. Additionally, because of the high likelihood that a child in 
foster care will be located outside parental custody and thus enrolled at a different address, 
these children were excluded from this analysis. 
Following the inclusion and exclusion criteria being applied to the population of 
children born on Kentucky Medicaid between 2014 and 2019, a total of 167,384 children 
of the original 192,379 children remained in the study population (i.e., 87.00% of the full 
population). Table 4.4 presents the demographics of this newly created study population, 
stratified by whether a child is enrolled at the same or different address during the study 
period. The children at a different address than the mother were more frequently diagnosed 
with NAS (approximately 7.1% compared to 2.7%) or prenatal opioid exposure 
(approximately 4.2% compared to 2.4%) than the group of children always enrolled at the 
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same address as the mother. Children enrolled at different addresses were also more likely 
to have a sibling with one of the prenatal opioid exposure diagnoses than children located 
at the same household, with 6.8% compared to 2.7% having this characteristic, 
respectively.  
The DAG utilized to identify the minimum sufficient adjustment set is shown in 
Figure 4.1. Code for the DAG is included in the Appendix. Table 4.5 provides logic and 
justification for the inclusion of variables within the DAG, as well as identified proxy 
variables within the model. The minimal sufficient adjustment set identified by the DAG 
included physical location for a child, sex, race, birth year cohort, continued substance use, 
and indicators of poverty. The results in Table 4.6 present the results of a logistic regression 
analysis conducted to ascertain the odds of a child with evidence of in utero opioid transfer 
being enrolled in an address different than the mother using this minimal sufficient 
adjustment set, as well as unadjusted (or bivariable) analyses. The adjusted equation 
modeled by the logistic regression analysis in Table 4.6 was 
 
𝑐𝑐 = −0.68 + 0.39𝑥𝑥1 + 0.10𝑥𝑥2 + 0.41𝑥𝑥3 + 0.32𝑥𝑥4 + 0.14𝑥𝑥5 − 0.01𝑥𝑥6 − 0.26𝑥𝑥7




 x1 is a dichotomous variable indicating whether a child had a diagnosis of NAS, 
 x2 is a dichotomous variable indicating whether a child had a diagnosis of prenatal 
opioid exposure, 
 x3 is a dichotomous variable indicating whether a child was born in 2014, 
 x4 is a dichotomous variable indicating whether a child was born in 2015, 
 x5 is a dichotomous variable indicating whether a child was born in 2016, 
 x6 is a dichotomous variable indicating whether a child was born in 2017, 
 x7 is a dichotomous variable indicating whether a child was born in 2018, 
 x8 is a dichotomous variable indicating whether a child’s race is identified as Black, 
 x9 is a dichotomous variable indicating whether a child’s race is identified as Other, 
 x10 is a dichotomous variable indicating whether a child’s sex at birth was female, 
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 x11 is a dichotomous variable indicating whether a child was born a resident of a 
county identified as Appalachian, 
 x12 is a dichotomous variable indicating whether a child was born a resident of a 
county identified as non-metropolitan, 
 x13 is a dichotomous variable indicating whether a child had a sibling on Medicaid, 
and x14 is a dichotomous variable indicating whether a child had a sibling diagnosed 
with a diagnosis indicating prenatal opioid exposure. 
Odds ratios are ascertained from logistic regression models by exponentiating each 
of the covariates in the model. SAS provides these odds ratios as part of the analytic output 
for the model. 
In the unadjusted analyses, children with a diagnosis of NAS had 2.81 (95% CI: 2.66, 
2.96) times higher odds of being enrolled at a different address than their mother than the 
comparator group; among children with a diagnosis of prenatal opioid exposure, these odds 
remained elevated, at 1.87 (95% CI: 1.77, 2.01) times higher odds than the comparator 
group; following the adjustment, these odds remained inflated, at 2.39 (95% CI: 2.26, 2.53) 
and 1.78 (95% CI: 1.67, 1.91).  
Consistent with the decreasing frequencies shown in Table 4.4, birth year cohort also 
saw decreasing odds of enrollment at a different address as the recency of the birth 
increased in both the unadjusted and adjusted models. Also consistent with the table, in 
both the bivariable and multivariable analyses, having a sibling on Medicaid seemed to be 
protective against enrollment at a different address while having a sibling diagnosed with 
prenatal opioid exposure seemed to have a large effect on enrollment at an address different 
than the mother’s address (bivariable odds 2.64 times higher than not having a sibling 
diagnosed with prenatal opioid exposure and odds in the multivariable analysis 2.17 times 
higher than not having a sibling diagnosed with prenatal opioid exposure, holding all other 
variables constant). 
In the bivariable analyses, sex at birth failed to obtain statistical significance, 
consistent with the lack of statistical significance showing difference between the strata in 
Table 4.4. However, standard procedures in epidemiology regarding evaluating the effect 
of sex on various conditions mandated the variable remaining in the analysis, despite its 
lack of statistical significance. 
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In the bivariable analyses, Appalachian status was statistically significant; in the 
adjusted model, the variable ceased being statistically significant. Additionally, non-
metropolitan status in the adjustment saw a slight shift, moving from 0.90 in the unadjusted 
to 0.87 in the adjusted model. These two facts in tandem provides suggestion that 
collinearity may exist between these two variables and merits additional investigation in 
the assessment of model assumptions. 
Race produced an interesting finding from the analysis, indicating that being enrolled 
in Medicaid as Black was protective against being located at a different address than the 
mother compared to children identified as White (unadjusted odds ratio of 0.94 with 95% 
CI of 0.91 to 0.98; adjusted odds ratio of 0.95 with 95% CI of 0.92 to 0.99). This did not 
hold for children identified as being of an Other race in the analysis, as these children had 
inflated odds compared to children identified as White (unadjusted odds ratio of 1.15 with 
95% CI of 1.12 to 1.19; adjusted odds ratio of 1.21 with 95% of 1.17 to 1.25). 
 
4.3.2 Model Fit Assessment and Assumptions 
To ensure adequate modeling of the exposure and outcome in this analysis, model fit 
statistics were considered to identify an optimal model for the assessment of the total effect 
of prenatal opioid exposure on enrollment at a different address than the mother. The model 
given in Table 4.6 had a c-statistic of 0.62. The c-statistic for a logistic regression model is 
equivalent to the area under of the curve of a ROC model, which models the predictive 
quality of a data; these areas range from 0 to 1.141 In general, models are considered 
reasonable fits for data if the c-statistic is greater than or equal to 0.7; a model is strongly 
predictive if the c-statistic is 0.8 or higher.142 The c-statistic for the model given in Table 
4.6 indicates a model that is acceptable, but shows significant room for improvement. Thus, 
an attempt was made to optimize the model fit of the data. Because the DAG was selected 
using human assumptions of relationships between variables, it is possible that a better 
model exists to explain the data over all; backwards selection allows SAS to select 
prespecified variables based on statistical significance until a reasonably parsimonious 
model is created. 
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Table 4.7 presents the results of post hoc analyses conducted to optimize model fit. 
In the first model, every variable identified by the DAG, regardless of its identification as 
part of the minimal sufficient adjustment set, was included in the analysis; this model was 
referred to as the “Fully Adjusted” model and is given by the equation, 
 
𝑐𝑐 = 1.71 + 0.39𝑥𝑥1 + 0.08𝑥𝑥2 + 0.41𝑥𝑥3 + 0.32𝑥𝑥4 + 0.14𝑥𝑥5 − 0.01𝑥𝑥6 − 0.26𝑥𝑥7 − 0.10𝑥𝑥8
+ 0.14𝑥𝑥9 − 0.01𝑥𝑥10 − 0.01𝑥𝑥11 − 0.07𝑥𝑥12 − 0.07𝑥𝑥13 + 0.39𝑥𝑥14
− 0.06𝑥𝑥15 + 𝜖𝜖 
 
where, 
 x1 is a dichotomous variable indicating whether a child had a diagnosis of NAS, 
 x2 is a dichotomous variable indicating whether a child had a diagnosis of prenatal 
opioid exposure, 
 x3 is a dichotomous variable indicating whether a child was born in 2014, 
 x4 is a dichotomous variable indicating whether a child was born in 2015, 
 x5 is a dichotomous variable indicating whether a child was born in 2016, 
 x6 is a dichotomous variable indicating whether a child was born in 2017, 
 x7 is a dichotomous variable indicating whether a child was born in 2018, 
 x8 is a dichotomous variable indicating whether a child’s race is identified as Black, 
 x9 is a dichotomous variable indicating whether a child’s race is identified as Other, 
 x10 is a dichotomous variable indicating whether a child’s sex at birth was female, 
 x11 is a dichotomous variable indicating whether a child was born a resident of a 
county identified as Appalachian, 
 x12 is a dichotomous variable indicating whether a child was born a resident of a 
county identified as non-metropolitan, 
 x13 is a dichotomous variable indicating whether a child had a sibling on Medicaid, 
  x14 is a dichotomous variable indicating whether a child had a sibling diagnosed 
with a diagnosis indicating prenatal opioid exposure, 




Additionally, backward selection was applied to this fully adjusted model, resulting 
in a model given by the equation, 
 
𝑐𝑐 = 1.71 + 0.39𝑥𝑥1 + 0.08𝑥𝑥2 + 0.41𝑥𝑥3 + 0.32𝑥𝑥4 + 0.14𝑥𝑥5 − 0.01𝑥𝑥6 − 0.26𝑥𝑥7 − 0.10𝑥𝑥8
+ 0.14𝑥𝑥9 − 0.07𝑥𝑥10 − 0.07𝑥𝑥11 + 0.39𝑥𝑥12 − 0.06𝑥𝑥13 + 𝜖𝜖 
 
where, 
 x1 is a dichotomous variable indicating whether a child had a diagnosis of NAS, 
 x2 is a dichotomous variable indicating whether a child had a diagnosis of prenatal 
opioid exposure, 
 x3 is a dichotomous variable indicating whether a child was born in 2014, 
 x4 is a dichotomous variable indicating whether a child was born in 2015, 
 x5 is a dichotomous variable indicating whether a child was born in 2016, 
 x6 is a dichotomous variable indicating whether a child was born in 2017, 
 x7 is a dichotomous variable indicating whether a child was born in 2018, 
 x8 is a dichotomous variable indicating whether a child’s race is identified as Black, 
 x9 is a dichotomous variable indicating whether a child’s race is identified as Other, 
 x10 is a dichotomous variable indicating whether a child was born a resident of a 
county identified as non-metropolitan, 
 x11 is a dichotomous variable indicating whether a child had a sibling on Medicaid, 
  x12 is a dichotomous variable indicating whether a child had a sibling diagnosed 
with a diagnosis indicating prenatal opioid exposure, 
and x13 is a continuous variable for each additional week of added gestational age for 
a child. 
This model was referred to as the “Backward Selected Model.” Backwards selection 
removed both sex and Appalachian status from the model. For the most part, results 
between the fully adjusted and adjusted model were largely consistent, with the only 
significant alteration occurring in the non-metropolitan status following the removal of 
Appalachian status from the model (odds ratio of 0.87 in the fully adjusted model and 0.86 
in the backward selected model). 
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The c-statistic for both the fully adjusted model and the backward selected model 
was 0.63, indicating slight improvement in model fit. Considering other model fit statistics, 
the AIC for the adjusted model in Table 4.6 was 160,544.09; for the fully adjusted model, 
the AIC was 159,886.39; and for the backward selected model, the AIC was 159,885.21. 
In general, when selecting an optimal model, smaller AIC indicates better fit143, and thus, 
based on the AIC criterion, the backward selected model is the more optimal model for the 
data. Contrastingly, considering -2 log-likelihood as a model fit statistic, the adjusted 
model had a -2 log-likelihood of 160,514,09; the fully adjusted model had a -2 log-
likelihood of 165,444.44; and the backward selected model had a -2 log-likelihood statistic 
of 159,857.21. For -2 log-likelihood, in contrast to the AIC, higher values indicate more 
optimal model fits, and thus the -2 log-likelihood statistic indicated the fully adjusted 
model as the optimal model fit. Most importantly, however, none of the model fit statistics 
identified the model adjusted using the minimal sufficient adjustment set from the DAG as 
the optimal dataset. 
The results in Table 4.8 show the c-statistics from the bivariable analyses for each of 
the variables in the study to show the relative strength of each variable in predicting 
whether a child would enroll at an address different than the mother. Overall, the variables 
had c-statistics around 0.5, indicating that the variables were quite neutral individually in 
predicting; none were strong predictors of such an outcome on their own. The “strongest” 
of the variables seemed to be birth year cohort, with a bivariable c-statistic of 0.59; the 
second “strongest” variable was prenatal opioid exposure, with a bivariable c-statistic of 
0.53. 
Model assumptions were also considered to identify the optimal model for the 
association between prenatal opioid exposure and enrollment at an address different than 
the mother’s address. Model assumptions for a logistic regression analysis require that the 
outcome variable be ordinal, observations be independent, lack multicollinearity, the log 
odds be linear, and a large sample size is obtained for analysis.144,145  
First, multicollinearity was considered, as previous analyses indicated that two of the 
models (the adjusted and fully adjusted models) may violate this assumption. Usually, a 
chi-square analysis is sufficient to ascertain multicollinearity between variables in models. 
However, the ability to detect statistical significance is largely dependent upon the 
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statistical power of a model146; in the case of big data analytics, as are utilized within the 
dissertation, analyses may be overpowered to detect significant differences and thus result 
in analyses very sensitive to slight changes; indeed, a chi-square analysis between 
Appalachian status and non-metropolitan status provided a p-value of <0.0001, indicating 
that Appalachian status and non-metropolitan status were likely associated with one 
another. This was deemed to be insufficient evidence, and a bivariable logistic regression 
analysis was conducted, utilizing metropolitan status as the outcome of interest and 
Appalachian status as the exposure of interest. Results from this analysis provided an odds 
ratio of 0.03 with a very narrow 95% confidence interval. This indicates a relatively strong 
inverse correlation between Appalachian status and metropolitan status: the more likely an 
observation is to the Appalachian, the less likely the observation is to be in a metropolitan 
area. This is confirmed by the maps of the counties identified as metropolitan and 
Appalachian available in the Appendix; there are very few, if any, overlaps between these 
counties.  
Based on the findings in Chapter 3, we also know that prenatal opioid exposure status 
is also associated with several of the variables in the study, which may suggest that 
multicollinearity is a problem in the model. One variable that is likely very associated with 
prenatal opioid exposure status is the variable indicating whether a child had a sibling with 
NAS. The logistic regression model may be violating this assumption because of these 
associations between variables. There is no sufficient fix for this violation as prenatal 
opioid exposure is the effect of interest in the model. Thus, to best safeguard against 
multicollinearity, the backwards selected model was determined to be the final model for 
the remaining investigations into model assumptions. 
Most variables included in the model are ordinal variables as opposed to continuous 
variables, and thus do not likely contribute significant outliers that influence the model. 
The notable exception to this is gestational age. With gestational age, in chapter 3, the 
censoring that took place by both OHDA and during the methodological overview are 
likely preventing significant outliers from influencing the data. A histogram of gestational 
age for the study population can be found in Appendix 6. For the most part, while the data 
is not perfectly normally distributed, the data is largely consistent with the overall 
distribution that would be expected of a normally distributed variable, with a significant 
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amount of clustering occurring around 38 weeks and with tails on both ends. Below 30 
weeks gestational age, observations are rare, only contributing a small percentage of the 
overall distribution. Above 42 weeks, observations are also rare. As noted in Chapter 3, 
OHDA censored data at the top at 47 weeks gestational age. Also noted in Chapter 3 was 
the bottom censoring that occurred as part of the overall study methodology, censoring 
observations less than 23 weeks.  
To check for linearity in the logit, gestational age was considered as a categorical 
variable in a bivariable analysis and odds were ascertained to ensure that increasing 
gestational age continued decreasing the odds of enrolling at a different address than the 
mother’s address. The full results of this assessment can be found in Appendix 7. The 
model does seem to be linear as far as it related to log odds, until the very tail end of the 
data when the weeks exceed 42 gestation and the data heads in the opposite direction of 
the trend of the remainder of the data. This may be due, in part, to small sample sizes rather 
than a violation in the model assumptions. If such a violation does exist in the model, a 
way to safeguard against both significant outliers and nonlinearity in the logit would be to 
categorize gestational age rather than keeping the variable as a continuous variable in the 
analysis, and thus eliminate the need for examination into continuous variables altogether. 
However, categorizing a variable like gestational age could result in the loss of granularity 
of information arising during the analysis. 
4.4 Discussion 
The logistic regression analysis identified that children with prenatal opioid 
transference had 3.6 and 2.5 times the odds of enrolling in Medicaid at an address different 
than the comparator group. This could be a result of several policies. Punitive policies for 
mothers with prenatal opioid exposure could explain the relocation of a child to a different 
household, whether foster care or otherwise, when prenatal exposure is identified. One 
method Kentucky has already begun utilizing to make progress in this area is through plans 
of safe care. Plans of safe care were established within Kentucky were created to assist in 
fostering the development of relationships between family and children following prenatal 
opioid exposure and ensuring a safer home environment for the neonate.147 Additionally, 
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programs such as START exist within Kentucky to create plans to keep families together 
following substance involvement.148 
The data also shows that approximately 91% of children in the study population have 
a mother also covered by Medicaid and a large percentage of children have a sibling that 
is covered by Medicaid. This suggests that there are a significant number of whole families 
that Medicaid is covering simultaneously. Health is symbiotic to the environment in which 
it is being experienced; one shift for a family member can change the trajectory of the entire 
family.149 Thus, any prophylactic measures and additional monitoring Medicaid creates for 
children has the potential to influence the entire family. Medicaid therefore has a 
significant opportunity for influence in the health of families by strategically targeting 
interventions toward the children covered by Medicaid. 
The data suggested that there seems to be a birth cohort effect among the children in 
this analysis, as the frequency of a child being enrolled at a different address decreased as 
the birth year cohorts became more recent. This birth cohort effect could be occurring for 
many reasons. One reason, and likely a large contributor to this effect, is that children born 
earlier have more time to be enrolled at a different address than their mothers, thus 
increasing the likelihood of such an event occurring; another reason, and likely a more 
minor contributor, could be increased efforts by social and child protective services to keep 
families together whenever possible.150 
The consensus among child development literature is that, when safe and 
appropriate, the optimal environment for child development occurs when a child can 
remain with their family.151,152 The relationship between a child and parent is critical to 
ensuring the child develops healthy relationships later in life; this relationship, as one of 
the earliest relationships formed by the infant, sets the stage for attachment for the child 
throughout their life.29,131,132 In instances where healthy, secure attachment with the parent, 
and in particular the mother, can be fostered, the infant is shown to have improved 
outcomes across several sectors of development.131 
 However, it is not always safe for an infant to maintain this connection; the best 
option for a child may be extraction and separation for a period until it can be determined 
that it is safe for the child to return to the custody of the parent. First, in these instances, 
best practice requires investigation to see if there is another family member or close family 
65 
 
friend that could raise the child temporarily until parental custody can be safely 
reinstated151; if such a relation cannot be found, or it is determined that the best course of 
action for the child is complete removal and relocation, then the child enters the foster care 
system152, at which time, under the Adoption and Safe Families Act, a clock for the 
complete revocation of parental rights to the child begins ticking.114 
 Children in the foster care system in Kentucky are covered by the Medicaid 
system153 until the child ages out of foster care, can return to the parent, or is adopted 
following the termination of parental rights to the child. Children with foster care 
involvement face unique challenges compared to their peers, and involvement with foster 
care has been shown to be associated with greater risk of mental health conditions, as well 
as other conditions.154 The utilization of antipsychotics in this population has also been 
established as an area for concern.155 
The results of this chapter also indicate that around 19.6% of children with a 
diagnosis of NAS and 15.5% of children with prenatal opioid exposure were ever involved 
in foster care, compared to 3.3% of the comparator group; this large gap indicates that 
foster care is a notable consideration for future analyses regarding this population. This 
indicates that prenatal opioid exposure is a large driver of the overall population increase 
to 4% of children overall. Thus, foster care is an important consideration when analyzing 
children with a history of prenatal opioid exposure, whether the child has experienced 
withdrawal or not. The data also trends toward a stark drop-off in first-time foster care 
involvement following the child’s first birthday. Medicaid, therefore, has a responsibility 
to ensure that these children are obtaining the needed healthcare and preventative visits to 
prophylactically intervene in adverse health outcomes for these children. All children in 
the foster care system have a standard for pediatric care visits established by the American 
Academy of Pediatrics that foster parents should adhere to.156 Children with a diagnosis of 
NAS involved with foster care are also designated as medically fragile157 and have a more 
stringent set of requirements.154 Medicaid bears a responsibility to ensure that children are 
being provided with adequate care and a safe environment for the child to develop in. 
Partnerships with DCBS could be utilized to create targeted interventions for these groups 




4.4.1 Limitations and Future Directions 
It should be noted that, within this analysis, reason for displacement from the 
mother’s household was not explored. Reasons outside foster care and kinship care, 
meaning the care of a child by a relative or family friend known to the child and facilitated 
by child protective services, could be contributing to the child’s displacement from the 
mother’s household address. Indeed, the child could be in primary custody of a father, 
either having always been in the custody of the father from birth or in the custody of the 
father following a divorce. Additionally, the child may be in the care of a grandparent for 
reasons unrelated to substance use159, or the mother could be in a substance use disorder 
treatment program and be unable to bring her child with her to the treatment program, as 
programs that allow mothers to bring children with them remain rare.160 It may also be 
likely that the child and the mother are located within the same household, but one or both 
parties may have not provided a current address to Medicaid, thus creating the appearance 
of a different household when, in truth, the dyad is together. Additionally, one cannot 
discount the possibility of the dyad being homeless161, and the discrepancy in address being 
a result of finding addresses to register so that healthcare could be received. Future research 
should focus on reasons for this discrepancy and the socioemotional developmental impact 
of these specific reasons for displacement. 
Additionally, paternal relationships of children with neonatal abstinence syndrome 
were not explored within this analysis. Older siblings of children with prenatal opioid 
exposure (meaning siblings born before 2014) were not able to be identified in the analysis. 
Currently, OHDA does not house data from OVS prior to 2014; historical information on 
children in the Kentucky Medicaid MMIS database does date back beyond 2014. By 
obtaining information from these two offices separately, it may be feasible to examine 
these historic relationships beyond 2014, though such a linkage would require the 
ascertainment of protected health information, such as social security numbers, to verify 
such a linkage. 
Third, this analysis proved the capability of OHDA to examine dyads, both for 
mother-infant pairs and siblings. The analysis did determine that approximately a quarter 
of children with a diagnosis of NAS have a sibling that was born with a diagnosis indicating 
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prenatal opioid exposure. Such a relationship was not examined within the context of this 
analysis and presents a limitation to this analysis. Little information is available in the 
literature on sibling pairs with a history of NAS. Given the large sample size available for 
analysis, a sibling study with prenatally exposed children compared against an unexposed 
comparator group could be feasible and represents an interesting future direction for 
research. 
Siblings born before 2014 could not be directly identified, as OVS data prior to this 
period was not available, and thus the siblings identified here were siblings born between 
2014 and 2019. It is likely, therefore, that many of the children with siblings have a sibling 
in the study population; however, these siblings were not linked for this analysis. 
Additionally, these findings were extracted from children born on a Medicaid 
program from one state within the United States. It is possible that the findings of these 
analyses may not be generalizable to other populations. 
Finally, it is also worth noting that, within this chapter, many aspects of foster care 
among children with prenatal opioid exposure remained unexplored. Future directions for 
this population could include a time-to-event analysis of entrance and exit from the foster 
care system, additional investigation of the relationship between NAS and foster care, and 
more careful examination of other family members of children with prenatal opioid 
exposure, including investigation into fathers of children with prenatal opioid exposure and 
health characteristics of mothers of children with prenatal opioid exposure and the 
incidence of foster care when such a relationship or connection can be determined. 
Additionally, further investigation into mothers with multiple children born with NAS 




Table 4.1 Cross-sectional frequencies of family characteristics of the children born on 
Kentucky Medicaid between 2014 and 2019, stratified by opioid exposure level. 



















7,393 (89.81%) 5,364 (91.63%) 162,534 (91.16%) 175,291 (91.12%) <0.0001 
Sibling (2014 
to 2019) on 
Medicaid 
3,798 (46.14%) 2,850 (48.68%) 78,892 (44.25%) 85,540 (44.46%) <0.0001 
Sibling (2014 
to 2019) with 
Diagnosed 
Evidence of In 
Utero Opioid 
Transfer 
2,286 (27.77%) 1,118 (19.10%) 3,948 (2.21%) 7,352 (3.81%) <0.0001 
Ever in Foster 
Care 
1,612 (19.58%) 906 (15.48%) 5,808 (3.26%) 8,326 (4.33%) <0.0001 
Enrolled at a 
Different 
Address as the 
Mother 
4,409 (53.56%) 2,578 (44.04%) 49,229 (27.61%) 56,216 (29.22%) <0.0001 
*A diagnosis of NAS was determined using ICD-9 code 779.5 and ICD-10 code P96.1. Prenatal opioid exposure 
diagnoses were determined using ICD-9 code 760.72 and ICD-10 code P04.49. Mother’s Medicaid status was obtained 
by obtaining identifiers for the mother from the infant’s birth certificate and scanning to see if a match ever existed in 
the Medicaid system. Siblings on Medicaid were obtained by using the mother’s identifiers from the infant’s birth 
certificate and looking for other children in the Vital Records data available from 2014 to 2019 with the same mother 
listed. Siblings with diagnosed evidence of in utero opioid transfer were obtained by identifying the siblings in the 
Medicaid data and looking into the administrative claims data for one of the qualifying codes (ICD-9: 779.5 and 
760.72; ICD-10: P96.1 and P04.49). Ever in foster care was a dichotomous variable created to identify any child that 
had ever been in foster care from the longitudinal variable obtained from OHDA identifying if a child had been in 
foster care in each year of life available for analysis. An infant was determined to be enrolled in a different household 
than the mother by first identifying the mother listed on the infant’s birth certificate and then identifying if the infant 




Table 4.2 Age at earliest entry into the foster care system for children born on Kentucky 
























Birth to 1 655 669 749 863 1,021 821 4,778 
1 to 2 260 261 287 337 234 -- 1,379 
2 to 3 234 274 296 191 -- -- 995 
3 to 4 254 242 164 -- -- -- 660 
4 to 5 228 154 -- -- -- -- 382 
5 to 6 132 -- -- -- -- -- 132 





Table 4.3 Age at earliest entry into the foster care system for children born on Kentucky 
Medicaid between 2014 and 2019, stratified by opioid exposure level. 









Birth to 1 1,230 634 2,914 4,778 
1 to 2 156 148 1,075 1,379 
2 to 3 105 64 826 995 
3 to 4 71 43 546 660 
4 to 6*** 50 17 447 514 
*Overall table p-value of <0.0001. 
**A diagnosis of NAS was determined using ICD-9 code 779.5 and ICD-10 code P96.1. Prenatal opioid exposure 
diagnoses were determined using ICD-9 code 760.72 and ICD-10 code P04.49. 
***Cell values less than 10 were required to be suppressed per the Memorandum of Understanding. To minimize 






Table 4.4 Demographics of the population of children born on Kentucky Medicaid 
between 2014 and 2019, not involved with foster care, and with a mother able to be 
identified in the Medicaid data, stratified by different household status. 






































































































38.66 (1.63) 38.43 (2.13) 38.61 (1.74) <0.0001 
Sibling on Medicaid 65,378 (48.41%) 15,072 (45.97%) 80,450 (47.93%) <0.0001 
Sibling with in 
Utero Opioid 
Transfer 
3,653 (2.70%) 2,240 (6.83%) 5,893 (3.51%) <0.0001 
*An infant was determined to be enrolled in a different household than the mother by first identifying the mother listed 
on the infant’s birth certificate and then identifying if the infant was ever enrolled in Medicaid at a different address 
than the address listed in the mother’s enrollment data. A diagnosis of NAS was determined using ICD-9 code 779.5 
and ICD-10 code P96.1. Prenatal opioid exposure diagnoses were determined using ICD-9 code 760.72 and ICD-10 
code P04.49. Siblings on Medicaid were determined by linking children of common mothers through data available 
from the infant’s birth certificate; these figures represent identified siblings from 2014 forward. A sibling with in utero 
opioid transfer was determined based on the identified siblings and then identifying if the sibling had one of the 
prenatal opioid exposure diagnoses (ICD-9: 779.5 and 760.72; ICD-10: P96.1 and P04.49). 
**A t-test was used to test for significant differences. The test for equality of variances yielded a p-value of <0.0001; 
because the variances were determined to be significantly different from one another, the Satterthwaite method of 






Table 4.5 Factors identified by the DAG, proxy variables available within the data, 
and justification for the logistic regression analysis evaluating the association 
between prenatal opioid exposure and being in a different household than the 
mother. 
Identified Factor Proxy Variable Justification 
Physical Location* Appalachian Status; 
Metropolitan Status 
The physical location, or the county in which a 
child resides, has a significant impact on the 
availability of services as well as the culture the 
child is exposed to. Additionally, access to care 
issues are known for Appalachian162 and rural 
areas.163 
Sex* Sex at Birth There may be sex differences in children 
involved with child protective services or 
displaced from families.164 
Abuse** N/A Abuse and neglect are significant factors in the 
involvement of child protective services and 
may be relevant to a child being displaced from 
their parents.165 
Birth Year* Birth Year Cohort The data seems to have a birth cohort effect 
where children born later in the data are less 
likely to be in a different household than their 
mother. This is likely because children born 
earlier have more time to be displaced than 
children born later. Additionally, renewed effort 
has contributed to additional efforts to keep 
families united whenever possible.148 
Race* Race There may be racial differences among children 
who are displaced from their families.166,167 
Continued Substance 
Use* 
Sibling with in Utero 
Opioid Transfer 
Diagnosis 
Having a sibling born with one of the prenatal 
opioid exposure codes indicates continued 
substance use among the parents of children, 
which could lead to displacement and/or child 
protective services involvement.168 
Foster Care Foster Care Children in foster care have been removed from 
parental custody for a period due to the 
environment being created by the parent being 
deemed unsafe for the child. 
Gestational Age Gestational Age Evidence in the literature suggests that infants 
born preterm are more likely to be abused than 
infants carried to term.169 
Poverty* Sibling on Medicaid Poverty is considered an ACE170 and has been 
shown to be a contributing factor to children 
being raised by grandparents or caretakers other 
than the parents.171,172 
*Identified as part of the minimal sufficient adjustment set for estimating the total effect based on the DAG in Figure 
4.1. Code for the DAG can be found in the Appendix. 




Table 4.6 Logistic regression analysis of likelihood that a child born on Kentucky 
Medicaid between 2014 and 2019 was enrolled in Medicaid at a different address than 
their mother. 
 Unadjusted Adjusted* 























































































Gestational Age 0.93 (0.93, 0.94) --- --- 
Sibling on 
Medicaid 
0.91 (0.89, 0.93) 0.85 (0.83, 0.87) 
Sibling with in 
Utero Opioid 
Transfer 
2.64 (2.50, 2.78) 2.17 (2.04, 2.30) 
¶ A diagnosis of NAS was determined using ICD-9 code 779.5 and ICD-10 code P96.1. Prenatal opioid exposure 
diagnoses were determined using ICD-9 code 760.72 and ICD-10 code P04.49. 
*Adjusted for physical location (Appalachian status and metropolitan status), sex at birth, birth year cohort, race, 
continued substance use (sibling with a prenatal opioid exposure diagnosis), and poverty (sibling on Medicaid). 
Referent group for opioid exposure is the comparator group; for birth year cohort, being born in 2019; for race, White; 
for sex at birth, male; for Appalachian status, non-Appalachian; for metropolitan status, metropolitan; for sibling on 
Medicaid, no sibling on Medicaid; for sibling with in utero opioid transfer, no evidence of in utero transfer. Gestational 
age was treated as a continuous variable. All other variables were considered categorical. 
**The c-statistic for the adjusted model is 0.621. The -2 log likelihood for the adjusted model is 160,514.09. The AIC 




Table 4.7 Post hoc sensitivity analyses of logistic regression models of the odds that a 
child born on Kentucky Medicaid between 2014 and 2019 was enrolled in Medicaid 
at a different address than their mother. 
 Fully Adjusted* Backwards Selection** 























































































Gestational Age 0.94 (0.93, 0.95)   
Sibling on 
Medicaid 
0.88 (0.85, 0.90) 0.88 (0.85, 0.90) 
Sibling with in 
Utero Opioid 
Transfer 
2.18 (2.05, 2.32) 2.18 (2.05, 2.32) 




AIC 159,886.39 159,885.21 
*The fully adjusted model accounts for all the factors identified in the DAG in Figure 4.1, regardless of statistical 
significance in the bivariable analyses. 
**Backwards selection identified opioid exposure diagnosis level, birth year cohort, race, metropolitan status, sibling 
on Medicaid, and sibling with in utero opioid transfer as the optimal model fit; Appalachian status and sex at birth were 
eliminated. In other models, sex at birth was kept in the model due to standard epidemiology protocol of keeping sex in 
the model. However, in this selection technique, the variable was removed, as statistical protocol would deem given the 
lack of evidence in Table 4.4 and Table 4.6 of any association between sex at birth and a child enrolling at a different 




Table 4.8 The c-statistics associated with each variable included in the logistic 
regression models of the odds that a child born on Kentucky Medicaid between 2014 
and 2019 was enrolled at a different address than their mother. 
Variable C-Statistic in the Bivariable Analyses 
Opioid Exposure Level 0.53 
Birth Year Cohort 0.59 
Race 0.52 
Sex at Birth 0.50 
Appalachian Status 0.50 
Metro Status 0.51 
Gestational Age 0.52 
Sibling on Medicaid 0.51 
Sibling with in Utero Opioid Transfer 0.52 
*An infant was determined to be enrolled in a different household than the mother by first identifying the mother listed 
on the infant’s birth certificate and then identifying if the infant was ever enrolled in Medicaid at a different address 
than the address listed in the mother’s enrollment data. A diagnosis of NAS was determined using ICD-9 code 779.5 
and ICD-10 code P96.1. Prenatal opioid exposure diagnoses were determined using ICD-9 code 760.72 and ICD-10 
code P04.49. Siblings on Medicaid were determined by linking children of common mothers through data available 
from the infant’s birth certificate; these figures represent identified siblings from 2014 forward. A sibling with in utero 
opioid transfer was determined based on the identified siblings and then identifying if the sibling had one of the 






Figure 4.1 Directed acyclic graph (DAG) hypothesizing the relationship between 
prenatal opioid exposure and residing in a different household than the mother. 





CHAPTER 5. PHYSICAL AND COGNITIVE DEVELOPMENT:  GASTROINTESTINAL, 
RESPIRATORY, AND MENTAL HEALTH CONDITIONS IN NEONATAL ABSTINENCE SYNDROME 
5.1 Background 
Identifying specific health outcomes in childhood for children with NAS has become 
an area of urgent need. Though the rate of death in this population is elevated, the death 
rate for NAS overall remains relatively low.55 Many of the children diagnosed with this 
condition at birth, and part of this study, are now children living their lives in Kentucky, 
involved in school systems and building relationships with others in their communities. 
Each number in this dissertation corresponds to an actual, real child with actual, real 
experiences utilizing healthcare services and real issues to overcome. It is important, then, 
for healthcare practitioners and healthcare systems to be anticipating the needs of this 
population. 
The intent of this Chapter is to further specify some exact health outcomes that could 
be associated with NAS in later childhood and determine whether associations exist in this 
population, as well as provide some possible biologic mechanisms for the development of 
such conditions. Two sides of health outcomes will be examined: physical health outcomes 
and mental health outcomes. 
5.2 Physical Development 
NAS is a set of multisystem symptomologies, with known impacts to the central 
nervous system (or the CNS, manifested in the emergence of symptoms such as seizures, 
jerking, and pedaling in the infant), the gastrointestinal system (diarrhea being a common 
symptom of NAS), and the respiratory system.4,18,104 CNS involvement is ubiquitous in 
many conditions173 and the emergence of exact conditions indicating adverse CNS health 
outcomes may take longer periods of time to develop than could be readily identified within 
the first five years of life174. Conditions that could readily be identified within the first five 






5.2.1 Gastrointestinal Conditions 
In the usual timeline of fetal development, the gastrointestinal system is one of the 
earliest organ systems to complete development.29,175 Exposure to opioids in adults is 
known to create chronic gastrointestinal dysfunction, the most well-known of which is 
chronic constipation following long-term opioid exposure.176 In adults, this constipation 
must be treated with medication for a significant period even following abstinence from 
the substance that created the condition.176 Because opioids are known to readily cross the 
placenta11 and knowing that opioids create alterations with long chronicity in the 
gastrointestinal function of adults176, it is plausible that opioid exposure during this critical 
period of development could impact the development of the GI tract in the fetus, which 
could manifest in gastrointestinal conditions in childhood. 
 
5.2.2 Respiratory Conditions 
One of the most discussed outcomes of adult opioid use is opioid overdose.177 
Though opioid overdose involves many systems, one of the most dangerous aspects of the 
overdose is respiratory depression.177 This depression arises from the area of the brain 
targeted by opioids, with opioid receptors in the pons activated178, leading to the slowing 
of breathing in the user; in the case of an overdose, this loss of breath can eventually lead 
to a loss of life when intervention is not taken by bystanders and emergency responders.177 
In fetal development, the respiratory system is one of the systems with the longest 
periods of development.29,179,180 The respiratory system begins developing within weeks of 
conception.29,179,180 In very early fetal development, the system has a gill-like manner of 
obtaining oxygen; as gestation continues, the gills give way to the lung and airway system 
that will become vital organs for life once the child is delivered into the world.29,179,180 At 
delivery, the respiratory system is still developing, with the infant’s first cries indicative of 
the healthy functioning of the system and the capability of the system in intaking oxygen. 
NAS has been more commonly associated with use of substances in the second and 
third trimesters of pregnancy.62 Because the respiratory system is still developing in this 
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trimester29,179,180, the added insult from the substances of abuse could manifest alterations 
in the function of the system in later childhood. 
 
5.2.3 Methods 
The study population was subset to the last observation available in a continuously 
enrolled year in the population of children born in birth year cohorts 2016, 2017, 2018, and 
2019. These children were specifically identified because of the ICD-10 code switch that 
occurred in October 2015 to create a homogenous population for analysis under a common 
code set. Children were stratified as in previous analyses based on in utero opioid exposure 
status. 
First, a data exploration occurred within categories of diagnoses identified within 
the dataset to identify signals for potential analyses. Gastrointestinal conditions and 
respiratory conditions were chosen for this analysis because of the relationship between 
NAS and these two systems. Explanation of hypothesized mechanisms for these 
relationships were discussed earlier in the chapter.  The intent of this exploration was to 
identify signals in a relatively unexplored domain of development for the children to merit 
additional analyses. As such, the intent of this study was to simply identify whether an 
association could possibly exist, not to quantify the magnitude of the association itself. 
Diagnosis codes from the Healthcare Cost and Utilization Project (HCUP)’s 
Clinical Classification Software Revised (CCSR)113 were used to identify gastrointestinal 
conditions, which included disorders of the teeth and mouth, and respiratory conditions113, 
which served as the primary outcomes of interest. The diagnosis codes identified by the 
CCW consisted of 1,103 ICD-10 codes for gastrointestinal conditions and 441 ICD-10 
codes for respiratory conditions. An additional dataset was also provided from OHDA 
identifying the diagnosis code associated with the condition for each unique child and the 
age at which the child was diagnosed. 
Following obtaining the number of diagnoses for each category, a proportion was 
calculated to identify signaling. The proportion was calculated as, 
 
𝑥𝑥 =  
𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑟𝑟𝑟𝑟 𝑜𝑜𝑜𝑜 𝑖𝑖𝑖𝑖𝑟𝑟𝑑𝑑𝑛𝑛𝑜𝑜𝑑𝑑𝑟𝑟𝑑𝑑





Signaling was considered for analysis if the signal indicated a stepwise increase of 
a considerable amount in the proportion (i.e., if the proportion among the NAS children 
exceeded the proportion among the children with prenatal opioid exposure which exceeded 
the proportion among the children in the comparator group). In addition to the stepwise 
increase, the increase in the proportion also had to be considerably large, and the category 
well-defined to merit further evaluation. 
Following the determination of signaling, a dichotomous indicator variable for the 
condition was created and merged back into the original dataset, which served as the 
outcome of interest in the formal analysis. Frequency analyses were conducted to describe 
the strata of children in the newly created study population, as well as to describe the strata 
of the children with the signal compared to other children. Chi-square analyses were 
conducted to ascertain statistically significant differences. A DAG was created using 
DAGitty v3.0 to identify variables confounding the relationship between prenatal opioid 
exposure and the signaling variable of interest. A logistic regression analysis was then 
conducted to ascertain the odds of children with prenatal opioid exposure being diagnosed 
with the signaling variable. All statistical analyses were conducted using SAS v9.4 (Cary, 




After the exclusion criteria was applied, the population consisted of 127,403 unique 
children available for analysis. Among these children, a total of 80,105 (62.84%) children 
were diagnosed with any gastrointestinal condition identified by the CCSR diagnosis 
codes113 and 104,698 children (82.13%) were diagnosed with any respiratory identified by 
the CCSR diagnosis codes.113 Raw counts of unique diagnoses in the CCSR categories 
determined by HCUP113 are shown in Table 5.1 and Table 5.3. Of note, in a deviation from 
the standards for the algorithm, only one diagnosis was sufficient to be included in the 
analysis, as the intent of the study was not to quantify the magnitude of an association, but 
merely to determine the possibility for such an association to exist. 
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Proportions for each of the categories of diagnoses were then calculated, as shown 
in Table 5.2 and Table 5.4. Based on these analyses, the large proportion of children with 
respiratory conditions is likely a result of the large percentage of acute bronchitis and other 
specified upper respiratory infections, for which it seems that, among children who 
received this diagnosis, received several different diagnoses within this category, as the 
results for these proportions were greater than one. 
Based on the results of the analysis, though several items in the gastrointestinal 
conditions list could merit further investigation, no strong signal was detected. Among 
respiratory conditions, however, two categories seemed to indicate that a signal could be 
identified: asthma and respiratory failure, insufficiency, and/or arrest. Corr et al. identified 
increased rates of respiratory diagnoses among the population of children with a history of 
NAS42. Additionally, Conner et al. found a high percentage of children with NAS 
prescribed antiasthmatic and bronchodilator agents in a finding in their analysis.79 Based 
on these two findings, asthma was chosen as a potential signal to investigate for additional 
associations in further analyses. 
The demographics of the study population stratified by prenatal opioid exposure 
status is shown in Table 5.5. The overall prevalence of NAS in this group was largely 
reflective of the percentage from the overall population analyzed in Chapter 3. The 
percentage of children with a diagnosis of prenatal opioid exposure were slightly higher. 
One reason for this discrepancy could be the ICD-10 code switch that occurred in October 
2015; the utilization of the prenatally exposed code rose in 2016, as shown in Chapter 3. 
This may be due to a dichotomization of infants with NAS from the group prenatally 
exposed following awareness of this code in the new codex. The remainder of the 
demographics for this population were largely reflective of the demographics provided in 
Chapter 3. 
Demographics stratified by evidence of an asthma diagnosis shown in Table 5.6. 
This population of children were more male than the population of children without a 
diagnosis of asthma and more Appalachian than the population of children without a 
diagnosis of asthma. Additionally, it seems the proportion of children who are Black and 
have a diagnosis of asthma is greater than the proportion of children who are Black and do 
not have a diagnosis of asthma.  
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An exploratory logistic regression analysis was then undertaken to gain additional 
evidence as to whether such an association exists. The DAG for the exploratory analysis is 
shown in Figure 5.1. Code for the DAG is available in the Appendix (Appendix 8). Overall, 
the DAG identified 6 covariates and one causal pathway in the relationship between 
prenatal opioid exposure and asthma. According to the results from the DAG, the minimum 
sufficient adjustment set to estimate the effect consists of gestational age, maternal 
smoking, physical environment, race, and sex. Physical environment in this analysis will 
be proxied by Appalachian status at birth and metropolitan status at birth, as was the case 
in Chapter 4. 
Univariable logistic regression analyses based on the findings of the DAG are 
shown in Table 5.7. Overall, not accounting for other factors, the odds of a child with a 
diagnosis of NAS being diagnosed with asthma were 1.77 times higher than children 
without a diagnosis of either NAS or prenatal opioid exposure; among children with a 
diagnosis of prenatal opioid exposure, these odds were 1.34 times higher. Odds were also 
higher among children born in Appalachian county and children born in a non-metro 
county of residence. Black children also saw increased odds compared to White children, 
though being of a race that fell under the category of “Other”, as described in Chapter 3, 
was protective against a diagnosis of asthma. Finally, one unit increases in gestational age 
also were incrementally protective against a diagnosis of asthma. 
Results from the adjusted logistic regression analysis are also shown in Table 5.7. 
These results were largely consistent with the findings from the univariable analyses with 
relatively few major shifts in the overall finding. Children with a diagnosis of NAS and 
children with a diagnosis of prenatal opioid exposure both had greater odds of being 
diagnosed with asthma compared to the comparator group, with adjusted odds ratios 
(aORs) of 1.40 and 1.19 respectively with all other factors held constant. The largest shift 
occurred among children who are Black in the analysis, increasing from 1.24 in the 
unadjusted to 1.63 in the adjusted compared to children who are White, all other factors 
held constant. This increase was not quite as pronounced among children whose race was 
categorized as “Other.” This indicates that race is likely related to another factor in the 
analysis, allowing the bias within the result from the univariable analyses to be removed, 
causing a right-shift in the variable. 
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5.3 Cognitive Development 
In 2019, an analysis by Sherman et al. found elevated rates of mental health 
conditions in children ages 1 to 5 in a national population of Medicaid-insured children 
after being diagnosed with NAS.78 This analysis was extended by Conner et al. to a 
commercially insured population with similar findings.79 These findings mimic earlier 
work in this area that suggest that children with NAS face significant challenges in their 
cognitive development in childhood.77,181 Less discussed, however, has been the fact that 
many children in these population could have been diagnosed with mental health 
conditions very early in childhood, such as at ages 1 and 2.78,79 Indeed, neither Sherman et 
al. nor Conner et al. explored age at diagnosis or factors associated with these early 
diagnoses of mental health conditions.78,79 Thus, the intent of this analysis is to expand the 
findings of Sherman et al.78 and Conner et al.79 using the mental health conditions identified 
by Sherman et al.78 diagnosed in the Kentucky Medicaid population to children to identify 
the prevalence of these diagnoses at early ages and to identify factors associated with the 
diagnosis of these conditions at early ages. 
 
5.3.1 Methods 
To replicate the tables produced by Sherman et al.78 and Conner et al.,79 the study 
population was subset to include only children born in birth year cohorts 2014 and 2015. 
These two birth year cohorts were chosen because there were the only two birth year 
cohorts to be eligible to be diagnosed with the ICD-9 codes identified by Sherman et al.78 
given the code switch that occurred in October 2015. This reduced the overall study 
population from to 64,896 children. Diagnosis codes identified by Sherman et al.78 were 
used to identify mental health conditions, which were then categorized based on the three 
leading numbers of the diagnosis. An additional dataset was also provided from OHDA 
identifying the diagnosis code associated with the mental health condition for the child and 
the age at which the child was diagnosed. 
To analyze factors associated with diagnoses of mental health conditions, the study 
population was then subset again to only include the observations available in year 1 among 
the continuously enrolled population of children born in birth year cohort 2014. This 
additional exclusion criterion was applied to provide a minimum of one year for a child to 
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have a sufficient period of enrollment to interact with the healthcare system and obtain one 
of these diagnoses. As was noted previously, children born in 2014 were specifically 
identified because of the ICD-10 code switch that occurred in October 2015 to create a 
homogenous population for analysis under a common code set; the codes identified by 
Sherman et al. consisted solely of ICD-9 codes, and thus children born in later birth year 
cohorts were either ineligible to be diagnosed with one of the identified codes or may not 
have had sufficient time to be diagnosed with one of the identified diagnosis codes. 
Children were stratified as in previous analyses based on in utero opioid exposure status. 
Frequency analyses were conducted to identify differences between the strata of 
children. Chi-square analyses were conducted to ascertain statistically significant 
differences between the strata for ordinal variables and ANOVA models were utilized to 
assess statistically significant differences between the strata for continuous variables. 
A DAG was created using DAGitty v3.0 to predetermine variables of interest based 
on hypothesized relationships between prenatal opioid exposure and one of the diagnosed 
mental health conditions. Logistic regression analyses were then conducted to obtain the 
odds of a child with in utero opioid exposure being diagnosed with one of the identified 
mental health conditions. Univariable logistic regression analyses were conducted for each 
of the identified variables, as well as two adjusted models: a model containing all the 
variables and proxy variables identified by the DAG and a model containing only the 
minimum sufficient adjustment set identified by the DAG. In a post hoc analysis, 
backwards selection was also run on the logistic regression model to create a more 
parsimonious model for analysis, and the c-statistic was examined to compare this model 
to the fully adjusted and DAG adjusted models. Additionally, post hoc frequency analyses 
of variables of interest from the logistic regression analyses were conducted to further 
describe a population and adjusted variable from the analysis. All statistical analyses were 
conducted using SAS v9.4 (Cary, NC). An α-threshold of 0.05 was utilized; p-values less 
than 0.05 were considered statistically significant. 
 
5.3.2 Results 
Table 5.8 replicates the table produced by both Sherman et al.78 and Conner et al.79 
in their respective analyses for the population of children born in Kentucky Medicaid in 
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2014 and 2015, with the added strata of children with a diagnosis of prenatal opioid 
exposure extracted from the comparator group. Overall, per the Memorandum of 
Understanding signed to be able to acquire the data, many of the cell values for this table 
were less than 10, and thus suppressed; additionally, zeros were not presented in this table, 
despite an impossibility of reidentifying a population in which nothing occurred, to 
minimize the potential for reidentification in another strata. Overall, approximately 8.44% 
of children with a diagnosis of NAS were diagnosed with any of the mental health 
conditions identified by Sherman et al., compared to 5.07% of children with prenatal opioid 
exposure and 3.29% of children from the comparator group. These percentages were 
largely being driven by delays in development. 
The study population was then further subset to include only those children born in 
birth year cohort 2014 and continuously enrolled by HEDIS standards for the first year of 
life. This reduced the study population further to a population of 29,067 children available 
for analysis. 
Demographics for the population identified are presented in Table 5.9, along with 
the frequency of mental health conditions in the 2014 birth year cohort in these early years 
of life. Consistent with the findings in both Sherman et al.78 and Conner et al.79, the 
prevalence of mental health conditions in this population are nearly three times that of the 
comparator group of children for both children diagnosed with NAS and children 
diagnosed with in utero opioid exposure (approximately 11% and 10% compared to 4%). 
This finding is also consistent with the supplement table with one year of continuous 
enrollment provided by Conner et al. showing elevated rates of mental health conditions in 
the population of children with only one year of continuous enrollment79, as opposed to the 
five years of continuous required by Sherman et al. and by Conner et al. in the primary 
analysis.78,79 
A DAG was then utilized to identify factors and hypothesized relationships between 
variables relevant to the association between prenatal opioid exposure and mental health 
conditions. The resultant DAG is available in Figure 5.2 with justification for each of the 
variables and the minimal sufficient adjustment set further explained in Table 5.10. 
This result was further validated by the logistic regression analysis in Table 5.11. 
In the unadjusted analysis, the odds of a child with a diagnosis of NAS being diagnosed 
86 
 
with a mental health condition was 3.08 times higher compared to the comparator group, 
while the odds of a child diagnosed with opioid exposure in pregnancy was 2.69 times 
higher compared to the comparator group. After adjusting for race, sex, metropolitan status, 
Appalachian status, foster care, different household, mother on Medicaid, sibling on 
Medicaid, gestational age, sibling with NAS, and foster care, the odds fell considerably, 
but remained elevated compared to the comparator group, at 1.46 and 1.39, respectively. 
Eliminating siblings with NAS from the adjustment, as shown in the DAG adjusted model, 
resulted in a further decline of the odds ratio to 1.42 and 1.36. Unadjusted and adjusted 
odds ratios for all other variables are also shown in Table 5.11. 
 Interestingly, from the adjustment in the logistic regression analysis, holding all 
other variables constant, foster care resulted in extremely high elevated odds ratios 
compared to the children not in the foster care system in the first year of life. In Chapter 4, 
we ascertained that children entering the foster care system most frequently have their first 
contact with the foster care system in the first year of life. Unadjusted, the odds of a child 
in foster care being diagnosed with a mental health condition were 14.41 times higher than 
the odds of a child not engaged with the foster system; with the adjustments in the fully 
adjusted and DAG adjusted models, these odds ratios fell to 9.79 and 9.72. This indicates 
that a large burden of the conditions being diagnosed in this analysis were borne by the 
children in the foster care system. 
 Model fit statistics were also assessed for the models to determine the final model 
resulting from the analysis. The c-statistic for both the fully adjusted model and the DAG 
adjusted models was 0.720. This represents a decent fit for a statistical model, as a c-
statistic of 0.70 is generally thought to be adequate while a c-statistic of 0.8 is generally 
considered to be strong. 
An additional model in Table 5.12 was created post hoc using the backwards 
selection process within the SAS software. Interestingly, this model had a c-statistic of 
0.718, slightly less than the manually identified model. The results of this analysis are 
available in Table 5.12 and are largely consistent with the findings in the other tables. 
While this model is more parsimonious, the fully adjusted and DAG adjusted models are 
likely accounting for some confounding that is not present in the backwards selected 
model. Thus, given the negligible difference identified by equal c-statistics between the 
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fully adjusted and DAG adjusted model, the final model for this analysis was determined 
to be the DAG adjusted model. 
 The DAG adjusted model was chosen due to the exclusion of the sibling with NAS 
variable in the model, which reversed in the fully adjusted model to become protective. 
One reason for this reversal may be due to the inclusion of the variable indicating a sibling 
on Medicaid and likely collinearity between these two variables. This created a final model 
of 
𝑐𝑐 =  6.52 + 0.13𝑥𝑥1 + 0.08𝑥𝑥2 − 0.18𝑥𝑥3 + 0.11𝑥𝑥4 − 0.11𝑥𝑥5 − 0.06𝑥𝑥6 + 0.21𝑥𝑥7
+ 1.14𝑥𝑥8 + 0.24𝑥𝑥9 + 0.03𝑥𝑥10 − 0.21𝑥𝑥11 − 0.22𝑥𝑥12 
where 
 x1 is a dichotomous indicator variable indicating whether an observation had a 
diagnosis of NAS, 
 x2 is a dichotomous indicator variable indicating whether an observation had a 
diagnosis of prenatal opioid exposure, 
 x3 is a dichotomous indicator variable indicating whether an observation was 
identified as Black on the enrollment form, 
 x4 is a dichotomous indicator variable indicating whether an observation had a race 
identified as Other, 
 x5 is a dichotomous indicator variable indicating whether an observation was 
identified as being female, 
 x6 is a dichotomous indicator variable indicating whether an observation was born 
a resident of a non-metropolitan county, 
 x7 is a dichotomous indicator variable indicating whether an observation was born 
a resident of an Appalachian county, 
 x8 is a dichotomous indicator variable indicating whether an observation was 
involved with foster care in their first year of life, 
 x9 is a dichotomous indicator variable indicating whether an observation resided in 
a different household than their mother, 
 x10 is a dichotomous indicator variable indicating whether an observation did not 
have a mother on Medicaid, 
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 x11 is a dichotomous indicator variable indicating whether an observation did not 
have a sibling on Medicaid, 
 and x12 is a variable corresponding with each additional week of added gestational 
age for an observation. 
 In Chapter 4, model assumptions for a logistic regression analysis were identified 
as requirements for the outcome variable be ordinal, observations be independent, lack 
multicollinearity, the log odds be linear, and a large sample size is obtained for 
analysis.144,145 For this analysis, the outcome variable was a dichotomous indicator 
variable, thus fulfilling the requirement for ordinality. Additionally, we have no reason to 
assume that the observations violate the independence assumption for logistic regression, 
as each child within this analysis is a unique child situated within unique circumstances. A 
sufficiently large sample size is also utilized within the analysis, with a population of 
29,067 children supplying the figures for the analysis. 
 As in Chapter 4, there is potential that the multicollinearity assumption has been 
violated, as many of the variables identified here seem to be significantly associated with 
prenatal opioid exposure. This is due in part to the large sample size in the analysis and the 
potential for the study to be overpowered. Nonetheless, the utilization of sensitivity 
analyses and backwards selection helps protect against the potential for multicollinearity 
to bias the result. As such, inference for the model is approximately equivalent for each of 
the model selection methodologies assessed. 
 Regarding the requirement that log odds be linear, for the overall model, the log 
odds do appear to provide a linear equation for analysis; within each variable, the only 
variable for which a violation could be occurring is gestational age. However, based on the 
results here, it seems that the log odds are linear, as the odds ratio estimate is the estimated 
change based on a one unit change in gestational age. It is worth noting that the range for 
the gestational age variable is a bounded number, meaning that the variable has defined 
lower limits and defined upper limits. Therefore, while these log odds may be linear, not 
all numerical values are available for analysis. A way to protect against this would be to 
create a categorical variable for gestational age to utilize within the analysis rather than 
utilizing the continuous variable, given this bounded criterion established in the 
methodology in Chapter 3. However, as was noted in Chapter 4, use of a categorical 
89 
 
variable removes a level of granularity from the analysis. During gestation, a week 
represents a significant and rapid period of development for a fetus.29 Therefore, each week 
becomes an important unit of measure for an infant, and thus provides the justification for 
the utilization of the continuous variable within the scope of this analysis. However, 
utilizing a categorical variable in this manner would further safeguard against violations of 
this assumption. 
 Finally, following the model selection, and given the highly influential nature of 
foster care in the analysis, the population of children within the study involved with foster 
care in the first year of life were examined. These demographic features are available in 
Table 5.13. The prevalence of NAS among the children born in 2014 and engaged with the 
foster care system was approximately 29%. This is a rate seven times higher than the 
prevalence of NAS in the entire study population. These children were also majority White, 
majority male, and largely from metropolitan and non-Appalachian regions of the state. 
Additionally, the prevalence of mental health conditions in this population was 
approximately 36%. Among children with NAS engaged in foster care, approximately 42% 
were diagnosed with one of the mental health diagnoses; among children in the comparator 
group, this approximately 34% were diagnosed with a mental health condition from this 
population of children. 
5.4 Discussion and Policy Implications 
After the exploration of the data related to gastrointestinal and respiratory conditions, 
asthma appeared as a diagnosis meriting further exploration. The intent of this analysis was 
not to establish an exact quantified impact of the effect of neonatal abstinence syndrome 
on the development of asthma, but rather to describe whether such an association exists. 
For the purposes of this dissertation, this analysis was purely exploratory and descriptive 
rather than analytical in nature. 
Nonetheless, it does seem that the association between diagnoses of childhood 
asthma and prenatal opioid exposure merits additional investigation. In the general 
pediatric population, the prevalence of asthma is estimated to be 7%.182 In our population, 
the prevalence of asthma in the comparator group, based on one diagnosis of a code 
identified as part of the asthma category in the CCSR system113, was approximately 15%; 
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in the group of children with prenatal opioid exposure, this prevalence was higher, at 
around 21%, and among children with a diagnosis of NAS, this was closer to 25%. 
Childhood asthma is frequently connected to many environmental triggers, from 
unclean household allergens to parental smoking.183 Pediatric asthma has also been 
associated with elevated costs to healthcare systems when compared to children without 
such a diagnosis.184 For Medicaid, this presents a significant area meriting further 
investigation into the costs associated with asthma in these populations of children. Policy 
could also be implemented to curtail many of the lifestyle-oriented factors associated with 
pediatric asthma, and renewed efforts targeting parental smoking may be needed in these 
populations183, given the high rates of maternal smoking among children with history of 
NAS and the high rates of asthma among children with a history of NAS. 
Regarding cognitive development, in 2021, Velasco et al. delved into the impact of 
prenatal opioid exposure on myelin generation and developmental brain physiology, 
concluding that prenatal exposure has the potential to create late myelination that persists 
within the prefrontal cortex for children through young adulthood.185 This reduced 
myelination has been connected with developmental delays in children.186 If the hypotheses 
supplied by both of these articles are valid, the findings of this chapter show novel 
consistency in connecting and explaining the biological mechanism behind the elevated 
rates of developmental delays among children with NAS identified within this chapter. 
In Chapter 4, it was discovered that a large percentage of children with in utero opioid 
exposure enter into the foster care system early in life. In this chapter, the results seem to 
indicate that not only are these children entering the foster care system early in life, children 
in foster care are also being diagnosed with mental health conditions earlier in life 
compared to other children. Many of these conditions require pharmacological treatment 
interventions to manage, such as stimulants to treat attention deficit hyperactivity disorder 
(ADHD)187 and antipsychotics for the management of more severe mental health 
conditions188. At a stage of critical brain and physical development for these children, the 
children are potentially facing exposure to medications designed to alter neurochemical 
function in the brain189, as well as medications that can alter physical health outcomes.190 
 Overutilization of medications for ADHD191 and the overdiagnosis of ADHD192 has 
been a topic of discussion in the literature, with more emphasis placed on the impact such 
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diagnoses have on males compared to females193. For all neurodivergent, the literature has 
traditionally focused on identifying and managing the conditions in young boys, though 
young girls also face challenges from such conditions.194 
Identifying the child with such conditions early in life creates many challenges. For 
one, many of the children in the foster care system have undergone serious trauma in their 
lives.195 The externalizing symptoms used to identify the conditions within these 
populations could be the result of the trauma experienced, not necessarily a chronic mental 
health condition itself.155 Children at these young ages lack autonomy and the efficacy to 
vocalize their needs, depending entirely on the caretaker to identify when such need 
meeting.29 In the absence of that caretaker recognizing and aiding the child, the child then 
adapts to survive the harsh environment in which they have been placed.29 The 
externalizing realities of this adaptation are frequently either withdrawal from the 
environment in which they have been placed (despondency) or lashing out (i.e., aggression, 
hyperactivity, alluding authority).196 These characteristics are not as much indicative of a 
“bad kid” as much as a child that has learned how to survive in their environment by 
exhibiting these characteristics to gain the attention of the caretaker or avoid further harm 
and/or hurt.196 
Overwhelmingly, children regress in behavior when under duress29, a fact that also 
makes the need for designated diagnostic tools that differentiate the characteristics and 
behaviors of full-term infants from that of preterm infants197. Providers should ask 
additional questions before applying a mental health diagnosis onto the children in 
question, especially if the provider becomes aware of an extenuating circumstance in the 
child’s life that could be impacting the environment in which a child develops. 
A prime example of this, as illustrated by the data, are for children involved with the 
foster care system. Foster care has been associated with many adverse cognitive and 
physical health outcomes for children.115,154,198 This study, through the current chapters, 
has highlighted the importance of considering the role foster care plays in the health 
outcomes of children with a history of NAS; the results of the analyses largely suggest that 
it may not be possible to separate the compounding effects of both in the overall 
development of a child. 
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The role of Medicaid in such instances should be to provide extra monitoring to 
children who obtain such diagnoses early in life and carefully follow up with parents and 
guardians of these children to ensure adequate treatment and safety for these children. 
Under managed care infrastructure, Medicaid has the power to assess children more 
vigilantly with these conditions and ensure more optimal development continues for the 
child. Because of the long retention of children to the Kentucky Medicaid system, 
Kentucky Medicaid has greater impetus to intervene in child development issues to subvert 
additional, greater health issues for these children later in life. 
Additionally, as previously noted, this chapter also highlights the need for increased 
vigilance for the population of children involved with the foster care system. Because these 
children remain on the Medicaid system, Medicaid has the capability to monitor and 
surveille this population of children for potentially problematic patterns of healthcare 
utilization or evidence of adverse health outcomes. By renewing their focus on these 
children, Medicaid has the potential to prophylactically curtail added healthcare 
expenditures later in life through early intervention. Physical and cognitive health 
outcomes have the potential to become sources of high utilization of healthcare resources 
and generate large healthcare expenditures among children. Additional investigation into 
the healthcare utilization of children with prenatal opioid exposure will be explored in 
greater detail in Chapter 6. 
 
5.4.1 Limitations and Future Directions 
Within this analysis, diagnoses were defined as the appearance of any diagnosis 
code on a child’s record. This is not consistent with algorithms established for evaluating 
conditions frequently diagnosed in outpatient settings, requiring the appearance of two 
outpatient claims for a diagnosis or one inpatient claim. This represents a limitation to this 
analysis for both the physical health and cognitive health sections of these analyses, as the 
diagnoses indicated here may not be reflective of actual diagnosed conditions.  
Nonetheless, these analyses were largely considered exploratory, and sought to 
explore and describe associations rather than quantify an effect; the goals of such studies 
were descriptive as opposed to analytic. The reason for this was to provide a foundational 
layer for the literature to build upon. In the hierarchy of evidence, descriptive studies sit 
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below analytic studies.199 To be able to progress to more formal analytic works, the nature 
of such an association should already be established through descriptive literature.199 The 
intent of this chapter was to provide descriptive evidence of associations that merit 
additional analysis. 
A future direction for all the studies in this chapter would be a more formalized 
study that is not cross-sectional in nature, but rather longitudinal. Causal inference 
methodologies could be utilized in an observational study design to aid in assessing 
whether prenatal opioid exposure causes the development of asthma or the mental health 
condition diagnoses listed here. Additionally, this study also highlights the need for 
additional research on the impact of foster care on these diagnoses, as well as foster care 
as it relates to NAS. 
Finally, the results within this chapter represent a homogenous population under 
common policy actions and within a common state. As such, results in these analyses may 
not be generalizable to other populations.  
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Table 5.1 Number of diagnoses in the categories of gastrointestinal conditions of 
















3,720 3,106 73,279 80,105 
Abdominal hernia 495 503 8,376 9,374 
Anal and rectal conditions 43 55 1,186 1,284 
Appendicitis and other 
appendiceal conditions 
Supp. Supp. 56 Supp. 
Biliary tract disease 25 22 289 336 
Diseases of the mouth 
(excludes dental) 
1,726 1,497 33,244 36,467 
Diseases of teeth and 
gingiva 
1,127 835 19,571 21,533 
Diverticulosis and 
diverticulitis 
Supp. Supp. Supp. Supp. 
Esophageal disorders 1,474 1,062 26,220 28,756 
Gastritis and duodenitis 52 51 1,130 1,233 
Gastroduodenal ulcer Supp. Supp. 29 Supp. 
Gastrointestinal and biliary 
perforation 
Supp. Supp. 99 Supp. 
Gastrointestinal hemorrhage 103 97 2,504 2,704 
Hemorrhoids Supp. 14 288 Supp. 
Hepatic failure Supp. 11 68 Supp. 
Intestinal infection 782 602 16,281 17,665 
Intestinal obstruction and 
ileus 
94 88 1,213 1,395 
Noninfectious 
gastroenteritis 
710 463 13,173 14,346 
Noninfectious hepatitis Supp. Supp. Supp. Supp. 
Other specified and 
unspecified disorders of the 
stomach and duodenum 
80 56 989 1,125 
Other specified and 
unspecified gastrointestinal 
disorders 
1,459 1,360 32,350 35,169 
Other specified and 
unspecified liver disease 
26 43 347 416 
Pancreatic disorders 
(excluding diabetes) 
Supp. Supp. 105 Supp. 
Peritonitis and intra-
abdominal abscess 




69 81 829 979 
Regional enteritis and 
ulcerative colitis 





Table 5.2 Proportion of diagnoses in the categories of gastrointestinal conditions to 
children born on Kentucky Medicaid between 2016 and 2019, stratified by opioid exposure 











67.98% 64.32% 62.53% 62.84% 
Abdominal hernia 9.05% 10.42% 7.15% 7.35% 
Anal and rectal conditions 0.79% 1.14% 1.01% 1.01% 
Appendicitis and other 
appendiceal conditions 
Supp. Supp. 0.05% Supp. 
Biliary tract disease 0.46% 0.46% 0.25% 0.26% 
Diseases of the mouth 
(excludes dental) 
31.54% 31.00% 28.37% 28.61% 
Diseases of teeth and 
gingiva 
20.60% 17.29% 16.70% 16.89% 
Diverticulosis and 
diverticulitis 
Supp. Supp. Supp. Supp. 
Esophageal disorders 26.94% 21.99% 22.38% 22.56% 
Gastritis and duodenitis 0.95% 1.06% 0.96% 0.97% 
Gastroduodenal ulcer Supp. Supp. 0.02% Supp. 
Gastrointestinal and biliary 
perforation 
Supp Supp. 0.08% Supp. 
Gastrointestinal hemorrhage 1.88% 2.01% 2.14% 2.12% 
Hemorrhoids Supp. 0.29% 0.25% Supp. 
Hepatic failure Supp. 0.23% 0.06% Supp. 
Intestinal infection 14.29% 12.47% 13.89% 13.86% 
Intestinal obstruction and 
ileus 
1.72% 1.82% 1.04% 1.10% 
Noninfectious 
gastroenteritis 
12.98% 9.59% 11.24% 11.25% 
Noninfectious hepatitis Supp. Supp. Supp. Supp. 
Other specified and 
unspecified disorders of the 
stomach and duodenum 
1.46% 1.16% 0.84% 0.88% 
Other specified and 
unspecified gastrointestinal 
disorders 
26.66% 28.16% 27.61% 27.59% 
Other specified and 
unspecified liver disease 
0.48% 0.89% 0.30% 0.33% 
Pancreatic disorders 
(excluding diabetes) 
Supp. Supp. 0.09% Supp. 
Peritonitis and intra-
abdominal abscess 




1.26% 1.68% 0.71% 0.77% 
Regional enteritis and 
ulcerative colitis 





Table 5.3 Number of diagnoses in the categories of respiratory conditions of children born 













Any respiratory diagnosis 4,708 4,056 95,934 104,698 
Acute and chronic tonsilitis 458 417 9,526 10,401 
Acute bronchitis 4,548 3,247 70,943 78,738 
Aspiration pneumonia 17 14 206 237 
Asthma 1,352 1,006 18,132 20,490 
Chronic obstructive pulmonary 
disease and bronchiectasis 
117 81 1,143 1,341 
Influenza 1,706 1,487 37,288 40,481 
Lung disease due to external 
agents 
15 12 205 232 
Mediastinal disorders Supp. Supp. 35 Supp. 
Other specified or unspecified 
lower respiratory diseases 
904 824 15,572 17,300 
Other specified or unspecified 
upper respiratory diseases 
3,478 2,614 58,442 64,534 
Other specified upper respiratory 
infections 
7,670 6,209 153,584 167,463 
Pleurisy, pleural effusion, and 
pulmonary collapse 
269 246 3,274 3,789 
Pneumonia (except caused by 
tuberculosis) 
931 772 16,279 18,000 
Pneumothorax 39 26 391 456 
Postprocedural or postoperative 
respiratory system complication 
50 64 831 945 
Respiratory failure; 
insufficiency; arrest 
481 466 5,549 6,496 





Table 5.4 Proportion of diagnoses in the categories of respiratory conditions to children 
born on Kentucky Medicaid between 2016 and 2019, stratified by opioid exposure status, 








Any respiratory diagnosis 86.04% 83.99% 81.87% 82.13% 
Acute and chronic tonsilitis 8.37% 8.64% 8.13% 8.16% 
Acute bronchitis 83.11% 67.24% 60.54% 61.76% 
Aspiration pneumonia 0.31% 0.29% 0.18% 0.19% 
Asthma 24.71% 20.83% 15.47% 16.07% 
Chronic obstructive pulmonary 
disease and bronchiectasis 
2.14% 1.68% 0.98% 1.05% 
Influenza 31.18% 30.79% 31.82% 31.75% 
Lung disease due to external 
agents 
0.27% 0.25% 0.17% 0.18% 
Mediastinal disorders Supp. Supp. 0.03% Supp. 
Other specified or unspecified 
lower respiratory diseases 
16.52% 17.06% 13.29% 13.57% 
Other specified or unspecified 
upper respiratory diseases 
63.56% 54.13% 49.87% 50.62% 
Other specified upper respiratory 
infections 
140.17% 128.58% 131.06% 131.36% 
Pleurisy, pleural effusion, and 
pulmonary collapse 
4.92% 5.09% 2.79% 2.97% 
Pneumonia (except caused by 
tuberculosis) 
17.01% 15.99% 13.89% 14.12% 
Pneumothorax 0.71% 0.54% 0.33% 0.36% 
Postprocedural or postoperative 
respiratory system complication 
0.91% 1.33% 0.71% 0.74% 
Respiratory failure; 
insufficiency; arrest 
8.79% 9.65% 4.74% 5.10% 





Table 5.5 Population demographics for the study population consisting of birth year 
cohorts 2016 through 2019 in the Kentucky Medicaid population, stratified by opioid 
exposure status. 
Characteristic NAS Diagnosis 
 
















































































































38.43 (1.75) 38.24 (2.16) 38.64 (1.73) 38.61 (1.75) <0.0001 




Table 5.6 Demographics of the population of children born on Kentucky Medicaid 
between 2016 and 2019, stratified by asthma diagnosis. 




















































































Table 5.7 Logistic regression analysis of the odds that a child born on Kentucky 
Medicaid between 2016 and 2019 with prenatal exposure to opioids received an asthma 
diagnosis. 
 Unadjusted Adjusted* 














































































*Adjusted for race, sex, Appalachian status, metropolitan status, gestational age, 
and maternal smoking status. 
**The reference group for prenatal opioid exposure was the comparator group; for 
race, White; for sex at birth, male; for Appalachian status, non-Appalachian; for 
metropolitan status, metropolitan; for maternal smoking, no maternal smoking. 





Table 5.8 Mental health conditions identified by Sherman et al. and Conner et al. in 
their respective articles in Psychiatric Services, applied to the population of children 





















233 (8.44%) 52 (5.07%) 2,010 (3.29%) 2,295 (3.54%) 
Psychoses with 
origin specific to 
childhood (299) 
Supp. Supp. Supp. Supp. 
Neurotic 
disorders (300) 




16 (0.58%) Supp. 253 (0.41%) 275 (0.42%) 
Acute reaction 
to stress (308) 
Supp. Supp. 11 (0.02%) Supp. 
Adjustment 
reaction (309) 
Supp. Supp. 12 (0.02%) Supp. 
Disturbance of 
conduct (312) 
58 (2.10%) Supp. 190 (0.31%) Supp. 
Disturbance of 
emotion specific 
to childhood and 
adolescence 
(313) 












Supp. Supp. Supp. Supp. 
*Cell counts less than 10 were suppressed per the Memorandum of Understanding to 
minimize the potential for the reidentification of data. Cell counts of zero were also 
suppressed to minimize potential for reidentification of data. 
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Table 5.9 Population demographics for the study population consisting of birth year cohort 
2014 in the Kentucky Medicaid population, continuously enrolled for the first year of life, 
stratified by opioid exposure status. 
Characteristic NAS Diagnosis 
 






(n = 27,474) 
Total 
 
































































Foster Care 170 (13.85%) 30 (8.20%) 386 (1.40%) 586 (2.02%) <0.0001 
Different 
Household 
683 (55.66%) 211 (57.65%) 8,360 (30.43%) 9,254 (31.84%) <0.0001 
Mother on 
Medicaid 
1,174 (95.68%) 348 (95.08%) 26,213 (95.41%) 27,735 (95.42%) 0.86 
Sibling on 
Medicaid 
568 (46.29%) 164 (44.81%) 12,732 (46.34%) 13,464 (46.32%) 0.84 
Gestational 
Age 
38.27 (1.78) 37.48 (2.76) 38.58 (1.75) 38.56 (1.77) <0.0001 
Sibling with 
NAS 
335 (27.30%) 95 (25.96%) 864 (3.14%) 1,294 (4.45%) <0.0001 
Mental Health 
Conditions 





Table 5.10 Factors identified by the DAG, proxy variables available within the data, 
justification, and models the variables were included in for the linear mixed model 
of the association between prenatal opioid exposure and mental health condition 
diagnoses at an early age. 
Item in the DAG Proxy 
Variable(s) 












Sociodemographic factors, such 
as location, sex, and race, often 
are vital social determinants of 











development depends upon the 
home environment in which 
they are raised.201 Instability in 








Families provide some of the 
earliest relationships to children 
and are thus vital components 
of their cognitive 
development.29,131,132 
X X 
Gestational age Gestational 
age 
Gestational age can be 
indicative of developmental 
delays as babies born preterm 
emerge before full development 








Adverse childhood events have 
known associations with 
cognitive development in 
children.204  
X  





Table 5.11 Logistic regression analysis for the association between mental health condition 
diagnoses at an early age and in utero opioid exposure among children born on Kentucky 
Medicaid in 2014 with continuous enrollment for the first year of life. 
 Unadjusted Fully Adjusted* DAG Adjusted** 
 Odds 
Ratio 
95% CI Odds 
Ratio 
























































1.13 (1.01, 1.26) 0.89 (0.76, 1.05) 0.89 (0.76, 1.05) 
Appalachian 1.40 (1.25, 1.57) 1.53 (1.30, 1.80) 1.52 (1.30, 1.79) 




2.25 (2.01, 2.52) 1.63 (1.43, 1.86) 1.62 (1.42, 1.84) 
No Mother on 
Medicaid 
1.27 (0.999, 1.62) 1.06 (0.56, 2.00) 1.06 (0.56, 2.00) 
No Sibling on 
Medicaid 
0.69 (0.61, 0.77) 0.64 (0.57, 0.73) 0.65 (0.58, 0.74) 
Gestational Age 0.80 (0.79, 0.82) 0.80 (0.79, 0.82) 0.80 (0.77, 0.82) 
No Sibling with 
NAS 
1.93 (1.56, 2.38) 0.87 (0.79, 0.82) -- -- 
*Adjusted for race, sex, metropolitan status, Appalachian status, foster care, different 
household, mother on Medicaid, sibling on Medicaid, gestational age, sibling with NAS, 
and foster care. Model c-statistic=0.72. 
**Adjusted for race, sex, metropolitan status, Appalachian status, foster care, different 
household, mother on Medicaid, sibling on Medicaid, and gestational age. Model c-
statistic=0.72. 
***Reference for opioid exposure level was the Comparator group; race was White; for 
sex, male, metropolitan status, metropolitan county at birth; Appalachian status, non-
Appalachian county at birth; foster care, no foster care; different household, same 
household; mother on Medicaid, having a mother on Medicaid; sibling on Medicaid, 





Table 5.12 Backwards selected logistic regression model of the predictors of mental 
health conditions among children born on Kentucky Medicaid in 2014 with 
continuous enrollment for the first year of life. 













Female Sex at Birth 0.81 (0.72, 0.91) 
Appalachian at Birth 1.46 (1.29, 1.65) 
Foster Care 9.80 (7.93, 12.11) 
Different Household than 
the Mother 
1.64 (1.44, 1.86) 
No Sibling on Medicaid 0.66 (0.58, 0.74) 
Gestational Age 0.80 (0.79, 0.82) 
*Reference for opioid exposure level was the Comparator group; for sex, male; 
Appalachian status, non-Appalachian county at birth; foster care, no foster care; different 





Table 5.13 Demographics of children involved with the foster care system among the 
children born on Kentucky Medicaid in 2014 with continuous enrollment. 
Characteristic Count (Percentage) 
Prenatal Opioid Exposure Level 
NAS 


























Appalachian 160 (27.30%) 
Mental Health Condition 211 (36.01%) 





72 (42.35% of 170 children) 
Supp. 







Figure 5.1 Directed acyclic graph (DAG) hypothesizing the relationship between 





Figure 5.2 Directed acyclic graph (DAG) hypothesizing the relationship between 
prenatal opioid exposure and cognitive development. (Code in the Appendix.)  
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CHAPTER 6. STRUCTURAL IMPACT:  HEALTHCARE UTILIZATION AND EXPENDITURES IN 
NEONATAL ABSTINENCE SYNDROME 
6.1 Background 
Children traditionally have low healthcare utilization205, as children tend to be 
healthier individuals than most adults. Overall, children have increased physical activity 
compared to adults and tend to consume healthier diets. As such, healthy children tend to 
be relatively low-risk individuals for companies to insure. The current well-child visit 
schedules recommended by the American Academy of Pediatrics, between ages 1 and 5, 
that a child see a pediatrician for a checkup within the 3 to 5 days of birth, at 1 month, 2 
month, 4 months, 6 months, 9 months, 12 months, 15 months, 18 months, 2 years, 2 ½ 
years, 3 years, 4 years, and 5 years.206 These well child visits are typically low complexity 
outpatient office visits with relatively low costs to the healthcare system. 
Increased utilization of healthcare in this population typically implies increased 
adverse health outcomes207, as children do not necessarily obtain care when it is not needed. 
The healthcare utilization of the child is linked to the caregiver’s capability and capacity 
to identify and fulfill the need for healthcare services to be obtained.208 This role of a parent 
then becomes a filter; less serious healthcare issues may not necessarily warrant an office 
visit. When a child obtains and utilizes healthcare, it is safe to assume the utilization of the 
services was necessary for the child. As such, the investigation of healthcare utilization of 
NAS children then becomes an important proxy to understanding the difference in health 
outcomes associated with NAS compared to children born without the condition.  
Medicaid has become an important stakeholder as rates of NAS rise. Anticipating 
the economic impact the system will face assists in preparing state Medicaid agencies for 
the healthcare these children will need as they grow older. Two seminal studies, one by 
Taylor et al.60 and one by Corr et al.42, have previously been conducted in this area, with 
Medicaid as the targeted population. Taylor et al. examined expenditures through the 
second year of life, finding significant differences.60 Corr et al. examined an eleven year 
cohort, finding that differences persist through the first few years of life, but those 
differences begin deteriorating around age 4 for all health services.42  
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Uncovering differences in healthcare utilization in these early periods of a child’s 
life could provide impetus for Medicaid systems to provide additional oversight and 
investment in the needs of these children to reduce overall burden and improve the 
efficiency of the services used by the children. Healthcare utilization here will be analyzed 
as the number of services obtained, the cost of the services obtained, the number and cost 
of inpatient visits, the number of pharmacy prescriptions, and the number of unique 
pharmacy prescriptions. The intent of this chapter is to analyze whether differences exist 
and provide a model of total healthcare expenditures as they relate to the Medicaid system 
to assess whether costs associated with prenatal opioid exposure decrease over time. 
6.2 Methods 
The entire study population identified in Chapter Three was utilized in the analysis. 
The entire study population was used in this instance due to the nature of the outcomes 
analyzed. The outcomes assessed within the chapter were composite annual summations 
of various types of healthcare expenditures available within the Kentucky Medicaid 
administrative claims database and were longitudinal in nature, permitting the investigation 
of changes over time for this group of children. From this overall population of children, 
the population was subset to include only children with one or more claim within a given 
year of life as well as expenditures totaling at least $1 for a year of life. Observations with 
missing information for any of the variables were removed from the analysis in the 
modeling step. 
Additionally, children were included in the analysis for each year of life these criteria 
were met; if a child obtained no healthcare utilization in one year, but did in the following 
year, the child was included in the following year, but their information was excluded for 
the year in which they had no healthcare expenditures. The intent of this was to identify 
the total impact of NAS to the Medicaid system, not necessarily quantify the degree to 
which NAS alters the mean expenditures for a child; to mimic a more realistic environment 
for the Medicaid system, children could pop in and out of the system and healthcare 
utilization and contribute only a small percentage of utilization and observations, yet still 
compound annual costs that are relevant to the Medicaid system. To subset the population 
to only consist of the children who were consistently utilizing services changes the overall 
111 
 
interpretation of the information being modeled. As the intent was to approach the analysis 
from the perspective of the Medicaid system and not necessarily the child, the entire study 
population was utilized. 
 
6.2.1 Statistical Analyses 
Frequency analyses were conducted to identify differences among the strata, with 
chi square analyses being utilized to identify statistically significant differences among the 
strata for categorical variables. ANOVA analyses were run to ascertain differences 
between the strata for the continuous variables within this study. 
A linear mixed effects model was utilized to assess total expenditures based on 
prenatal opioid exposure level and year of life. A DAG was utilized to identify potential 
main effects for the model. The DAG was created using DAGitty v3.0. Main effects for 
each of these variables, as well as time, were utilized in the analysis; an interaction term 
accounting for the influence of time on prenatal opioid status was also included in the 
analysis as the intent of the model was to assess changes in NAS expenditures over time. 
The working mean structure was chosen based on the AIC selection criteria after 
the application of the covariance structure to a saturated means model based on the items 
identified by the DAG. Covariance parameters were estimated using restricted maximum 
likelihood (or REML) estimators. REML was utilized because REML tends to produce less 
biased estimates of the variance compared to maximum likelihood (ML) estimators. 
Model-based standard errors were utilized in this analysis. The overall population had 
many observations, which could result in inconsistencies in the empirical standard error 
estimates. Also, because of the large number of subjects and multiple observations from 
most subjects (minimum 1, maximum 6), no small-sample corrections were utilized in this 
analysis. 
Two-sided F-tests were utilized ascertain statistical significance for all variables in 
the analysis; statistical inference was drawn from the parameter estimates given by the 
model. A significance level of 0.05 was utilized in the analysis; a p-value less than 0.05 




6.3.1 Children with No Healthcare Utilization within a Given Year 
With the establishment of the study population with the exclusion criteria of one 
claim and at least $1 of healthcare expenditures during the study period, a population of 
children that did not utilize any healthcare services within a given year of life were 
discovered. These children contributed 36,786 observations to the study period. The 
frequency of children with no healthcare expenditures, stratified by year of life and birth 
year cohort, are shown in Table 6.1. Among these children, it did seem that most children 
did obtain healthcare services while enrolled in Medicaid within the first year of life, with 
only around 200 children in each birth year cohort not utilizing any services or acquiring 
any expenditures. An exception to this is in birth year cohort 2014, in which over 400 
children, approximately double the other years, met this criterion. From there, at each age 
and among each birth year cohort, the children seemed rather evenly dispersed, not 
suggesting any birth cohort and age effects contributing to this phenomenon. 
Demographic details of these children were explored in Table 6.2. Though these 
children contributed over 36,700 observations to the study, meaning they were enrolled at 
Medicaid at some point in the year but did not utilize any services, the unique population 
of children was only composed of 27,029. This suggests that there is a group of children in 
this analysis enrolled in Medicaid in multiple successive years that are not receiving any 
healthcare services. The demographics of this population were also largely reflective of the 
larger population identified in Chapter 3, with one notable exception: this group of children 
was considerably less Appalachian than the overall population. This is an interesting 
finding from the data: despite access to care being a known issue in Appalachia162, the data 
suggests that children in Appalachia are largely receiving healthcare services. 
 
6.3.2 Children with Healthcare Utilization 
Table 6.3 presents a table providing the number of observations contributed by each 
age and each birth year cohort among the entire population of children, once the exclusion 
criteria was applied to the data. In total, the number of observations contributed by the 
study population reduced to 583,845 qualifying observations. While there are reductions 
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in the total number of observations for each birth cohort over time, the drop-out rate is 
rather constant for each of the birth year cohorts, providing a steady stream of data to 
analyze among all the children. Demographics for the study population are also presented 
in Table 6.4. As expected, because few children and few observations were eliminated for 
this analysis, the population is largely reflective of the overall population identified in 
Chapter 3. 
Measures of central tendency as they relate to several determinations of healthcare 
utilization are shown in Table 6.5 for healthcare services and Table 6.6 for pharmacy-
related claims. In Table 6.5, significant differences were found for overall healthcare 
expenditures, overall number of claims, and overall inpatient expenditures. Outpatient 
expenditures, however, did not obtain statistical significance, and thus do not provide 
evidence of differences in outpatient costs.  
Table 6.7 presents a repeated measures ANOVA of the difference in total healthcare 
expenditures among each age group. Consistent with the findings of Taylor et al.60 and 
Corr et al.42, these expenditures were significantly different through the third year of life. 
After age four, however, these costs ceased being statistically different.42 
These findings identify several areas for improvement for other models of healthcare 
expenditures as they relate to children with prenatal opioid exposure. First, there does seem 
to be a lessening of statistically significant differences over time, as was suggested by Corr 
et al.42 This suggests that there may be cause to examine for the importance of an 
interaction between prenatal opioid exposure level and year of life in models of total 
healthcare expenditures over time. Secondly, it is reasonable to assume that a year’s 
healthcare expenditures are related to a previous year’s healthcare expenditures, thus 
presenting a need to account for within-subject variability in a created statistical model. 
 
6.3.3 Modeling Total Annual Healthcare Expenditures 
A linear mixed model was proposed to accommodate all the improvements noted 
above. A linear mixed model was targeted as the outcome of interest, healthcare 
expenditures, is a continuous, real number outcome, meaning that the number can be any 
number that is part of the real numbers. Linear mixed models require this type of number 
as a dependent variable. It is worth noting that a lower bound of one was applied to the 
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dependent outcome of interest, thus preventing the data from dipping below one. However, 
the range of the data and the size of the population is sufficient to the degree that this should 
not matter or alter findings of the model. 
First, a DAG was utilized to establish a saturated means model for analysis. The 
DAG for the study is shown in Figure 6.1, with additional explanation for the inclusion of 
each of the variables available in Table 6.8. The variables and proxy variables identified 
will be utilized in the determination of the covariance matrix with a saturated means model, 
meaning a model that is potentially overfit, as well as a more parsimonious model, which, 
here, will be identified as a model adjusted for the variables considered to be the minimal 
sufficient adjustment set through the utilization of the DAG. 
Next, a linear mixed model assumes that the dependent variable is normally 
distributed. Figure 6.2 shows an untransformed distribution of total healthcare 
expenditures, which shows an extreme left skew in the data. To correct this, a natural log 
transformation was attempted, as shown in Figure 6.3, with goodness of fit statistics 
assessing the model fit to a normal distribution shown in Table 6.9. Visually, assessing 
Figure 6.3, the natural log transformation seemed to benefit the distribution immensely, 
though the fit does vary from a normal distribution in several locations as data clustered 
around a certain area. The model fit statistics in Table 6.9 also indicated that the model 
does likely deviate from a normal distribution. 
To attempt to correct this, two additional transformations were attempted, with a 
second and third natural log applied to the variable, producing transformations of 
𝑖𝑖𝑛𝑛(𝑖𝑖𝑛𝑛(𝑟𝑟𝑜𝑜𝑟𝑟𝑟𝑟𝑖𝑖 𝑟𝑟𝑥𝑥𝑝𝑝𝑟𝑟𝑛𝑛𝑖𝑖𝑖𝑖𝑟𝑟𝑛𝑛𝑟𝑟𝑟𝑟𝑑𝑑) and 𝑖𝑖𝑛𝑛(𝑖𝑖𝑛𝑛(𝑖𝑖𝑛𝑛(𝑟𝑟𝑜𝑜𝑟𝑟𝑟𝑟𝑖𝑖 𝑟𝑟𝑥𝑥𝑝𝑝𝑟𝑟𝑛𝑛𝑖𝑖𝑖𝑖𝑟𝑟𝑛𝑛𝑟𝑟𝑟𝑟𝑑𝑑))) to be assessed. The 
model fit statistics for these models continued producing results consistent with the 
distribution being significantly different than a normal distribution. Visually, as shown in 
Figures 6.4 and 6.5, the distributions began to skew to the right with additional applications 
of the log transformation. Thus, the transformation of 𝑖𝑖𝑛𝑛(𝑟𝑟𝑜𝑜𝑟𝑟𝑟𝑟𝑖𝑖 𝑟𝑟𝑥𝑥𝑝𝑝𝑟𝑟𝑛𝑛𝑖𝑖𝑖𝑖𝑟𝑟𝑛𝑛𝑟𝑟𝑟𝑟𝑑𝑑) was 
applied to the dependent variable in the final model. 
The saturated means model was first used to determine a working covariance 
structure. The design in this study was unbalanced, meaning that all subjects did not 
contribute equal numbers of time points, which means that many covariance structures 
were invalid out-of-hand and were thus not included in the analysis. Covariance structures 
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that work with unbalanced designs include compound symmetry and exponential power 
decay covariance structures. Usually, whenever possible, an unstructured covariance 
matrix should be utilized, as this covariance matrix does not force the data to follow any 
specific pattern as far as the within-subject variability. However, unstructured matrices 
generally only work with balanced designs; because the study design here is unbalanced, 
an unstructured covariance matrix was not considered for analysis. 
The results of the tests to determine the working covariance matrix are shown in 
Table 6.10. The AIC was utilized in this analysis to select a model. Of note, when a 
compound symmetry covariance structure with heterogenous variance was attempted, SAS 
returned that the model had infinite likelihood and would not complete the analysis. This 
is likely due to many subjects with only one observation contributing to the analysis; 
because SAS could not locate additional observations, SAS could not determine the 
variance between the observations, as a variance inherently assumes more than one 
repeated measure for each subject. To fix this, the population would need to be filtered 
down to those observations for which a minimum of two observations contributed to the 
analysis. Nonetheless, the results in Table 6.10 indicated than an exponential power decay 
model may be the best fit for the data. Inherently, this may be sensible; an exponential 
power decay model assumes that the variability decreases over time, as is shown by the 
decreasing ranges in Table 6.7, though the rate at which these variances decrease in an 
exponential power decay structure may be faster than what is realistically possible. 
However, because this covariance structure was inherently more sensible than a compound 
symmetry covariance structure, this was the working covariance structure selected to be 
included in the remaining analyses. 
The saturated means model used to determine the covariance structure is provided in 
Table 6.11, with the parsimonious model presented in Table 6.12. A post hoc additional 
adjusted model is also provided in Table 6.13, where the model only kept in the statistically 
significant variables. All three of these models point to the same conclusion, though the 
quantification of the amount varies between the models due to the additions and 
subtractions from the model adjustment: total expenditures for the population of children 
with NAS and children with prenatal opioid exposure are higher than the comparator group. 
Annually, expenditures for all children decrease as the children grow older. However, when 
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considering the interaction between the opioid exposure variable and the age variable, the 
rate at which total expenditures for the population of children with NAS and with prenatal 
opioid exposure decrease over time is faster than that of the comparator group. This 
suggests that, as time continues and if the trend continues, expenditures for children with 
some level of prenatal opioid exposure will eventually reach an inflection point and equal 
out to the expenditures accrued by the comparator group. 
Additionally, within the adjustment, foster care children also have a higher rate of 
healthcare utilization than children not in foster care. Conversely, children that are enrolled 
as female have lower expenditures than children that are enrolled as male. Increasing 
gestational age also appears to decrease total expenditures. Conversely, while residing in a 
rural area does decrease total expenditures, residing in Appalachia increases expenditures. 
One interesting finding is prenatal care; it appears that increased amounts of prenatal 
care also increase the total expenditures for a child; however, this may be because mothers 
that obtain prenatal care are also more likely to use other healthcare services for her 
children, such as well-child visits. It is also worth noting that the amount by which prenatal 
care increases total expenditures is negligible and does not provide an argument against 
advocating for prenatal care for mothers and babies. 
Model fit statistics via the AIC are shown in Table 6.14 for all three of these models. 
AIC was chosen as the model fit comparison because BIC values tend to favor simpler 
models and AICC values are best utilized in small samples.143 When using AIC values to 
select models, the smallest value represents the best fit.143 Here, the smallest AIC value 
actually belonged to the largest model, the saturated means model, thus producing a final 
model from this analysis of 
𝑖𝑖𝑛𝑛(𝑟𝑟𝑜𝑜𝑟𝑟𝑟𝑟𝑖𝑖 𝑟𝑟𝑥𝑥𝑝𝑝𝑟𝑟𝑛𝑛𝑖𝑖𝑖𝑖𝑟𝑟𝑛𝑛𝑟𝑟𝑟𝑟𝑑𝑑)  
=  8.84 +  0.99𝑥𝑥1 + 0.84𝑥𝑥2 − 0.32𝑥𝑥3 − 0.24𝑥𝑥1𝑥𝑥3 − 0.27𝑥𝑥2𝑥𝑥3 + 0.7𝑥𝑥4
− 0.3𝑥𝑥5 + 0.02𝑥𝑥6 + 0.0002𝑥𝑥7 − 0.05𝑥𝑥8 + 0.1𝑥𝑥9 + 0.05𝑥𝑥10 + 0.3𝑥𝑥11
+ 0.03𝑥𝑥12 − 0.04𝑥𝑥13 + 0.0005𝑥𝑥14 
where 
x1 is a dichotomous variable indicating whether a child had a diagnosis of NAS, 




 x3 is a continuous variable indicating the year of life for a child, 
 x4 is a dichotomous variable indicating whether a child began the year in an 
Appalachian county, 
 x5 is a dichotomous variable indicating whether a child began the year in a non-
metropolitan county, 
 x6 is a dichotomous variable indicating whether a child’s race was identified as 
Black, 
 x7 is a dichotomous variable indicating whether a child’s race was identified as 
Other, 
 x8 is a dichotomous variable indicating whether a child’s sex was identified as 
female, 
 x9 is a dichotomous variable indicating whether a child’s mother was in the 
Medicaid database, 
 x10 is a dichotomous variable indicating whether a child had a sibling born after 
2014 identified in the Medicaid database, 
 x11 is a dichotomous variable indicating whether a child was in foster care for that 
year of life, 
 x12 is a continuous variable indicating the number of claims a child accrued for that 
year of life, 
 x13 is a continuous variable indicating the gestational age identified on the birth 
certificate for the child, 
and x14 is a continuous variable indicating the number of prenatal visits the child’s 
mother obtained during pregnancy for the child. 
6.4 Discussion 
While many of the findings reached statistical significance, the actual meaningful 
difference of the values must be considered. For example, the mean values for unique 
pharmacy prescriptions for the three strata of children in Table 6.6 were 1.31, 1,42, and 
1.40; median values for this were 1 for all strata. Functionally, these values do not represent 




Statistical power is driven by both the effect size and the population size, and is 
calculated as 1-β, or one minus the probability of a true positive.146 As sample size 
increases, the probability that we will reject the null hypothesis also increases, thus creating 
the phenomenon in administrative claims-based analyses of results that are wildly 
statistically significant or wildly statistically insignificant. Thus, when considering 
findings that are statistically significant in these types of analyses, functional (or clinical) 
meaningfulness of the differences must be considered.  
Many of our statistically significant differences in Table 6.5 and Table 6.6 are likely 
due to the large sample size alone rather than the effect size, as the actual difference 
between the groups for many of these figures are quite small. Therefore, though statistically 
significant findings were discovered, those differences should be approached with caution 
in interpretation. 
Table 6.7 looked at overall total healthcare expenditures by year of life, as they apply 
to the Medicaid system. In this table, we found results consistent with the findings of Corr 
et al.42, finding that expenditures ceased being statistically different around ages four and 
five for the population of children born on Kentucky Medicaid between 2014 and 2015. 
There are many reasons this could be the case. One reason could be the introduction of 
school into the child’s life around this time, leading to less contact with the parent and 
therefore less time to obtain healthcare utilization. Additionally, many school systems have 
nurses on staff, and small healthcare needs may be handled and brought to the caretaker’s 
attention by the school nurse rather than by a billable physician. Another reason could be 
the end of services such as NICU graduate programs that children with NAS may have 
been involved with, where developmental screenings and enhanced attention and follow-
up to these children were previously established.  Nonetheless, this presents an interesting 
pattern for Medicaid to consider when planning for expenditures in the future, and an area 
where policies, such as enhancing managed care oversight for these children, could prove 
beneficial in ensuring that no healthcare waste is being obtained and that caretakers have 
adequate information on when care should be sought for children. 
Conversely, in Table 6.1 and Table 6.2, it was determined that there is a population 
of children that are not receiving any healthcare within a year of life in which they are, at 
some point, enrolled in the Medicaid system. While a reason for this could be that the child 
119 
 
was not enrolled long enough during that year of life to utilize healthcare services, it is also 
probable that the child simply did not receive any healthcare services for that year. 
Considering both the years of life examined and the American Academy of Pediatrics well-
child visit schedule, this is a deviation from the standards established by that group of 
practitioners. Medicaid then should prompt managed care organizations to intervene when 
children are not receiving their recommended well-child visits to ensure that children are 
having healthy childhoods. 
 
 
6.4.1 Limitations and Future Directions 
 
This chapter provides two novel approaches to economic analyses for this population 
within the literature: first, the utilization of a non-Gaussian model to account for within-
subject variability, as a previous year’s healthcare expenditures are likely related to the 
current year’s expenditures, as well as the utilization of an intercept variable for NAS and 
time, indicating the rate at which expenditures for NAS and prenatal opioid exposure are 
decreasing when compared to the comparator group. The utilization of the non-Gaussian 
model and model-based standard errors does present the possibility that the covariance 
structure was mis-specified in the model, thus creating inaccurate inference. One way to 
protect against this in future analyses would be through the utilization of robust standard 
errors as opposed to model-based standard errors; robust standard errors would act as a 
protective measure ensuring that inference that is approximately correct while 
acknowledging that the covariance matrix utilized in the analysis is likely mis-specified. 
A sensitivity analysis was therefore conducted using the fully adjusted model to 
ascertain whether inference from the model-based standard errors was approximately 
unbiased by utilizing robust empirical standard error estimates. The results from this 
sensitivity analysis are shown in Table 6.15 and given by the equation 
𝑖𝑖𝑛𝑛(𝑟𝑟𝑥𝑥𝑝𝑝𝑟𝑟𝑛𝑛𝑖𝑖𝑖𝑖𝑟𝑟𝑛𝑛𝑟𝑟𝑟𝑟𝑑𝑑)  
=  8.84 + 0.99𝑥𝑥1 + 0.84𝑥𝑥2 − 0.32𝑥𝑥3 − 0.24𝑥𝑥1𝑥𝑥3 − 0.27𝑥𝑥2𝑥𝑥3 + 0.07𝑥𝑥4
− 0.03𝑥𝑥5 + 0.02𝑥𝑥6 + 0.002𝑥𝑥7 − 0.05𝑥𝑥8 + 0.10𝑥𝑥9 + 0.05𝑥𝑥10 + 0.05𝑥𝑥11




x1 is a dichotomous variable indicating whether a child had a diagnosis of NAS, 
x2 is a dichotomous variable indicating whether a child had a diagnosis of prenatal 
opioid exposure, 
x3 is a continuous variable indicating the year of life for a child, 
x4 is a dichotomous variable indicating whether a child began the year in an 
Appalachian county, 
x5 is a dichotomous variable indicating whether a child began the year in a non-
metropolitan county, 
x6 is a dichotomous variable indicating whether a child’s race was identified as 
Black, 
x7 is a dichotomous variable indicating whether a child’s race was identified as Other, 
x8 is a dichotomous variable indicating whether a child’s sex was identified as 
female, 
x9 is a dichotomous variable indicating whether a child’s mother was in the Medicaid 
database, 
x10 is a dichotomous variable indicating whether a child had a sibling born after 2014 
identified in the Medicaid database, 
x11 is a dichotomous variable indicating whether a child was in foster care for that 
year of life, 
x12 is a continuous variable indicating the number of claims a child accrued for that 
year of life, 
x13 is a continuous variable indicating the gestational age identified on the birth 
certificate for the child, 
and x14 is a continuous variable indicating the number of prenatal visits the child’s 
mother obtained during pregnancy for the child. 
This equation is approximately equal to the final equation given by the results in 
Table 6.11, indicating that the inference based on the final model is likely approximately 
correct. The standard errors also showed minimal correction. While it remains true that the 
covariance structure utilized within the scope of the analysis may possibly be mis-
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specified, the results of the sensitivity analysis indicate that the inference likely was not 
impact by the error. 
Another significant limitation to the findings of these analyses was the lack of 
information surrounding diagnoses or reasons for the utilization of healthcare. The 
comparator group population consisted of all children without evidence of prenatal opioid 
exposure; while the group did, by definition, consist of children without any evidence of 
prenatal opioid exposure, the group could have contained children with pediatric cancer 
diagnoses, congenital defects, and children that were involved with traumatic automobile 
accidents. However, the intent of this analysis was not to ascertain whether a child with 
NAS accrued more healthcare costs than a child without evidence of health complications, 
but to ascertain whether the average cost of a child with NAS varied from that of their 
peers. That peer group does consist of both children with no evidence of health issues and 
children with severe health issues. Additionally, having a diagnosis of NAS does not 
necessarily pre-empt a child from experiencing a congenital defect, as was established by 
Wen et al.,41 a cancer diagnosis, or an automobile accident, which may lead to increased 
expenditures for those children as well. Additionally, children who died during the study 
period were not identified or examined within the context of this work. 
Given these limitations, future directions for this work would be to partner with an 
economist to optimize the model utilized within this dissertation. The model produced here 
was a mixed linear model as established by an epidemiologist; the model could benefit 
significantly through consultations with an economist to understand more of the 
econometrics required to accurate model such a relationship. Additionally, insight into 
reasons for healthcare utilization should be examined in the future. Finally, additional 




Table 6.1 Year of life and birth year cohort for children with no healthcare 
expenditures during a year of life among the children born on Kentucky Medicaid 
between 2014 and 2019. 
Year of 
Life 
2014 2015 2016 2017 2018 2019 Total 
Birth to 1 416 287 244 198 229 261 1,635 
1 to 2 2,113 1,976 1,928 1,772 2,111 -- 9,900 
2 to 3 2,512 2,387 2,172 2,592 -- -- 9,663 
3 to 4 2,748 2,552 3,166 -- -- -- 8,466 
4 to 5 2,035 2,620 -- -- -- -- 4,655 
5 to 6 2,467 -- -- -- -- -- 2,467 





Table 6.2 Demographics of the children born on Kentucky Medicaid between 2014 
and 2019 who had at least one year of no healthcare expenditures. 
Characteristic Number of 
Children 
Percent among 

























































Foster Care 876 3.24% 10.52% 



















Table 6.3 Number of observations for each birth year cohort and year of life for the 
population of children with at least $1 in healthcare expenditures and 1 paid claim 
among the children born on Kentucky Medicaid between 2014 and 2019. N=583,845. 
Year of 
Life 
2014 2015 2016 2017 2018 2019 Total 
Birth to 1 31,502 32,643 31,981 32,120 31,579 30,807 190,632 
1 to 2 28,387 29,652 28,890 28,941 27,861 -- 143,731 
2 to 3 26,255 27,117 26,278 25,106 -- -- 104,756 
3 to 4 24,929 25,519 23,569 -- -- -- 74,017 
4 to 5 24,381 23,815 -- -- -- -- 48,196 
5 to 6 22,513 -- -- -- -- -- 22,513 





Table 6.4 Demographics of the study population of children born on Kentucky 
Medicaid between 2014 and 2019 with at least $1 of healthcare expenditures and 1 
claim, stratified by opioid exposure status. N=191,156. 
Characteristic NAS Diagnosis 
 













































































38.40 (1.75) 38.14 (2.26) 38.63 (1.73) 38.61 (1.75) <0.0001 
Foster Care 1,612 (19.58%) 905 (15.46%) 5,750 (3.25%) 8,267 (4.32%) <0.0001 
*A suppressed number of observations (n ≤10) are missing from these tallies; to minimize the potential for 




Table 6.5 Measures of central tendency for select health utilization figures for the 
population of children born on Kentucky Medicaid between 2014 to 2019 with at 
least one claim and $1 of healthcare expenditures in each year of life, stratified by 
opioid exposure status. N=583,845. 
TOTAL HEALTHCARE EXPENDITURES 
 Mean Median Stan. Dev. Minimum Maximum P-Value 
NAS 10,580.02 2,284 38,465.12 2 3,479,574 <0.0001 
Prenatal 
Exposure 
8,967.70 2,180 32,099.08 1 1,079,300 
Comparator 4,446.95 1,457 23,557.61 1 3,305,638 
Total 
Population 
4,844.26 1,489 24,772.57 1 3,479,574 
TOTAL HEALTHCARE UTILIZATION 
 Mean Median Stan. Dev. Minimum Maximum P-Value 
NAS 31.50 17 36.34 1 670 <0.0001 
Prenatal 
Exposure 
27.52 18 34.78 1 656 
Comparator 31.50 22 28.47 1 907 
Total 
Population 
24.68 17 29.09 1 907 
TOTAL INPATIENT EXPENDITURES 
 Mean Median Stan. Dev. Minimum Maximum P-Value 
NAS 22,366.89 19,262 59,590.21 50 3,370,499 <0.0001 
Prenatal 
Exposure 
15,582.03 7,158 41,565.50 86 1,007,445 
Comparator 7,518.46 1,269 37,086.58 1 3,216,231 
Total 
Population 
8,521.18 1,410 38,801.82 1 3,370,499 
TOTAL OUTPATIENT EXPENDITURES 
 Mean Median Stan. Dev. Minimum Maximum P-Value 
NAS 868.84 360.50 2,070.11 1 118,378 0.21 
Prenatal 
Exposure 
916.35 387 1,892.93 1 53,062 
Comparator 827.25 364 5,835.07 1 2,155,788 
Total 
Population 




Table 6.6 Measures of central tendency for select pharmacy utilization figures and 
components for the population of children born on Kentucky Medicaid, 2014 to 
2019, stratified by opioid exposure status. 
TOTAL PHARMACY EXPENDITURES 
 Mean Median Stan. Dev. Minimum Maximum P-Value 
NAS 376.52 80 3,344.82 1 197,064 <0.0001 
Prenatal 
Exposure 
593.26 60 6,988.94 1 381,706 
Comparator 316.19 62 4,269.38 1 1,544,841 
Total 
Population 
326.64 63 4,330.30 1 1,544,841 
TOTAL NUMBER OF PRESCRIPTIONS 
 Mean Median Stan. Dev. Minimum Maximum P-Value 
NAS 7.21 5 9.32 0 154 <0.0001 
Prenatal 
Exposure 
5.80 4 8.29 0 115 
Comparator 5.60 4 7.74 0 433 
Total 
Population 
6.04 4 7.95 0 433 
NUMBER OF UNIQUE PRESCRIPTIONS 
 Mean Median Stan. Dev. Minimum Maximum P-Value 
NAS 1.40 1 0.66 1 8 <0.0001 
Prenatal 
Exposure 
1.42 1 0.65 1 12 
Comparator 1.31 1 0.54 1 14 
Total 
Population 
1.32 1 0.55 1 14 
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Table 6.7 Measures of central tendency for overall healthcare expenditures for the 
population of children born on Kentucky Medicaid, 2014 to 2019, stratified by 





































































































































*To account for multiple comparisons, a Bonferroni adjustment was applied to the 
α threshold, creating an adjusted α threshold of 0.008. An asterisk denotes a 




Table 6.8 Factors identified by the DAG, proxy variables available within the data, 
justification, and models the variables were included in for the linear mixed model 
of the association between prenatal opioid exposure and healthcare expenditures. 












The ability to obtain healthcare 
depends upon the proximity to 
healthcare.209 Known shortages of 
doctors in rural areas of the 
United States.210 Appalachian 
Kentucky has traditionally 
struggled with access to care.211  
X X 
Race Race Race often determines the care 
one can access, as well as the care 
received in a healthcare setting.212 
X X 
Sex Sex There may be gender differences 
in healthcare utilization in 
children.213,214 Male sex has been 










Parents determine when a child 
gets healthcare.215 Foster care 










Best indicator of sickness in a 
child available in the dataset is 
the utilization of healthcare 
resources. Gestational age has 
been associated with increased 
healthcare utilization.216 Prenatal 
care is vital for a healthy birth, 
though long-term effects are still 
in question.217 
X  




Table 6.9 Goodness of fit tests for a normal distribution of the transformation 
ln(Total Expenditures). 
Test Statistic P-Value 
Kolmogorov-Smirnov 0.03 <0.01 
Cramer-von Mises 84.22 <0.005 
Anderson-Darling 537.40 <0.005 
*The results in Table 6.9 indicate that the distribution shown in Figure 6.3 is significantly 




Table 6.10 Covariance structure selection criteria following the fitting of a saturated 
means model into a linear mixed effects model. 
Covariance Structure AIC** 
Compound symmetry, common variance 1,555,282 
Exponential power decay, common 
variance 
1,543,380 
*The observational study in Chapter 6 is an unbalanced design, therefore, testing unstructured covariance structures, 
Toeplitz covariance structures, AR-1 covariance structures, and banded covariance structures were considered 
impractical and inappropriate for the model and therefore excluded from consideration. 
**AIC selection criterion dictates that the model with the smallest AIC value is the most efficient estimate of the 





Table 6.11 Results of the linear mixed effects model modeling differences in overall 
healthcare expenditures for children with prenatal opioid exposure over time, 







































































































-0.05 0.003 -0.06 -0.04 <.0001 
Mother on 
Medicaid 
0.10 0.020 0.06 0.14 <.0001 
Sibling on 
Medicaid 
0.05 0.003 0.04 0.06 <.0001 
Foster Care 
Involvement 
0.30 0.008 0.28 0.32 <.0001 
Number of 
Claims 
0.03 0.00006 0.03 0.03 <.0001 
Gestational 
Age 
-0.04 0.001 -0.04 -0.04 <.0001 
Prenatal 
Care 
0.0005 0.00009 -0.001 0.002 <.0001 
*175,731 subjects composed the model population. Of the 583,845 observations 




Table 6.12 Results of the linear mixed effects model modeling differences in overall 
healthcare expenditures for children with prenatal opioid exposure over time, 



















































































































-0.13 0.004 -0.14 -0.12 <.0001 
*191,154 subjects composed the model population. Of the 583,845 observations 





Table 6.13 Results of the linear mixed effects model modeling differences in overall 
healthcare expenditures for children with prenatal opioid exposure over time, 

































































































-0.13 0.004 -0.14 -0.12 <.0001 
*191,154 subjects composed the model population. Of the 583,845 observations 





Table 6.14 Model comparison following the fitting of three different models into a 
linear mixed effects model with an exponential power decay covariance structure. 
Means Model AIC* 
Saturated means model (Table 6.11) 1,543,380 
Parsimonious means model (Table 6.12) 1,915,859 
Parsimonious means model, additional 
adjustment (Table 6.13) 
1,915,843 
*AIC selection criterion dictates that the model with the smallest AIC value is the 
most efficient estimate of the covariance structure of the model. The AIC selection 




Table 6.15 Results of the linear mixed effects model modeling differences in overall 
healthcare expenditures for children with prenatal opioid exposure over time, 





















































Female at Birth -0.05 0.003 <.0001 
Mother on Medicaid 0.10 0.021 <.0001 
Sibling on Medicaid 0.05 0.003 <.0001 
Foster Care 
Involvement 
0.30 0.009 <.0001 
Number of Claims 0.03 0.0003 <.0001 
Gestational Age -0.04 0.001 <.0001 
Prenatal Care 0.0005 0.00001 <.0001 
*175,731 subjects composed the model population. Of the 583,845 observations 







Figure 6.1 Directed acyclic graph (DAG) illustrating the relationship between 







Figure 6.2 Distribution of all total expenditures for the population of children born 
on Kentucky Medicaid between 2014 and 2019 and with at least $1 in expenditures 






Figure 6.3 Distribution of all total expenditures for the population of children born 
on Kentucky Medicaid between 2014 and 2019 and with at least $1 in expenditures 








Figure 6.4 Distribution of all total expenditures for the population of children born 
on Kentucky Medicaid between 2014 and 2019 and with at least $1 in expenditures 






Figure 6.5 Distribution of all total expenditures for the population of children born 
on Kentucky Medicaid between 2014 and 2019 and with at least $1 in expenditures 






CHAPTER 7. CONCLUSION 
7.1 Summary 
In an American healthcare context, it is impossible to separate the provision of 
healthcare from a person’s insurance coverage. One of the largest strides in healthcare 
coverage occurred in 2012 with the passage of the Affordable Care Act.88 Kentucky was 
one of the first states to expand their state Medicaid program.88 Prior to this expansion, 
back in 1990s, Kentucky made the decision to house their CHIP program within Medicaid. 
In 1990, the passage of KRS 205.592 mandated Medicaid coverage for the duration of the 
first year of a child’s life.38 All these items in tandem, along with the creation of OHDA as 
a “data hub” in existence to provide analytics for the Kentucky Department for Medicaid 
Services, permitted the Kentucky Medicaid MMIS to be an optimal dataset to use in the 
examination of childhood outcomes for NAS. 
The literature synthesis in Chapter 2 identified significant gaps in the published 
literature, as well as validated the ICD-9 and ICD-10 codes used to ascertain a diagnosis 
of NAS in the literature using Tennessee Medicaid data linked to medical records.59 
Additionally, many of these studies identified factors that would be important 
considerations in the work of later chapters. 
Chapter 3 contained the methodology and demographics for the study population 
utilized within the chapters in this dissertation. Consistent with most of the published 
literature, the population of children with a diagnosis of NAS were largely White, mostly 
male, and the majority resided in non-metropolitan counties and/or Appalachian counties 
within Kentucky. Additionally, retention to Kentucky Medicaid and HEDIS continuous 
enrollment were assessed, showing a long retention to the Kentucky Medicaid system for 
the study population utilized within this dissertation. 
Chapter 4 presented evidence that family units (i.e., mothers and children) are 
frequently covered in tandem within the Medicaid system and that a significant number of 
opioid exposed children are involved with the foster care system. Additionally, a large 
percentage of children with evidence of placental transference of opioids seem to be living 
apart from their mother. 
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The studies in Chapter 5 determined that, while differences identified were 
considered statistically different, there may not be clinically meaningful differences in 
gastrointestinal conditions for the population of children with NAS. Asthma, however, did 
present a significant signal that is consistent with other prior published work in this 
area.42,79 Mental health conditions, however, consistent with the findings of Sherman et 
al.78 and Conner et al.79, appeared to be elevated for one- and two-year-old children 
diagnosed with NAS in the study population. As was hypothesized in Chapter 1, these were 
largely driven by developmental delays. Foster care also seemed to be an important driver 
within this analysis. 
Finally, the study of healthcare utilization in Chapter 6 found results consistent with 
the seminal studies conducted by Taylor et al.60 and Corr et al.42 in this area. In this analysis, 
total expenditures were found to be significantly different between the strata of children 
through age three, with the differences ceasing at ages 4 and 5. Finally, in the modeled 
analysis, while total expenditures for NAS and prenatal opioid exposure were higher than 
the comparator group and while costs did decrease over time, the costs decreased at a faster 
rate over time than the comparator group, suggesting that, eventually, if the trend continues, 
there should be an inflection point where the expenditures of the children with a diagnosis 
of NAS and the expenditures of the children with a diagnosis of prenatal opioid exposure 
would eventually reach the level of their peers.  
 
7.1.1 Policy Recommendations 
This dissertation identifies several options for Medicaid policy to be enacted to 
stimulate better health outcomes for this population. First, because of the large number of 
families on Medicaid coupled with the long retention of children to the Medicaid system, 
Medicaid would stand to benefit from investing in prophylactic measures for this 
population. Additionally, all children in the Kentucky Medicaid system are currently 
managed by one managed care organization (MCO). By taking advantage of the MCO 
structure, families could be pressed when children are not meeting well-child visit 
thresholds or are accumulating excess expenditures. 
Second, Medicaid also has a responsibility to ensure the health and safety of 
children involved with the foster care system. Foster care was identified within this 
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dissertation as an important factor in all analyses surrounding NAS. As shown in Chapter 
5, the group of children with a diagnosis of NAS involved in the foster care system is 
largely driving the diagnoses of mental health conditions. As identified in Chapter 4, 
children entering foster care between these ages are most commonly doing so within the 
first year of that child’s life, when the well-child visit schedule for an infant is more 
demanding than for other ages.206 Medicaid should monitor whether this group of children 
is meeting this schedule and Medicaid should seek interventions and reminders when a 
child has missed several well-child visit milestones. As developmental delays are driving 
the diagnoses obtained by these children in these early years of life, ensuring that children 
are meeting those well-child visits in early childhood is critical to ensuring that adequate 
child development is occurring and that children are receiving proper health interventions 
when needed to ensure happy and healthy childhoods. 
Third, participation in prophylactic measures and well-child visits should be 
incentivized for families, as are already being offered by some health insurance coverage 
plans.218 By offering rewards and perks for adherence to the schedule, such as car seats218, 
Medicaid could offset some of the healthcare expenditures that could arise because of 
accumulated healthcare problems that become urgent medical needs when the situation 
could have been handled at a routine care visit prior to becoming an issue. The Medicaid 
system also stands to benefit from an investment in prophylaxis given the long retention to 
the system for children born on Kentucky Medicaid due to the long duration of retention 
to the Kentucky Medicaid system, as established in Chapter 3. As children are maintaining 
their Medicaid enrollment for relatively long durations of time, Medicaid has the potential 
to see a benefit from such measures being implemented within the next decade as the 
children assessed progress into adolescence and then finally into adulthood. 
 
7.1.2 Future Directions 
The creation of this dataset identified several areas for future research. One of the 
most opportunistic areas that should be further examined with this population is the 
creation of mother-baby dyads and sibling-dyads among children with evidence of prenatal 
opioid exposure. Because almost a quarter of children with NAS in this population have a 
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sibling with some sort of prenatal opioid exposure, both children could be followed in 
tandem to see how their life course differs over time. 
 Additionally, more extensive examination of physical health outcomes related to 
NAS is warranted. NAS impacts an extensive number of body systems of an infant; little 
information exists on the result of this assault later in the child’s life. 
 Finally, additional examination of the economic impact of NAS on the Medicaid 
system should be conducted. As these children grow and develop, more information will 
come to light as the years move forward. Moreover, the Opioid Epidemic continues shifting 
and moving; the state and the drugs at the center of the epidemic in 2014 differ from those 
at the center of the Epidemic today. There is growing evidence that methamphetamine, for 
which no medication assisted therapy exists as of the time of writing, is a growing problem 
within the United States. The influence these changes have on the results of these analyses 
should not be dismissed; though these findings are accurate to the best of the author’s 
knowledge as of the time of writing, the results may differ as changes occur within the 
Medicaid system and within the culture in the years to come. These analyses should be 
returned to in a few years to see if any differences in the findings arisen. 
7.2 Conclusion 
Between ages 1 to 5, this dissertation provides evidence that prenatal exposure to 
opioids continues to have a lasting impact on a child’s life. Placental transference of opioids 
is associated with residing in a different household than the mother, with increased asthma 
diagnoses, and increased mental health condition diagnoses within this population, and has 
a lasting fiscal impact that diminishes over time. Special attention and additional policy 
considerations should be given to these children to ensure the children have safe, strong 









APPENDIX 1. DATA ELEMENTS OBTAINED FROM THE OFFICE OF HEALTH 
DATA AND ANALYTICS WITHIN THE KENTUCKY DEPARTMENT FOR 
MEDICAID SERVICES. 




Utilized to be able to link 
successive years of claims 
together 
Random character variable, 
unique for each child in the 
analysis 
Prenatal opioid exposure 
identifier 
An indicator variable 
identifying whether a child 
was diagnosed with ICD-9 
codes 779.5 or 760.72 or 
ICD-10 codes P96.1 or 
P04.49. 
Dichotomous variable (1 – 
Yes; 0 – No) 
Prenatal opioid exposure 
diagnosis code 
The exact prenatal opioid 
exposure diagnosis code 
the child was diagnosed 
with at birth; in instances 
where the child obtained 
both, the withdrawal code 
was preferred. 
Character variable of five 
levels: 7795, 76072, P961, 
P0449, or 0 
Birth year cohort The year the child was 
born 
Categorical variable 
ranging between 2014 and 
2019 
Year of life A variable indicating the 
year of life the variables 
applied to for an 
observation for each child 
Categorical variable 
ranging between 1 
(meaning the time from 
birth to the day before the 
child’s first birthday, or the 
child’s first full year of 
life) to 6 (meaning the time 
from the child’s fifth 
birthday to the day before 
the child’s sixth birthday, 
or the child’s sixth year of 
life) 
Race The race of the child 
provided on the enrollment 
form 
Character variable of three 
levels: WHITE, BLACK, 
OTHER 
Sex The sex of the child 
provided on the enrollment 
form 
Character variable of three 
levels: M, F, U. U was 




County of residence at the 
beginning of the child’s 
year of life 
The county of residence 
provided on the enrollment 
form at the beginning of 
the year of life 
Categorical variable 
ranging from 1 to 120, with 
a few outliers indicating a 
child resided outside 
Kentucky 
County of residence at the 
end of the child’s year of 
life 
The county of residence 
provided on the enrollment 
form at the end of the year 
of life 
Categorical variable 
ranging from 1 to 120, with 
a few outliers indicating a 
child resided outside 
Kentucky 
RUC code at the beginning 
of the child’s year of life 
The RUC code associated 
with the child’s county of 
residence at the beginning 
of the year of life 
Categorical variable 
ranging from 1 to 9 
RUC code at the end of the 
child’s year of life 
The RUC code associated 
with the child’s county of 
residence at the beginning 
of the year of life 
Categorical variable 
ranging from 1 to 9 
Foster care flag A longitudinal variable 
indicating whether the 
child was involved with the 
foster care system during 
that year of life 
Dichotomous variable (1 – 
Yes, 0 – No) 
Continuous enrollment flag A variable indicating 
whether the child was 
continuously enrolled by 
HEDIS standards for that 
year of life 
Dichotomous variable (Y – 
yes; N – no) 
Mother on Medicaid A variable indicating 
whether the child’s mother 
could be identified in the 
MMIS system 
Dichotomous variable (1 – 
Yes; 0 – No) 
Sibling on Medicaid A variable indicating 
whether a sibling for the 
child (born between 2014 
and the end of the study 
period) could be identified 
in the MMIS system 
Dichotomous variable (1 – 
Yes; 0 – No) 
Sibling with NAS A variable indicating 
whether an identified 
sibling was diagnosed with 
one of the prenatal opioid 
exposure codes at birth 
Dichotomous variable (1 – 
Yes; 0 – No) 
Same household as the 
mother 
A variable indicating 
whether a child was always 
enrolled in the Medicaid 
Dichotomous variable (1 – 
Yes; 0 – No) 
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system at the same address 
as the mother 
Maternal smoking A variable obtained from 
the birth certificate 
indicating whether the 
mother was a smoker at 
birth 
Categorical variable: 1 – 
Yes; 0 – No; 9 – Unknown 
Gestational diabetes 
mellitus 
A variable obtained from 
the birth certificate 
indicating whether the 
mother was diagnosed with 
gestational diabetes 
Categorical variable: 1 – 
Yes; 0 – No; 9 – Unknown 
Gestational hypertension A variable obtained from 
the birth certificate 
indicating whether the 
mother was diagnosed with 
gestational hypertension 
Categorical variable: 1 – 
Yes; 0 – No; 9 – Unknown 
Multigravida A variable obtained from 
the birth certificate 
indicating whether this was 
the mother’s first child 
Categorical variable: 1 – 
Yes; 0 – No; 9 – Unknown 
Infant hepatitis C A variable obtained from 
the birth certificate 
indicating whether the 
infant was exposed to 
hepatitis C in utero 
Categorical variable: 1 – 
Yes; 0 – No; 9 – Unknown 
Number of prenatal visits A variable obtained from 
the birth certificate 
indicating the number of 
prenatal visits the mother 
acquired 
Continuous variable, with 
99 coded as missing 
Gestational age A variable obtained from 
the birth certificate 
estimating the gestational 
age of the child at birth 
Continuous, bounded 
variable with 99 coded as 
missing 
Mental health conditions 
indicator 
A variable identifying if 
the child had been 
diagnosed with one of the 
diagnosis codes indicating 
a mental health condition 
Dichotomous variable (1 – 
Yes; 0 – No) 
Gastrointestinal conditions 
indicator 
A variable identifying if 
the child had been 
diagnosed with one of the 
diagnosis codes indicating 
a gastrointestinal condition 
Dichotomous variable (1 – 





A variable identifying if 
the child had been 
diagnosed with one of the 
diagnosis codes indicating 
a respiratory condition 
Dichotomous variable (1 – 
Yes; 0 – No) 
Total expenditures A variable summing the 
annual expenditures for a 
child 
Continuous numeric 
Total number of claims A variable summing the 
annual number of claims 
for a child 
Continuous numeric 
Well child expenditures The total cost of the well 
child visits for a child 
Continuous numeric 
Number of well child 
claims 
The total number of claims 
for a well child visit each 
year for a child 
Continuous numeric 
Outpatient expenditures The total cost of the 
outpatient claims each year 
for a child 
Continuous numeric 
Number of outpatient 
claims 
The total number of the 
outpatient claims each year 
for a child 
Continuous numeric 
Inpatient expenditures The total cost of the 
inpatient claims each year 
for a child 
Continuous numeric 
Number of inpatient claims The total number of the 
inpatient claims each year 
for a child 
Continuous numeric 
Birth total The estimated total cost of 
the birth event as a child, 
defined as time from birth 
to first 48-hour gap 
Continuous numeric 
Behavioral health claims The total number of 
behavioral health claims 
each year for a child 
In theory, continuous 
numeric; here, all 0 
Pharmacy expenditures The total cost of all 
pharmacy claims each year 
for a child 
Continuous numeric 
Number of pharmacy 
claims 
The total number of 
pharmacy claims each year 
for a child 
Continuous numeric 
Unique pharmacy drugs The total number of unique 





APPENDIX 2.  COUNTIES IDENTIFIED AS APPALACHIAN COUNTIES BY THE 




APPENDIX 3. COUNTIES IDENTIFIED AS METROPOLITAN OR NON-
METROPOLITAN BASED ON THE RURAL URBAN CONTINUUM CODES 




APPENDIX 4. KENTUCKY 2010 POPULATION DISTRIBUTION BASED ON 








APPENDIX 5. CODE FOR THE DIRECTED ACYCLIC GRAPH CREATED TO 
ILLUSTRATE THE RELATIONSHIP BETWEEN PRENATAL OPIOID EXPOSURE 
AND BEING LOCATED IN A DIFFERENT HOUSEHOLD IN CHAPTER 4. 
dag { 
"Birth Year" [pos="0.058,-0.800"] 
"Continued Substance Use" [pos="0.599,-0.006"] 
"Different Household" [outcome,pos="0.433,0.505"] 
"Foster Care" [pos="-0.295,0.054"] 
"Gestational Age" [pos="-0.557,1.124"] 
"Physical Location" [pos="-1.153,-0.122"] 





"Birth Year" -> "Different Household" 
"Birth Year" -> "Foster Care" 
"Birth Year" -> "Prenatal Opioid Exposure" 
"Continued Substance Use" -> "Different Household" 
"Continued Substance Use" -> "Foster Care" 
"Continued Substance Use" -> "Prenatal Opioid Exposure" 
"Continued Substance Use" -> Abuse 
"Foster Care" -> "Different Household" 
"Foster Care" <-> "Physical Location" 
"Gestational Age" -> Abuse 
"Physical Location" -> "Continued Substance Use" 
"Physical Location" -> "Different Household" 
"Physical Location" -> "Prenatal Opioid Exposure" 
"Physical Location" -> Poverty 
"Physical Location" -> Race 
"Prenatal Opioid Exposure" -> "Different Household" 
"Prenatal Opioid Exposure" -> "Foster Care" 
"Prenatal Opioid Exposure" -> "Gestational Age" 
"Prenatal Opioid Exposure" -> Abuse 
Abuse -> "Different Household" 
Abuse -> "Foster Care" 
Poverty -> "Different Household" 
Poverty -> "Foster Care" 
Poverty -> "Gestational Age" 
Poverty -> "Prenatal Opioid Exposure" 
Poverty -> Abuse 
Poverty -> Race 
Race -> "Continued Substance Use" 
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Race -> "Different Household" 
Race -> "Foster Care" 
Race -> "Gestational Age" 
Race -> "Prenatal Opioid Exposure" 
Race -> Abuse 
Sex -> "Different Household" 






APPENDIX 6. HISTOGRAM SHOWING THE DISTRIBUTION OF GESTATIONAL 






APPENDIX 7.  CHECKING FOR LINEARITY IN THE LOG ODDS OF THE 
ASSOCIATION BETWEEN GESTATIONAL AGE AND A CHILD ENROLLING IN 
MEDICAID AT A DIFFERENT ADDRESS THAN THE MOTHER’S. 
Odds Ratio Estimates 
Effect Point Estimate 95% Wald 
Confidence Limits 
23 Weeks vs 40 16.667 7.658 36.275 
24 Weeks vs 40 5.601 3.761 8.342 
25 Weeks vs 40 5.113 3.544 7.374 
26 Weeks vs 40 4.632 3.301 6.499 
27 Weeks vs 40 3.006 2.147 4.208 
28 Weeks vs 40 3.120 2.310 4.214 
29 Weeks vs 40 2.891 2.175 3.844 
30 Weeks vs 40 1.998 1.558 2.563 
31 Weeks vs 40 1.267 1.001 1.603 
32 Weeks vs 40 1.682 1.404 2.016 
33 Weeks vs 40 1.420 1.211 1.665 
34 Weeks vs 40 1.260 1.114 1.425 
35 Weeks vs 40 1.356 1.232 1.492 
36 Weeks vs 40 1.176 1.096 1.260 
37 Weeks vs 40 1.069 1.019 1.122 
38 Weeks vs 40 1.093 1.050 1.139 
39 Weeks vs 40 0.984 0.952 1.017 
41 Weeks vs 40 0.990 0.930 1.053 
42 Weeks vs 40 0.981 0.753 1.279 
43 Weeks vs 40 1.132 0.422 3.032 
44 Weeks vs 40 2.151 0.394 11.744 
45 Weeks vs 40 <0.001 <0.001 >999.999 





APPENDIX 8. CODE FOR THE DIRECTED ACYCLIC GRAPH CREATED TO 
ILLUSTRATE THE RELATIONSHIP BETWEEN PRENATAL OPIOID EXPOSURE 
AND ASTHMA IN CHAPTER 5. 
dag { 
"Gestational Age" [pos="-0.253,0.843"] 
"Maternal Smoking" [pos="-1.515,-0.200"] 
"Physical Environment" [pos="-0.290,-0.298"] 





"Gestational Age" -> "Prenatal Opioid Exposure" 
"Gestational Age" -> Asthma 
"Maternal Smoking" -> "Gestational Age" 
"Maternal Smoking" -> "Prenatal Opioid Exposure" 
"Maternal Smoking" -> Asthma 
"Maternal Smoking" <-> "Physical Environment" 
"Physical Environment" -> "Gestational Age" 
"Physical Environment" -> "Prenatal Opioid Exposure" 
"Physical Environment" -> Asthma 
"Prenatal Opioid Exposure" -> Asthma 
Genetics -> Asthma 
Race -> "Gestational Age" 
Race -> "Physical Environment" 
Race -> "Prenatal Opioid Exposure" 
Race -> Asthma 
Sex -> "Gestational Age" 
Sex -> "Prenatal Opioid Exposure" 






APPENDIX 9. CODE FOR THE DIRECTED ACYCLIC GRAPH CREATED TO 
ILLUSTRATE THE RELATIONSHIP BETWEEN PRENATAL OPIOID EXPOSURE 
AND COGNITIVE DEVELOPMENT IN CHAPTER 5. 
dag { 
"Cognitive Development" [outcome,pos="0.642,0.646"] 
"Family Structure" [pos="0.674,-0.016"] 
"Gestational Age" [pos="-0.295,-0.826"] 
"Home Environment" [pos="-0.285,-0.326"] 
"Prenatal Opioid Exposure" [exposure,pos="-1.159,0.610"] 
"Socioedemographic Factors" [pos="-1.358,-0.207"] 
ACEs [pos="-0.280,0.962"] 
"Family Structure" -> "Cognitive Development" 
"Family Structure" -> "Prenatal Opioid Exposure" 
"Family Structure" -> ACEs 
"Gestational Age" -> "Cognitive Development" 
"Gestational Age" -> "Prenatal Opioid Exposure" 
"Home Environment" -> "Cognitive Development" 
"Home Environment" -> "Family Structure" 
"Home Environment" -> "Prenatal Opioid Exposure" 
"Home Environment" -> ACEs 
"Prenatal Opioid Exposure" -> "Cognitive Development" 
"Prenatal Opioid Exposure" -> ACEs 
"Socioedemographic Factors" -> "Cognitive Development" 
"Socioedemographic Factors" -> "Home Environment" 
"Socioedemographic Factors" -> "Prenatal Opioid Exposure" 
"Socioedemographic Factors" -> ACEs 




APPENDIX 10. CODE FOR THE DIRECTED ACYCLIC GRAPH CREATED TO 
ILLUSTRATE THE RELATIONSHIP BETWEEN PRENATAL OPIOID EXPOSURE 
AND HEALTHCARE EXPENDITURES IN CHAPTER 6. 
dag { 
"Access to Care" [pos="-1.107,-0.312"] 
"Caretaker Efficacy" [pos="-0.363,0.223"] 
"Clinical Characteristics" [pos="-0.217,0.934"] 
"Healthcare Expenditures" [outcome,pos="0.496,0.575"] 




"Access to Care" -> "Clinical Characteristics" 
"Access to Care" -> "Healthcare Expenditures" 
"Access to Care" -> "Prenatal Opioid Exposure" 
"Access to Care" <-> "Caretaker Efficacy" 
"Caretaker Efficacy" -> "Clinical Characteristics" 
"Caretaker Efficacy" -> "Healthcare Expenditures" 
"Clinical Characteristics" -> "Healthcare Expenditures" 
"Prenatal Opioid Exposure" -> "Caretaker Efficacy" 
"Prenatal Opioid Exposure" -> "Clinical Characteristics" 
"Prenatal Opioid Exposure" -> "Healthcare Expenditures" 
Genetics -> "Clinical Characteristics" 
Genetics -> "Healthcare Expenditures" 
Race -> "Access to Care" 
Race -> "Healthcare Expenditures" 
Race -> "Prenatal Opioid Exposure" 
Sex -> "Healthcare Expenditures" 
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